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Abstract: Radiotherapy is one of the most potent treatment modalities among anti-cancer therapies
and is used in the treatment of as many as 50% of all cancer patients worldwide. Ionizing radiation
(IR) is often combined with chemotherapeutic agents and/or surgery, leading to further improved tumor
growth control. Patupilone (epothilone B) is a clinically relevant microtubule stabilizing agent, which
impairs the dynamic instability of the microtubule network important for cell division, migration and
invasion. Furthermore, patupilone has the potential to accumulate cells in the radiosensitive G2/M-
phase of the cell cycle and also possesses anti- vascular and anti-angiogenic properties. Our laboratory
has previously demonstrated an additive effect of combined IR and patupilone treatment in vitro and
even a supra-additive tumor growth delay effect in vivo. In this work, we investigated mechanistic and
efficacy-oriented aspects of the combined treatment modality of patupilone in combination with IR on
xenografts derived from several genetically defined human tumor cell lines. A specific focus was set on
the analysis of the tumor microenvironment, especially treatment-induced tumor hypoxia. The human
non-small cell lung carcinoma cell line A549 and its patupilone-resistant counterpart A549.EpoB40 were
used to investigate the role of patupilone in the radiosensitization of both the tumor cell compartment
and the tumor microenvironment. A549.EpoB40 cells harbor a genetically defined mutation in ￿-tubulin,
which impairs the binding of patupilone leading to patupilone resistance. Combined IR and patupilone
treatment of the two different cell lines in vitro and in vivo showed an additive anti-proliferative effect
for sensitive A549 cells but not for their resistant counterparts. Analysis of microvessel density and the
hypoxic marker pimonidazole revealed a decrease in microvessel density and a consequent increase in
pimonidazole-positive areas after patupilone treatment in the A549- derived xenografts, while no differ-
ence was observed in the xenografts derived from the resistant cell line. These results indicated a tumor
cell-mediated effect on tumor hypoxia in response to microtubule interference by patupilone. Hypoxia
inducible factor 1 (HIF-1) is the major transcription factor specifically activated under hypoxia. HIF-1
is responsible for the transcription of various pro-angiogenic cytokines, such as VEGF, which is the most
prominent HIF-1 target gene regulating endothelial cell growth and protection. We therefore analyzed the
effect of patupilone and IR on the HIF-1￿ protein level and its activity. HIF-1￿ protein and activity levels
both decreased in the A549 cell line but not in the resistant A549.EpoB40 cell line in response to patupi-
lone treatment. VEGF expression and secretion were analyzed in vitro under the different treatment
conditions. Patupilone treatment of the A549 cell line resulted in decreased levels of both VEGF mRNA
and secreted protein. No difference was observed under treatment with patupilone or irradiation in the
resistant A549.EpoB40 cell line. An increase in tumor hypoxia was observed in the patupilone-sensitive
tumor xenografts after treatment with patupilone alone or when combined with IR. This increase in tu-
mor hypoxia is most likely mediated by the decrease in secreted VEGF from patupilone-sensitive tumor
cells, leading to a more fragile or damaged tumor microvasculature. Hypoxic tumors are 2-3 times more
radiation resistant than normoxic tumors. Furthermore, hypoxia increases the aggressiveness and also
chemoresistance of tumors. Therefore, we were interested in monitoring the development of tumor hy-
poxia under treatment over a prolonged time period in the A549-derived xenografts. For this purpose we
developed a luciferase-based reporter system, in which part of the oxygen-dependent degradation domain
of HIF-1￿ was fused to the luciferase reporter gene. In this hypoxia reporter system, the luciferase gene
is stabilized under hypoxia and degraded under normoxia independently of the transcriptional activity of
HIF-1. Tumor xenografts derived from A549 cells, stably expressing this luciferase construct, revealed a
prolonged, transient increase in luciferase activity after patupilone treatment in comparison to untreated
control tumor xenografts. Interestingly, luciferase activity did not increase in tumor xenografts of mice
that did not respond to patupilone treatment at the level of tumor growth. These results suggest that an
increase in tumor hypoxia might be used as a surrogate marker for the antitumoral treatment response
to patupilone. Irradiation in combination with patupilone was investigated as part of both concomitant
and adjuvant treatment modalities in A549 xenografts. Importantly, despite patupilone-induced hypoxia,
the potency of IR was not reduced in either treatment scheme. As part of our efficacy-oriented studies,
we investigated the combined treatment of patupilone and IR on medulloblastoma cell lines in vitro and
in vivo. Medulloblastoma is the most common malignant brain tumor in children with poor prognosis
and is typically treated with surgery followed by IR and adjuvant chemotherapy. Patients suffer severe
side effects after therapy with the microtubule destabilizing agent vincristine, a part of many chemother-
apy regimens. Analysis of the effect of the microtubule stabilizing agent patupilone on medulloblastoma
cell lines in vitro revealed cellular accumulation in the radiosensitive G2/M phase of the cell cycle, a
decrease in proliferation and an induction of apoptosis or autophagy. The combined treatment with IR
led to a reduction in clonogenicity in an at least additive manner. Interestingly, combined treatment of
medulloblastoma-derived xenografts revealed a strong supra-additive tumor growth control with complete
tumor regression in vivo. These results indicate that patupilone might be a promising replacement for
vincristine as part of a combined treatment strategy with IR. This study demonstrates that the combined
treatment modality of patupilone and IR is an effective and attractive strategy for anti-cancer treatment.
The sensitizing effect of patupilone for IR treatment acts at multiple layers: patupilone has the potential
to accumulate cells in the most radiosensitive phase of the cell cycle and to sensitize endothelial cells to IR
by the inhibition of paracrine signals provided by tumor cells. Furthermore, patupilone exhibits anti- pro-
liferative activity under normoxic and hypoxic conditions, and patupilone-induced tumor hypoxia does not
hamper the radiation response of tumor xenografts, as demonstrated at the level of tumor growth delay.
These results demonstrate that the combined treatment of patupilone and IR might be of great benefit
for cancer therapy but still needs to be evaluated in clinical trials. Die Radiotherapie ist eine der poten-
testen Krebstherapieformen, die bei der Behandlung von 50% aller Krebspatienten eingesetzt wird. Die
ionisierende Bestrahlung wird oft mit Chemotherapie und/oder Chirurgie kombiniert, um schlussendlich
zu einer besseren Tumorkontrolle zu führen. Patupilone ist ein klinisch relevanter Wirkstoff, der zu
einer Stabilisierung der Mikrotubuli führt. Patupilone beeinträchtigt somit die dynamische Instabilität
des Mikrotubulinetzwerkes, die wichtig für die Zellteilung, Migration und Invasion ist. Des Weiteren
führt Patupilone zu einer Ansammlung der Zellen in der radiosensitiven G2/M-Phase des Zellzyklus und
zu einer negativen Beeinflussung der Tumorvaskulatur. Studien unseres Labors zeigten einen additiven
Effekt der kombinierten Therapie von Patupilone und ionisierender Bestrahlung auf die Hemmung des Tu-
morzellwachstum in vitro und eine noch stärkere Hemmung des Tumorwachstums in vivo. In dieser Arbeit
wurden verschiedene mechanistische und auf Effizienz ausgerichtete Aspekte der kombinierten Therapie
von Patupilone und Bestrahlung, in verschiedenen Tumormodellen definierter humaner Tumorzelllinien
untersucht. Ein besonderer Fokus lag dabei auf der Untersuchung der Tumorumgebung. Insbesondere
wurde der durch Behandlung induzierte Sauerstoffmangel (Hypoxie) innerhalb des Tumors analysiert.
Die humane Lungenkrebszelllinie A549, sowie ihr Patupilone resistentes Pendant A549.EpoB40, wurden
für die Untersuchung der Rolle von Patupilone in der Sensibilisierung für die Bestrahlung, auf der Ebene
der Tumorzellen und der Tumorumgebung verwendet. Die A549.EpoB40 Zelllinie besitzt eine genetisch
definierte Mutation innerhalb des ￿-Tubulin, welche die Bindung von Patupilone verhindert und somit zu
einer Resistenz gegen den Wirkstoff führt. Die Behandlung der zwei verschiedenen Zelllinien mit der kom-
binierten Therapie von Patupilone und Bestrahlung, in vitro und in vivo, zeigten einen additiven Effekt
auf die Hemmung des Tumorzellwachstums der sensitiven A549 Zelllinie, nicht aber für ihr resistentes
Pendant. Untersuchungen der Dichte kleinster Blutgefässe, sowie der Bindung des Hypoxie Markers Pi-
monidazole, ergaben eine Verringerung der Blutgefässdichte mit gleichzeitiger Zunahme der Bindung von
Pimonidazole nach Behandlung mit Patupilone in den Tumoren der A549 Tumorzelllinie, nicht aber in
Tumoren der resistenten Zelllinie. Diese Resultate weisen darauf hin, dass die Tumorhypoxie als Antwort
auf die Beeinträchtigung der Mikrotubulifunktion der Tumorzellen durch die Behandlung mit Patupi-
lone beeinflusst wird. Der Hypoxie-induzierte Faktor 1 (HIF-1) ist der wichtigste Transkriptionsfaktor
der unter Hypoxie aktiviert wird. HIF-1 ist für die Transkription verschiedener Angiogenese fördernde
Zytokine, wie dem vascular endothelial growth factor (VEGF) verantwortlich. VEGF ist das wichtig-
ste Zielgen von HIF-1, das das Wachstum und den Schutz von Endothelzellen reguliert. Aus diesem
Grund wurde der Effekt von Patupilone und Bestrahlung auf die HIF- 1￿ Proteinmenge, der sauerstoff-
sensitiven Untereinheit von HIF-1, und die HIF-1 Aktivität untersucht. Die Proteinmenge von HIF-1￿￿
sowie die HIF-1 Aktivität, verringerten sich in der A549 Zelllinie als Antwort auf die Behandlung mit
Patupilone, nicht aber in den resistenten A549.EpoB40 Zellen. Die VEGF Expression und Sekretion
2
wurde in vitro unter den verschiedenen Therapieformen analysiert. Die Behandlung mit Patupilone in
der sensitiven Zelllinie führte zu einer Abnahme von VEGF mRNA, sowie in der Menge des sekretierten
Proteins. Stattdessen konnte in den resistenten A549.EpoB40 Zellen nach Behandlung mit Patupilone
oder Bestrahlung kein Unterschied bezüglich der VEGF mRNA und Proteinmenge festgestellt werden.
Tumorxenografts der Patupilone sensitiven Zelllinie zeigten einen Anstieg in der Tumorhypoxie nach
Behandlung mit Patupilone, oder Patupilone in Kombination mit Bestrahlung. Dieser Anstieg der Tu-
morhypoxie wird vermutlich durch die Abnahme an sekretiertem VEGF der Patupilone sensitiven Zelllinie
verursacht, der zu einer schwachen oder geschädigten Tumorvaskulatur führt. Hypoxische Tumore sind
2-3mal strahlenresistenter als normoxische Tumore. Des Weiteren führt Hypoxie zu einer verstärkten
Aggressivität und Chemoresistenz von Tumoren. Aus diesem Grund waren wir daran interessiert, die
Entwicklung der Tumorhypoxie, während der Behandlung mit verschiedenen Therapieformen, über eine
verlängerte Zeitspanne in A549-Xenografts zu verfolgen. Wir entwickelten ein, auf das Enzym Luciferase
basierendes, Reporter System. In diesem System wurde ein Teil der sauerstoffabhängigen Domäne von
HIF-1￿, die für den Abbau des Proteins unter Normoxie verantwortlich ist, an das Luciferase Gen kloniert.
Hypoxie führt in diesem Reporter System zu einer Stabilisierung des Luciferase Proteins, unabhängig von
der HIF-1 Aktivität, und zu einem Abbau unter Normoxie. Tumorxenografts der A549 Zelllinie, die das
Luciferase Konstrukt stabil exprimierten, zeigten einen verlängerten transienten Anstieg der Luciferase
Aktivität nach Behandlung mit Patupilone im Vergleich zu unbehandelten Kontrolltumoren. Interes-
santerweise stieg die Luciferase Aktivität in Mäusen, die hinsichtlich des Tumorvolumens nicht auf die
Behandlung mit Patupilone ansprachen, nicht an. Diese Resultate deuten darauf hin, dass eine Zunahme
in der Tumorhypoxie als Surrogat für das Tumoransprechen auf die Behandlung mit Patupilone verwen-
det werden könnte. Die Bestrahlung in Kombination mit Patupilone wurde als Teil einer adjuvanten und
konkomitierenden Behandlungsmethode in A549 Xenografts untersucht. Trotz einer durch Patupilone
induzierten Hypoxie wurde die Wirksamkeit der ionisierenden Bestrahlung weder in der konkomitieren-
den noch in der adjuvanten Behandlungsmethode reduziert. Als Teil unserer Effizienz orientierten Studie
wurde der Einfluss der kombinierten Behandlung mit Bestrahlung und Patupilone auf Medulloblastoma
Zelllinien in vitro und in vivo untersucht. Medulloblastoma ist der häufigste bösartige Gehirntumor mit
schlechter Prognose und massiven Nebenwirkungen nach der Therapie, zum Beispiel nach dem Mikro-
tubuli destabilisieren Wirkstoff Vincristine, in Kindern. Untersuchungen von dem Mikrotubuli stabil-
isierenden Wirkstoff Patupilone auf Medulloblastoma Zelllinien zeigten eine Anhäufung der Zellen in der
radiosensitiven G2/M Phase des Zellzyklus, eine Verringerung der Proliferation sowie eine Induktion von
Apoptose oder Autophagie. Die kombinierte Behandlung mit Bestrahlung führte zu einer mindestens
additiven Verringerung der Klonogenität der Zellen. Interessanterweise führte die kombinierte Behand-
lung von Xenografts einer Medulloblastoma Zelllinie zu einer sehr starken Tumorkontrolle mit teilweise
kompletter Tumorremission. Diese Resultate weisen darauf hin, dass Patupilone eine vielversprechende
Alternative zu Vincristine in der kombinierten Therapieform mit Bestrahlung sein könnte. Diese Studie
zeigt, dass die kombinierte Behandlungsmethode von Patupilone und Bestrahlung eine effektive und
attraktive Strategie in der Krebsbehandlung ist. Zusammenfassend wirkt der strahlensensibilisierende
Effekt von Patupilone auf verschiedenen Ebenen. Patupilone hat einerseits das Potential Zellen in der
radiosensitiven Phase des Zellzyklus anzuhäufen, andererseits sensibilisiert Patupilone die Endothelzellen,
durch eine Inhibierung parakriner Signale der Tumorzellen, auch für die Bestrahlung. Des Weiteren kann
Patupilone seine wachstumsinhibierende Wirkung sowohl unter Hypoxie als auch unter Normoxie entfal-
ten. Ausserdem wird die Strahlenwirksamkeit in einer kombinierten Therapie nicht von der Patupilone
induzierten Hypoxie beeinflusst, wie auf der Ebene der Tumorwachstumshemmung gezeigt werden kon-
nte. Diese Resultate weisen darauf hin, dass die kombinierte Behandlung von Patupilone und Bestrahlung
einen grossen Nutzen für die Krebstherapie haben könnte, nachdem sie in klinischen Studien validiert
worden ist.
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Abstract 
 
Radiotherapy is one of the most potent treatment modalities among anti-cancer therapies and 
is used in the treatment of as many as 50% of all cancer patients worldwide. Ionizing radiation 
(IR) is often combined with chemotherapeutic agents and/or surgery, leading to further 
improved tumor growth control. Patupilone (epothilone B) is a clinically relevant microtubule 
stabilizing agent, which impairs the dynamic instability of the microtubule network important 
for cell division, migration and invasion. Furthermore, patupilone has the potential to 
accumulate cells in the radiosensitive G2/M-phase of the cell cycle and also possesses anti-
vascular and anti-angiogenic properties. Our laboratory has previously demonstrated an 
additive effect of combined IR and patupilone treatment in vitro and even a supra-additive 
tumor growth delay effect in vivo.  
In this work, we investigated mechanistic and efficacy-oriented aspects of the combined 
treatment modality of patupilone in combination with IR on xenografts derived from several 
genetically defined human tumor cell lines. A specific focus was set on the analysis of the 
tumor microenvironment, especially treatment-induced tumor hypoxia.  
The human non-small cell lung carcinoma cell line A549 and its patupilone-resistant 
counterpart A549.EpoB40 were used to investigate the role of patupilone in the 
radiosensitization of both the tumor cell compartment and the tumor microenvironment. 
A549.EpoB40 cells harbor a genetically defined mutation in -tubulin, which impairs the 
binding of patupilone leading to patupilone resistance. Combined IR and patupilone treatment 
of the two different cell lines in vitro and in vivo showed an additive anti-proliferative effect 
for sensitive A549 cells but not for their resistant counterparts. Analysis of microvessel 
density and the hypoxic marker pimonidazole revealed a decrease in microvessel density and 
a consequent increase in pimonidazole-positive areas after patupilone treatment in the A549-
derived xenografts, while no difference was observed in the xenografts derived from the 
resistant cell line. These results indicated a tumor cell-mediated effect on tumor hypoxia in 
response to microtubule interference by patupilone. 
Hypoxia inducible factor 1 (HIF-1) is the major transcription factor specifically activated 
under hypoxia.  HIF-1 is responsible for the transcription of various pro-angiogenic cytokines, 
such as VEGF, which is the most prominent HIF-1 target gene regulating endothelial cell 
growth and protection. We therefore analyzed the effect of patupilone and IR on the HIF-1 
protein level and its activity. HIF-1 protein and activity levels both decreased in the A549 
cell line but not in the resistant A549.EpoB40 cell line in response to patupilone treatment. 
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VEGF expression and secretion were analyzed in vitro under the different treatment 
conditions. Patupilone treatment of the A549 cell line resulted in decreased levels of both 
VEGF mRNA and secreted protein. No difference was observed under treatment with 
patupilone or irradiation in the resistant A549.EpoB40 cell line.  
An increase in tumor hypoxia was observed in the patupilone-sensitive tumor xenografts after 
treatment with patupilone alone or when combined with IR. This increase in tumor hypoxia is 
most likely mediated by the decrease in secreted VEGF from patupilone-sensitive tumor cells, 
leading to a more fragile or damaged tumor microvasculature. Hypoxic tumors are 2-3 times 
more radiation resistant than normoxic tumors. Furthermore, hypoxia increases the 
aggressiveness and also chemoresistance of tumors. Therefore, we were interested in 
monitoring the development of tumor hypoxia under treatment over a prolonged time period 
in the A549-derived xenografts. For this purpose we developed a luciferase-based reporter 
system, in which part of the oxygen-dependent degradation domain of HIF-1 was fused to 
the luciferase reporter gene. In this hypoxia reporter system, the luciferase gene is stabilized 
under hypoxia and degraded under normoxia independently of the transcriptional activity of 
HIF-1. Tumor xenografts derived from A549 cells, stably expressing this luciferase construct, 
revealed a prolonged, transient increase in luciferase activity after patupilone treatment in 
comparison to untreated control tumor xenografts. Interestingly, luciferase activity did not 
increase in tumor xenografts of mice that did not respond to patupilone treatment at the level 
of tumor growth. These results suggest that an increase in tumor hypoxia might be used as a 
surrogate marker for the antitumoral treatment response to patupilone. Irradiation in 
combination with patupilone was investigated as part of both concomitant and adjuvant 
treatment modalities in A549 xenografts. Importantly, despite patupilone-induced hypoxia, 
the potency of IR was not reduced in either treatment scheme.  
As part of our efficacy-oriented studies, we investigated the combined treatment of patupilone 
and IR on medulloblastoma cell lines in vitro and in vivo. Medulloblastoma is the most 
common malignant brain tumor in children with poor prognosis and is typically treated with 
surgery followed by IR and adjuvant chemotherapy.  Patients suffer severe side effects after 
therapy with the microtubule destabilizing agent vincristine, a part of many chemotherapy 
regimens.  Analysis of the effect of the microtubule stabilizing agent patupilone on 
medulloblastoma cell lines in vitro revealed cellular accumulation in the radiosensitive G2/M 
phase of the cell cycle, a decrease in proliferation and an induction of apoptosis or autophagy. 
The combined treatment with IR led to a reduction in clonogenicity in an at least additive 
manner. Interestingly, combined treatment of medulloblastoma-derived xenografts revealed a 
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strong supra-additive tumor growth control with complete tumor regression in vivo. These 
results indicate that patupilone might be a promising replacement for vincristine as part of a 
combined treatment strategy with IR. 
This study demonstrates that the combined treatment modality of patupilone and IR is an 
effective and attractive strategy for anti-cancer treatment. The sensitizing effect of patupilone 
for IR treatment acts at multiple layers: patupilone has the potential to accumulate cells in the 
most radiosensitive phase of the cell cycle and to sensitize endothelial cells to IR by the 
inhibition of paracrine signals provided by tumor cells. Furthermore, patupilone exhibits anti-
proliferative activity under normoxic and hypoxic conditions, and patupilone-induced tumor 
hypoxia does not hamper the radiation response of tumor xenografts, as demonstrated at the 
level of tumor growth delay. These results demonstrate that the combined treatment of 
patupilone and IR might be of great benefit for cancer therapy but still needs to be evaluated 
in clinical trials.  
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Zusammenfassung 
 
Die Radiotherapie ist eine der potentesten Krebstherapieformen, die bei der Behandlung von 
50% aller Krebspatienten eingesetzt wird. Die ionisierende Bestrahlung wird oft mit 
Chemotherapie und/oder Chirurgie kombiniert, um schlussendlich zu einer besseren 
Tumorkontrolle zu führen. Patupilone ist ein klinisch relevanter Wirkstoff, der zu einer 
Stabilisierung der Mikrotubuli führt. Patupilone beeinträchtigt somit die dynamische 
Instabilität des Mikrotubulinetzwerkes, die wichtig für die Zellteilung, Migration und 
Invasion ist. Des Weiteren führt Patupilone zu einer Ansammlung der Zellen in der 
radiosensitiven G2/M-Phase des Zellzyklus und zu einer negativen Beeinflussung der 
Tumorvaskulatur.  Studien unseres Labors zeigten einen additiven Effekt der kombinierten 
Therapie von Patupilone und ionisierender Bestrahlung auf die Hemmung des 
Tumorzellwachstum in vitro und eine noch stärkere Hemmung des Tumorwachstums in vivo.  
 
In dieser Arbeit wurden verschiedene mechanistische und auf Effizienz ausgerichtete Aspekte 
der kombinierten Therapie von Patupilone und Bestrahlung, in verschiedenen Tumormodellen 
definierter humaner Tumorzelllinien untersucht. Ein besonderer Fokus lag dabei auf der 
Untersuchung der Tumorumgebung. Insbesondere wurde der durch Behandlung induzierte 
Sauerstoffmangel (Hypoxie) innerhalb des Tumors analysiert.  
Die humane Lungenkrebszelllinie A549, sowie ihr Patupilone resistentes Pendant 
A549.EpoB40, wurden für die Untersuchung der Rolle von Patupilone in der Sensibilisierung 
für die Bestrahlung, auf der Ebene der Tumorzellen und der Tumorumgebung verwendet. Die 
A549.EpoB40 Zelllinie besitzt eine genetisch definierte Mutation innerhalb des -Tubulin, 
welche die Bindung von Patupilone verhindert und somit zu einer Resistenz gegen den 
Wirkstoff führt. Die Behandlung der zwei verschiedenen Zelllinien mit der kombinierten 
Therapie von Patupilone und Bestrahlung, in vitro und in vivo, zeigten einen additiven Effekt 
auf die Hemmung des Tumorzellwachstums der sensitiven A549 Zelllinie, nicht aber für ihr 
resistentes Pendant. Untersuchungen der Dichte kleinster Blutgefässe, sowie der Bindung des 
Hypoxie Markers Pimonidazole, ergaben eine Verringerung der Blutgefässdichte mit 
gleichzeitiger Zunahme der Bindung von Pimonidazole nach Behandlung mit Patupilone in 
den Tumoren der A549 Tumorzelllinie, nicht aber in Tumoren der resistenten Zelllinie. Diese 
Resultate weisen darauf hin, dass die Tumorhypoxie als Antwort auf die Beeinträchtigung der 
Mikrotubulifunktion der Tumorzellen durch die Behandlung mit Patupilone beeinflusst wird.  
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Der Hypoxie-induzierte Faktor 1 (HIF-1) ist der wichtigste Transkriptionsfaktor der unter 
Hypoxie aktiviert wird. HIF-1 ist für die Transkription verschiedener Angiogenese fördernde 
Zytokine, wie dem vascular endothelial growth factor (VEGF) verantwortlich. VEGF ist das 
wichtigste Zielgen von HIF-1, das das Wachstum und den Schutz von Endothelzellen 
reguliert. Aus diesem Grund wurde der Effekt von Patupilone und Bestrahlung auf die HIF-
1 Proteinmenge, der sauerstoffsensitiven Untereinheit von HIF-1, und die HIF-1 Aktivität 
untersucht. Die Proteinmenge von HIF-1 sowie die HIF-1 Aktivität, verringerten sich in der 
A549 Zelllinie als Antwort auf die Behandlung mit Patupilone, nicht aber in den resistenten 
A549.EpoB40 Zellen.  
Die VEGF Expression und Sekretion wurde in vitro unter den verschiedenen Therapieformen 
analysiert. Die Behandlung mit Patupilone in der sensitiven Zelllinie führte zu einer Abnahme 
von VEGF mRNA, sowie in der Menge des sekretierten Proteins. Stattdessen konnte in den 
resistenten A549.EpoB40 Zellen nach Behandlung mit Patupilone oder Bestrahlung kein 
Unterschied bezüglich der VEGF mRNA und Proteinmenge festgestellt werden.  
Tumorxenografts der Patupilone sensitiven Zelllinie zeigten einen Anstieg in der 
Tumorhypoxie nach Behandlung mit Patupilone, oder Patupilone in Kombination mit 
Bestrahlung. Dieser Anstieg der Tumorhypoxie wird vermutlich durch die Abnahme an 
sekretiertem VEGF der Patupilone sensitiven Zelllinie verursacht, der zu einer schwachen 
oder geschädigten Tumorvaskulatur führt. Hypoxische Tumore sind 2-3mal strahlenresistenter 
als normoxische Tumore. Des Weiteren führt Hypoxie zu einer verstärkten Aggressivität und 
Chemoresistenz von Tumoren. Aus diesem Grund waren wir daran interessiert, die  
Entwicklung der Tumorhypoxie, während der Behandlung mit verschiedenen 
Therapieformen, über eine verlängerte Zeitspanne in A549-Xenografts zu verfolgen. Wir 
entwickelten ein, auf das Enzym Luciferase basierendes, Reporter System. In diesem System 
wurde ein Teil der sauerstoffabhängigen Domäne von HIF-1, die für den Abbau des Proteins 
unter Normoxie verantwortlich ist, an das Luciferase Gen kloniert. Hypoxie führt in diesem 
Reporter System zu einer Stabilisierung des Luciferase Proteins, unabhängig von der HIF-1 
Aktivität, und zu einem Abbau unter Normoxie.  
Tumorxenografts der A549 Zelllinie, die das Luciferase Konstrukt stabil exprimierten, zeigten 
einen verlängerten transienten Anstieg der Luciferase Aktivität nach Behandlung mit 
Patupilone im Vergleich zu unbehandelten Kontrolltumoren.  Interessanterweise stieg die 
Luciferase Aktivität in Mäusen, die hinsichtlich des Tumorvolumens nicht auf die 
Behandlung mit Patupilone ansprachen, nicht an. Diese Resultate deuten darauf hin, dass eine 
Zunahme in der Tumorhypoxie als Surrogat für das Tumoransprechen auf die Behandlung mit 
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Patupilone verwendet werden könnte. Die Bestrahlung in Kombination mit Patupilone wurde 
als Teil einer adjuvanten und konkomitierenden Behandlungsmethode in A549 Xenografts 
untersucht. Trotz einer durch Patupilone induzierten Hypoxie wurde die Wirksamkeit der 
ionisierenden Bestrahlung weder in der konkomitierenden noch in der adjuvanten 
Behandlungsmethode reduziert.  
Als Teil unserer Effizienz orientierten Studie wurde der Einfluss der kombinierten 
Behandlung mit Bestrahlung und Patupilone auf Medulloblastoma Zelllinien in vitro und in 
vivo untersucht. Medulloblastoma ist der häufigste bösartige Gehirntumor mit schlechter 
Prognose und massiven Nebenwirkungen nach der Therapie, zum Beispiel nach dem 
Mikrotubuli destabilisieren Wirkstoff Vincristine, in Kindern. Untersuchungen von dem 
Mikrotubuli stabilisierenden Wirkstoff Patupilone auf Medulloblastoma Zelllinien zeigten 
eine Anhäufung der Zellen in der radiosensitiven G2/M Phase des Zellzyklus, eine 
Verringerung der Proliferation sowie eine Induktion von Apoptose oder Autophagie. Die 
kombinierte Behandlung mit Bestrahlung führte zu einer mindestens additiven Verringerung 
der Klonogenität der Zellen. Interessanterweise führte die kombinierte Behandlung von 
Xenografts einer Medulloblastoma Zelllinie zu einer sehr starken Tumorkontrolle mit 
teilweise kompletter Tumorremission. Diese Resultate weisen darauf hin, dass Patupilone eine 
vielversprechende Alternative zu Vincristine in der kombinierten Therapieform mit 
Bestrahlung sein könnte. 
Diese Studie zeigt, dass die kombinierte Behandlungsmethode von Patupilone und 
Bestrahlung eine effektive und attraktive Strategie in der Krebsbehandlung ist. 
Zusammenfassend wirkt der strahlensensibilisierende Effekt von Patupilone auf 
verschiedenen Ebenen. Patupilone hat einerseits das Potential Zellen in der radiosensitiven 
Phase des Zellzyklus anzuhäufen, andererseits sensibilisiert Patupilone die Endothelzellen, 
durch eine Inhibierung parakriner Signale der Tumorzellen, auch für die Bestrahlung. Des 
Weiteren kann Patupilone seine  wachstumsinhibierende Wirkung sowohl unter Hypoxie als 
auch unter Normoxie entfalten. Ausserdem wird die Strahlenwirksamkeit in einer 
kombinierten Therapie nicht von der Patupilone induzierten Hypoxie beeinflusst, wie auf der 
Ebene der Tumorwachstumshemmung gezeigt werden konnte. Diese Resultate weisen darauf 
hin, dass die kombinierte Behandlung von Patupilone und Bestrahlung einen grossen Nutzen 
für die Krebstherapie haben könnte, nachdem sie in klinischen Studien validiert worden ist.  
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1. Introduction 
 
1.1. Cancer and Cancer treatment  
1.1.1. Cancer distribution and incidence 
Cancer is a disease caused by uncontrolled proliferation of cells that can subsequently invade 
the organ of origin and spread to more distant parts of the body. The uncontrolled 
proliferation of cancer cells impairs the function of healthy cells in the affected organ. In 
cases where the growing tumor disrupts essential organs and tissues, the disease becomes 
lethal. Often, more aggressive tumor cells metastasize to different organs within the whole 
body complicating the treatment and therefore treatment outcome.  
Cancer is the leading cause of death in economically developed countries and the second 
leading cause of death in developing countries after cardiovascular diseases (Global cancer, 
Facts and Figures, 2011). The incidence of cancer is continuously rising due to longer life 
expectancies and the increase in cancer-promoting behaviors like smoking, unhealthy diets 
and physical inactivity, especially in economically developing countries. Worldwide, in 2008 
the cancer incidence rate was estimated to be 12.7 million , with 7.6 million cancer deaths [1]. 
The cancer type with the highest death rate in the U.S is lung cancer, responsible for  26-28% 
of cancer deaths for both sexes, followed by prostate and breast cancer and colon cancer [2]. 
The highest cancer incidence worldwide, however, remains breast cancer for women and lung 
and bronchus followed by prostate cancer for men [1]. Studies on cancer epidemiology show 
a higher trend for certain cancer types in specific countries, such as melanoma in Australia, 
cervical cancer in eastern Africa or liver cancer in middle Africa (see Figure 1.1.). The high 
numbers of cervical and liver cancers are mainly caused by chronic infections from hepatitis 
B virus (HBV), hepatitis C virus (HCV) and some types of Human Papilloma Virus (HPV). 
Besides the cancers caused by virus infections, a high percentage of cancers like lung or head 
and neck cancer, could be prevented by reducing tobacco and alcohol use. In addition, 
prevention of melanoma can be improved by the use of sun cream, huts, tight fitting 
sunglasses and minimizing sun exposure during the hours with high UV alert. Although the 
cancer incidence rate in developing countries is lower than in economically developed 
countries, the death rate remains the same, which is mainly due to late detection of the 
disease, poor cancer prevention and limited access to basic cancer treatments in developing 
countries [1]. 
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Figure 1.1. Cancer Incidence Worldwide 2008, adapted from Cancer Research UK,  
source GLOBOCAN 2008, http://globocan.iarc.fr 
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Standard cancer therapy is composed of three different approaches: surgery, radiotherapy and 
chemotherapy. Surgery and radiotherapy are used for the local treatment of the disease, 
whereas chemotherapy can also be used for systemic treatment, e.g. for lymphoma or 
metastatic disease. Surgery aims to excise the malignant tumor or part of affected organs in 
order to eliminate or reduce the tumor burden and to prevent further spreading. Surgery is 
used in about 60% of cancer patients. Radiotherapy is also used for local treatment of tumors, 
where precise planning allows application of high-dose radiation to malignant tissue while 
minimizing radiation to the surrounding healthy tissue. Radiotherapy affects all cells, 
malignant as well as benign. Malignant cancer cells are highly proliferative cells that often 
harbor defects in cell cycle checkpoints. Therefore, damage induced by ionizing radiation (IR) 
is often not repaired properly, and triggered by mitotic catastrophe eventually leads to cell 
death in these cells compared to benign ones. Radiotherapy is applied in around 50% of all 
cancer patients [3]. Chemotherapy uses agents that prevent proliferation of rapidly dividing 
cells and thus targets malignant cells but also healthy epithelial and bone marrow cells. It is 
applied as adjuvant treatment after radiotherapy or surgery to prevent recurrence, as well as 
neo-adjuvant therapy for surgery or in case of high risk for metastatic spread. The different 
approaches are often combined during treatment to achieve a better survival rate or shorter 
treatment time. 
 
1.1.2. Tumor biology 
Cancer can be caused by various external (infections, tobacco, chemicals, etc.) as well as 
internal (inherited or spontaneous mutations, immune conditions etc.) factors. Hanahan and 
Weinberg describe eight distinct hallmarks that enable tumor growth and metastatic 
dissemination of malignant cells [4]. The first hallmark is sustained proliferative signaling: 
cancer cells evade the normal regulation of the cell cycle which is controlled by growth-factor 
signaling. Tumor cells can release factors like the transforming growth factor(TGF), that 
in turn increase production of the growth factor hepatocyte growth factor (HGF) by 
surrounding fibroblasts [5]. Tumor cells can also upregulate growth factor receptors on their 
surface, allowing proliferation even at a low level of surrounding growth factors. 
Alternatively, they can express ligands leading to an autocrine activation of their own surface 
receptors. A very high percentage of cancer cells express constitutively activate components 
of the signaling pathways downstream of growth factor receptors like mutated K-ras in order 
to proliferate in the absence of growth factors [6]. 
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The second hallmark of cancer is evasion from growth suppression. The proliferation of 
normal cells is usually impaired by different factors such as shortage of space, a lack of 
nutrients or internal damage. The proliferation under these non-favorable circumstances is 
tightly regulated by different growth suppressors. The most prominent growth or tumor 
suppressors are p53 and the retinoblastoma-associated (Rb) protein. Rb primarily regulates 
extracellular signals and determines whether cells can proceed in the cell cycle. p53 instead 
receives signals from within the cell indicating damage to the genome or lack or shortage of 
nucleotides, glucose or oxygenation and acts as gatekeeper for cell cycle progression. In case 
of severe DNA damage, p53 can also induce apoptosis. Mutations in these tumor suppressors 
lead to uncontrolled proliferation of tumor cells. The high importance of p53 in the regulation 
of growth suppression is supported by the fact that more than 50% of all human cancer 
display different mutations in the TP53 gene [7].  
The third hallmark of cancer is resistance to cell death. Programmed cell death or apoptosis 
serves as natural defense against cancer development or uncontrolled proliferation. Apoptosis 
can be induced by extrinsic factors via Fas binding to the death receptor FasR, or by intrinsic 
factors in response to multiple intracellular stress conditions via activation of the caspase 
cascade. However, cancer cells often evade apoptosis by overexpression of anti-apoptotic Bcl-
2 family regulatory proteins or downregulation of pro-apoptotic proteins like Bax, Bim or 
Puma.  Caspase-independent intrinsic apoptosis is mediated by the apoptosis-inducing factor 
(AIF) and endonuclease G (ENDOG), which relocate to the nucleus and induce large scale 
DNA fragmentation [8]. A further mode of cell death that gains more and more interest is 
mitotic catastrophe. Mitotic catastrophe is triggered by aberrant mitosis and executed during 
mitosis or in the subsequent interphase by caspase-2 activation. It has been proposed that 
mitotic catastrophe is an oncosuppressive pathway that precedes apoptosis, necrosis or 
senescence [9]. Another pathway to avoid cell death is the induction of autophagy or 
senescence. This latter dormant-like, reversible state allows the recovery of cancer cells from 
treatment, which eventually leads to a more persistent tumor or to tumor regrowth after end of 
treatment.  
The fourth hallmark of cancer is enabling replicative immortality. Cells pass only a limited 
number of cell cycle divisions before entering senescence or cell death. The block in cell 
division is caused by shortening of telomeres, which are hexanucleotide repeats at the end of 
chromosomes protecting the chromosome ends. However, tumor cells often overexpress the 
enzyme telomerase which adds additional telomere repeats to the end of telomeric DNA and 
therefore prevents cells from undergoing senescence or cell death. 
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Figure 1.2. The Hallmarks and Enabling 
characteristics of Cancer. Research 
conducted in the past years led to the 
description of two new hallmarks of cancer: 
avoidance of immune destruction and 
deregulation of cellular energetics. Enabling 
characteristics include tumor promoting 
inflammation and genome instability and 
mutation. (Hanahan et al, 2011) 
 
The fifth hallmark of cancer is the ability to induce angiogenesis. In adult tissues, 
angiogenesis is either in a quiescent state or transiently active. Tumor cells, however, induce 
an angiogenic switch which leads to a constant sprouting of new vessels to supply the 
growing tumor with nutrients and oxygen [10]. The upregulation of angiogenesis is initiated 
by the expression and secretion of pro-angiogenic factors like vascular endothelial growth 
factor (VEGF) or fibroblast growth factor (FGF). The expression of these proteins can either 
be triggered by oncogene signaling or by tumor hypoxia.  
The sixth hallmark of cancer is activation of invasion and metastasis. In order to progress to 
higher pathological stages, cancer cells develop different alterations in cell shape and express 
pro-metastatic genes promoting the consecutive steps in metastasis formation. The different 
steps in the malignant progression are: First, the invasion of cancer cells into the local tissue 
followed by the intravasation into nearby blood or lymphatic vessels and transition within the 
vascular network. The next step is the extravasation out of the vasculature into the new tissue 
and the establishment of micrometastases. Finally, tumor cells have to adapt to the new 
microenvironment in order to form macrometastases. The first step of invasion is often 
accompanied by the loss of E-cadherin, a cell-to-cell adhesion molecule expressed in 
epithelial cells that normally keeps cells in a quiescent state. The high frequency of this 
mutation indicates that E-cadherin is a key suppressor for invasion. An adhesion molecule 
frequently upregulated in cancer cells is N-cadherin, which is important for migration of 
neurons and mesenchymal cells during organogenesis. The specific changes within the 
expression of the adhesion molecules are part of a process called epithelial to mesenchymal 
 6
transition (EMT), which is activated in most malignant tumor cells. EMT changes the 
morphology of cells into a more fibroblastic shape, decreases E-cadherin expression and 
increases N-cadherin expression, increases the expression of matrix-degrading enzymes and 
consequently increases the invasive capacities of the cells [11].  
Invasion of tumor cells is also influenced by crosstalk with the neoplastic stroma, which 
contains cancer associated fibroblasts, endothelial cells, extracellular matrix, pericytes and 
also inflammatory cells. Inflammatory cells contribute to the invasive capacities of a tumor by 
secretion of matrix-degrading enzymes. Therefore, a new enabling characteristic of cancer is 
tumor promoting inflammation that contributes to several steps in tumor progression. 
Inflammatory cells, mainly from the innate immune system, can provide tumor cells with 
growth and survival factors to promote tumor cell proliferation. Further, they can provide pro-
angiogenic factors, induce EMT or even lead to a higher mutation rate in tumor cells by 
secretion of reactive oxygen species (ROS).  
However, the immune system is also involved in the prevention of tumor initiation, and thus, 
an additional emerging hallmark of cancer is the evasion of immune destruction. Cancer cells 
may paralyze infiltrating natural killer cells (NK) and cytotoxic T-cells (CTL) cells by 
transforming growth factor  (TGF- secretion or attract immunosuppressive cells like 
regulatory T-cells to avoid immune destruction. Nevertheless, only rudimentary evidence 
demonstrates that the immune system protects from cancer formation. Pages and colleagues 
demonstrated that human ovarian and colon carcinoma with a very high number of infiltrating 
CTL and NK cells results in a better prognosis than tumors with fewer CTL and NK cells 
[12,13].  
A further emerging hallmark for cancer is the deregulation of cellular energetics allowing 
tumor cells to perform anaerobic glycolysis even under aerobic conditions. Thereby tumor 
cells are limiting their metabolism to glycolysis, which allows them to redirect glycolytic 
intermediates into other biosynthetic pathways to generate nucleosides or amino acids used 
for cell growth and proliferation. Glycolysis yields 18 times less ATP which is the reason why 
tumor cells frequently increase their glucose uptake by overexpressing the Glut-1 transporter 
[14,15]. Interestingly, some tumors contain two different subpopulations regarding their 
energy generating pathways. The hypoxic subpopulation uses glucose as main energy source, 
thereby producing lactate which in turn is consumed by the better oxygenated subpopulation 
to generate energy by feeding lactate into the citric acid cycle [16,17]. 
In addition to tumor promoting inflammation described above, Hanahan and Weinberg 
suggest a second enabling characteristic for cancer, genome instability and mutation. They 
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propose that the loss of important components of the DNA repair machinery or increased 
sensitivity to mutagenic agents can further lead to increased rates of mutation and hence 
facilitate tumor progression. However, the loss or inactivation of a tumor suppressor can also 
be acquired by epigenetic mechanisms such as DNA methylation or histone modification and 
consequently inherited by the daughter cells [18].  
 
In conclusion, several mutations and changes in different regulatory systems must occur 
within benign cells in order to promote cancer development. Further research will improve 
our understanding of the important features of invasion and metastasis formation and will 
shed light on the importance and role of immune cells in cancer progression or prevention. 
In the present work we were focusing on one specific hallmark of cancer, “angiogenesis”. 
Therefore I would like to describe in more detail factors influencing angiogenesis and tumor 
hypoxia, which results from damaged or non-functional angiogenesis. 
 
1.1.3. Microenvironment of the tumor 
Tumors are composed not only of malignant tumor cells, but also consist of other cell types 
forming the tumor microenvironment. Tumor stroma, which is an important element of the 
microenvironment, is composed of extracellular matrix, endothelial cells, mural cells and 
fibroblasts. Endothelial cells forming the blood vessels supply the tumor with nutrients and 
oxygen and may also play an important role in modulating the aggressiveness of a tumor.  
Endothelial cells are often activated by angiogenic and growth factors secreted by the tumor 
cells, which then induces the so-called angiogenic switch promoting the growth and 
development of new vessels. Depending on the pathways activated in the endothelial cells, 
tumor cell invasion can be facilitated. Loss of HIF-1the oxygen-sensitive subunit of the 
transcription factor hypoxia inducible factor 1 (HIF-1), in endothelial cells leads e.g. to a 
reduction in NO synthesis and retards tumor cell migration.  The loss of HIF-2 the oxygen-
sensitive subunit of the transcription factor HIF-2, instead has the opposite effect [19]. 
Endothelial cells are associated with supporting pericytes or vascular smooth muscle cells 
which help building the vascular basement membrane and fortify the vessels. A lack of 
pericytes often results in leakage of the vessels and increased tumor cell intravasation [20]. 
Indeed, deficient pericyte coverage of the tumor vasculature in human colon carcinoma was 
associated with an increase in metastasis [21]. 
Cancer-associated fibroblasts are another group of cells found within tumors. Myofibroblasts 
are usually present in wounds and at sites of chronic inflammation and can be identified by 
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the expression of -smooth muscle actin. They may derive from locally proliferating stromal 
cells but can also descend from bone marrow-derived stem and progenitor cells [22]. Cancer-
associated fibroblasts are involved in promoting cancer cell proliferation, angiogenesis, 
invasion and migration [23,24]. Loss of HIF-1 and VEGF-A, a pro-angiogenic target gene of 
HIF-1, in cancer-associated fibroblasts accelerates tumor growth in a murine mammary tumor 
model. This loss also leads to a decrease in vascular density and myeloid cell infiltration 
correlating with improved perfusion of the tumor [25].  
Finally, the immune inflammatory cells found in tumors can play varying roles in tumor 
promotion as well as in tumor suppression functions as discussed above. Recent work 
suggests a very complex role that needs to be further explored: deletion of VEGF secreted 
from tumor myeloid cells leads to normalization of tumor vessels and unexpectedly 
accelerates tumor growth [26].  
A complex signaling network connects the different cells forming the whole tumor complex, 
and the diverse interactions are only starting to be understood. The fact that blockage of 
VEGF secreted by cancer-associated fibroblasts and myeloid cells leads to enhanced tumor 
growth might explain the modest objective responses in clinical trials after single treatment 
with anti-angiogenic drugs [27]. Therapies should therefore be developed not only to target 
tumor cells but also further components of the tumor microenvironment to optimize an 
antitumor response.  
 
 
1.2. Tumor oxygenation 
1.2.1. Tumor hypoxia 
Normal atmospheric air contains 21% oxygen which corresponds to 190 mmHg partial 
oxygen pressure (pO2) in dry air at sea level. Oxygen of inspired air has already fallen to a 
pO2 of about 100 mmHg upon reaching the alveoli. In most adult tissues pO2 pressure exceeds 
20 mmHg [28]. However, hypoxic zones can be found in different organs in the body, for 
example the inner medulla of the kidneys, with partial oxygen pressures ranging from 10–15 
mmHg [29]. Clinically relevant tumor hypoxia is reached at a pO2 below values of 5-10 
mmHg [30].  
Tumor hypoxia is mainly caused by insufficient angiogenesis or can be induced after 
treatment affecting the tumor vasculature. Abnormal angiogenesis in tumors compared to 
normal tissue was already observed in the mid-1800s by contrast agents. Later, functional 
angiogenesis was proposed to be essential for the growth of tumors by supplying enough 
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nutrients and oxygen. However, tumor vasculature is often not sufficient or functional, 
consequently leading to tumor hypoxia. Dewhirst and colleagues summarize seven features in 
tumor vasculature that influence tumor oxygenation and lead to tumor hypoxia (as displayed 
in figure 1.3.) [28].  
However, one of the most important features of tumor hypoxia is its high instability and 
cycling character. There is evidence that cycling hypoxia appears in two dominant timescales. 
The first timescale has a frequency of a few cycles per hour, whereas the second timescale has 
a period of hours or days. The cycling hypoxia with the higher frequency is mainly caused by 
changes in blood flow. The amount of circulating red blood cells can decrease in small 
networks, causing an increase of hypoxia within a period of 3 hours. Another possibility for 
fast hypoxia changes is vasodilatation of another vessel, leading to higher blood flow in the 
direction of the dilated vessel and lower flow in the parallel vessel, increasing hypoxia. This 
phenomenon might especially play a role during ongoing angiogenesis. Vasculature 
remodeling instead is responsible for the slower cycling hypoxia in which blood flow adapts 
to new vessels or intersections. 
The second form of tumor hypoxia, besides the hypoxia caused by abnormal vasculature, is 
chronic hypoxia starting at a distance of 70-100 µm from tumor blood vessels [31]. 
 
 
 
 
 
 
Figure 1.3. Regulation of tumor oxygenation by 
seven features contributing to hypoxia. (a) 
Intravascular pO2 can drop with increasing distance 
from feeding arterioles. (b) At the end of a long 
vessel, red blood cells have already lost all oxygen 
and cannot provide further oxygen to the tumor 
tissue. (c) Shunt flows redirect oxygen and nutrients 
away from the tumor. (d) Low vascular density leads 
to hypoxia due to the limitations in the diffusion 
distance. (e) Inefficient orientation of vessels leads to 
insufficient supply within the tumor. (f) Oxygen 
consumption of a tumor can increase, leading to 
insufficient supply and consequent increase in 
hypoxia. (g) Intravascular hypoxia reduces red blood 
cell deformability, increasing blood viscosity which 
in turn reduces flow rate. [28] 
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Hypoxia-inducible factor (HIF)-1 is a transcription factor composed of two subunits, the 
constitutively expressed -subunit and the oxygen-sensitive -subunit. Under hypoxic 
conditions, HIF-1 binds together with the transcriptional cofactors p300 and CBP to the 
promoter regions of target genes like VEGF, leading to their transcription [32]. Cycling 
hypoxia leads to increased activity of HIF-1 that supersedes the level of activity under chronic 
hypoxia. In particular, repeated cycles of hypoxia can lead to a total higher expression of HIF-
1 in comparison to chronic hypoxia and thus alter angiogenesis [33].  
The oxygen-sensitive -subunit (HIF-1) of HIF-1 is mainly regulated by the oxygen status 
of the cell, but also by different hypoxia independent mechanisms. Under normoxic 
conditions, HIF-1 is hydroxylated by prolylhydroxylases on proline402 and proline564 
within the oxygen-dependent degradation (ODD) domain. Hydroxylation leads to recognition 
by the von Hippel Lindau (VHL) protein, ubiquitination and subsequent degradation [34]. 
HIF-1 can also be degraded by binding to the RACK1 protein. RACK1 binds HIF-1 in 
competition with the heat shock protein Hsp90, which normally stabilizes HIF-1. Under 
normoxic conditions, the activity of HIF-1 is inhibited by hydroxylation of asparagine803 
by the factor inhibiting HIF-1 (FIH-1). This hydroxylation prevents interaction with the 
transcriptional cofactors p300 and CBP. 
However, stabilization of HIF-1 can also occur under normoxic conditions. The Akt-mTOR 
pathway stimulates translation of HIF-1 in response to different growth factors, signaling 
molecules or cytokines such as epidermal growth factor (EGF), fibroblast growth factor 
(FGF-2), insulin-like growth factor (IGF-1 and IGF-2) and interleukin 1 (IL1).  
HIF-1 is the major regulator in the hypoxic adaptive response and leads to the expression of 
several pro-angiogenic factors such as VEGF or angiopoietins (ANG-1 and -2), thereby 
promoting angiogenesis. HIF-1 is, however, also involved in several other mechanisms, 
including the blockage of proliferation by inhibiting c-myc through the Max interactor 1 
(Mxi1) and interference in the balance of pro- and anti-apoptotic proteins by regulating 
Bcl2/adenovirus EIB interacting protein 3 (BNIP3) or BCL-xL [35]. 
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1.2.2. Methods to measure tumor hypoxia 
1.2.2.1. Invasive imaging of tumor hypoxia 
Hypoxia is one of the most important parameters determining treatment response, and 
different methods have been developed to measure tumor hypoxia in an invasive and non-
invasive manner. The main invasive measurement is obtained by using the pO2 electrode.  
Invasive polarographic electrodes have been used extensively in human and animal tumors 
and are considered gold standard. The main advantage of pO2 electrodes is the exact 
determination of the partial oxygen pressure in a tissue, in particular pressures below 10 
mmHg. Determination of tumor hypoxia with this technique allowed prediction of treatment 
outcome and metastatic potential depending on the hypoxic status of the tumor. It has been 
shown that low oxygen pressures under 2.5 mmHg determined by the pO2 electrode in head 
and neck cancer is prognostic for poor loco-regional control after radiotherapy [36,37].  
Similarly, tumor hypoxia under 5 mmHg leads to a poor prognosis in both non-small cell lung 
carcinoma [38] and uterine cervix carcinoma [39]. However, the use of the electrodes requires 
localised easily accessible tumors like head and neck tumors or cervical tumors and great 
expertise. The disadvantages of this technique are its invasiveness, causing disruption of the 
tissue, and the challenge to distinguish between already necrotic tissue and hypoxic tissue. 
 
Indirect hypoxia measurement 
Tumor hypoxia can also be determined by detection of endogenous markers through 
immunohistochemistry. The most common endogenous markers are HIF-1 or HIF-1 target 
genes like Glut-1 or carbonic anhydrase 9 (CA IX).  Glut-1 is a membrane-associated glucose 
transporter that is mainly expressed in erythrocytes and endothelial cells. It is upregulated at 
low glucose concentrations and under hypoxia through the transcriptional regulation of HIF-1.  
CA IX is a membrane-associated enzyme involved in respiration and acid-base balance. It 
shows only limited distribution in normal tissue like gastric mucosa, small intestine and 
muscle but is overexpressed in many tumors.  
Both markers are widely used for hypoxia detection in tissue samples. Due to the various 
factors regulating HIF-1 independently of hypoxia, these markers often do not correspond 
with other hypoxia measurements like F-MISO PET or the pO2 electrode [40,41]. 
The described invasive measurements give only a partial view of the hypoxic status of a 
tumor. Therefore, non-invasive measurements of tumor hypoxia were developed which allow 
monitoring oxygenation status of the whole tumor. 
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1.2.2.2. Non-invasive imaging of tumor hypoxia 
PET imaging  
The most common non-invasive measurement of tumor hypoxia is positron emission 
tomography (PET) using specific imaging agents. Organic molecular markers are labeled with 
positron-emitting radioisotopes, mainly 18F, 124I and 60/64Cu, to measure tumor hypoxia (figure 
1.4.). Under severe hypoxic conditions, the different markers form stable adducts that can be 
measured with the PET scanner. Under normoxic conditions, they are rapidly reoxidized and 
removed from cells, thereby providing a good difference between normoxic and hypoxic cells 
for imaging.  
Fluoromisonidazole (F-MISO) belongs to the first generation of nitroimidazole markers used 
in PET imaging and requires hypoxic levels of less than 10 mmHg to accumulate in hypoxic 
cells. It is used in a broad range of tumors for the detection of hypoxia [42,43]. However, its 
accumulation shows a vide variation between different cancer types and patients.  Studies 
using F-MISO revealed controversial data in correlating an increase in F-MISO with an 
increase in hypoxia and with prognosis [44,45].  
Therefore, the second generation of nitroimidazoles – fluoroetanidazole (FETA), EF5 [2-(2-
nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] and 18F- 
fluoroerythronitroimidazole (FETNIM) - was developed. These nitroimidazoles have the 
advantages of being more water soluble and degraded under most of the oxidizing 
mechanisms in the body. EF5, the most stable of these derivates, showed a high specificity for 
hypoxic areas. The main disadvantage of EF5 is its complex labeling chemistry. 
Iodinated analogs, developed as hypoxic radiotracers, had low resolution and long half-lives 
requiring longer patient exposure to irradiation and are therefore not used in the clinics. 
Cu-labeled organic markers are mainly dithiosemicarbazones, especially diacetyl-bis(-
methylthiosemicarbazone) (ATSM), labeled with 60Cu-64Cu. They are reduced in living 
aerobic cells but trapped in hypoxic cells. They have shown to be effective tracers especially 
in situations were blood flow is limited. Furthermore, they revealed good correlation with 
hypoxia measurements using the pO2 electrode, and the imaging results are comparable to F-
MISO when measured at a later time point after injection [46]. Radiation emitted by 64Cu can 
cause DNA damage and induces apoptosis in hypoxic cells, 64Cu-ATSM could therefore be 
used as both an imaging and therapeutic agent [47]. However its efficacy varies between 
different tumor types.  
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Fig. 1.4. Chemical structures of hypoxia PET imaging agents [47] 
 
BOLD magnetic resonance imaging 
BOLD magnetic resonance imaging (MRI) uses the differences between oxyhemoglobin and 
deoxyhemoglobin to directly estimate pO2 by differences in the relaxation rates of the 
surrounding protons [48]. However, this technique allows only measurement of vessel 
oxygenation and not tissue oxygenation and can be easily disturbed by others factors like 
changes in blood flow, hematocrit, pH or temperature [47].  
19F Magnetic resonance imaging 
F-MRI uses different types of markers, perfluorocarbons (PFC) or fluorinated 
nitroimidazoles. The F spin lattice relaxation rate of PFCs varies linearly with the oxygen 
concentration, allowing measurement of vascular oxygen. PFCs are used for detecting 
changes in oxygen after radio-sensitizing and oxygen-augmenting treatments, but 
measurement is disturbed by changes in dilution, pH or temperature. Other disadvantages are 
slow clearance and the risk of embolism after intratumoral injection. Usage of nitroimidazoles 
instead resulted in neuropathy or central nervous system toxicity. 
Taken together, the different methods for tumor hypoxia measurement have to be considered 
for their advantages and disadvantages regarding the specific question. The most used non-
invasive imaging measurement up to now is PET using the markers FMISO or EF5. However, 
the combination of specific techniques or tracers, like injection of 18F-FMISO and 18F-
fluorodeoxyglucose (18F-FDG) to determine the hypoxic as well as the glycolytic status of a 
tumor, might give more specific results than the use of a single tracer. Nevertheless, there is 
still need for a non-invasive technique to measure hypoxia allowing the discrimination of 
acute and cycling hypoxia, as well as low oxygen concentrations in the range of 0.1 to 1% 
pO2. 
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1.2.2.3. Hypoxia measurements using in vivo bioluminescence  
Different approaches have been used to measure hypoxia using bioluminescence reporter 
systems in mouse models. In these imaging systems, cells of interest express the enzyme 
luciferase in response to hypoxia. Luciferase converts the injected substrate D-luciferin into 
oxyluciferin, thereby producing CO2, PPi, AMP and light. The light output can be measured 
and quantified with the help of an in vivo bioluminescence imaging apparatus. In a first 
approach, the promoter regions of HIF target genes were cloned in front of the luciferase 
gene. They often contained different numbers of the hypoxia response element (HRE) as 
shown in figure 1.4. These constructs were used to create stably expressing single clones or 
pools to follow the activity of HIF-1 in vitro and in vivo [40,49]. However, different factors 
influencing HIF-1 levels led to a hypoxia-independent increase or decrease of the luciferase 
signal [50]. These HRE-luciferase constructs were therefore not feasible to measure tumor 
hypoxia in vivo, showing no significant correlation between HIF-1 activity and PET 
measurement [40]. Harada and colleagues designed a new construct that displayed HIF-1 
activity even more stringently by including a part of the ODD domain fused to the luciferase 
gene. This HRE-ODD-luciferase construct is induced under HIF-1 activity and degraded in 
the same fashion as HIF-1 itself, allowing real time imaging of HIF-1 activity [51]. Tumor 
xenografts expressing the HRE-ODD-luciferase construct were used to follow HIF-1 activity 
after treatment with a HIF-1 inhibitor in combination with ionizing radiation. The data 
showed that irradiation followed by treatment with the HIF-1 inhibitor YC-1 delayed tumor 
growth, whereas the opposite order of treatment led to a suppression of the growth delay 
induced by radiotherapy [52].  
Finally, a construct was developed to follow the dynamics of the HIF-prolylhydroxylases in 
vivo. Safran and colleagues developed a mouse model expressing luciferase, fused to a part of 
the ODD domain (530 to 652 aa of HIF-1), ubiquitously. They observed emitted light after 
D-luciferin injection in the kidney, known to by slightly hypoxic, in mice breathing normal 
air. The signal increased 5-10-fold when mice were placed in a low oxygen environment (8% 
oxygen). Finally, they showed that the prolylhydroxylase inhibitor FG-4383 led to an increase 
of luciferase signal mainly in the kidney and the liver as well as an increase in the circulating 
erythropoietin (EPO) level [53]. The same ODD-luciferase construct was used in 2010 by Lu 
and colleagues to investigate the influence of hypoxia on a metastatic organotropic breast 
cancer model. They showed that hypoxia has distinct functions in the regulation of 
angiogenesis and metastases in different organ microenvironments [54]. Viola and colleagues 
used a similar ODD-luciferase construct, containing the full-length ODD domain, to measure 
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HIF-1 levels in a xenograft mouse model. They observed an increase in luciferase signal after 
treatment with chemotherapy. However, the increased signal was caused by the stabilization 
of the construct through NO-dependent nitrosylation at Cys530 caused by infiltrating 
macrophages rather than an increase in hypoxia [55]. Taking the different properties of the 
described constructs into account, the short version of the ODD-luciferase construct can be 
used for longitudinal in vivo measurement of tumor hypoxia, whereas the luciferase constructs 
containing HRE-elements are indicated for the detection of HIF-1 activity.   
 
 
Figure 1.5. Luciferase constructs. Luciferase control 
construct with a minimal promoter, HRE-Luciferase 
construct with HRE elements 5’ of the minimal 
promoter (minP), ODD-luciferase construct with a 
part of the ODD domain of HIF-1 fused 5’ to the 
luciferase gene, HRE-ODD-luciferase construct 
combining the HRE and the ODD-domain of the 
described constructs.  
 
 
 
1.3. Radiotherapy  
1.3.1. R’s of radiotherapy 
The discovery of X-rays in 1895 by Wilhelm Conrad Röntgen opened the door for radiation 
therapy, with which 50% of all cancer patients are treated nowadays. Fast accelerated 
secondary electrons – induced by the interaction of photons with matter - lead to the 
generation of reactive oxygen species (ROS) which induce permanent damage of cellular 
components like membranes, proteins or DNA [56]. The damage to DNA is, however, the 
most relevant for the intended killing of the cells [57]. DNA damage can occur in different 
forms, including the formation of intra- and inter-strand crosslinks, oxidative base damage, 
dimer formation or single and double strand breaks (DSB). In order to repair such lesions, the 
cell uses different DNA damage sensing and repair mechanisms. The most complex lesions 
for the cells to repair in order to maintain genomic integrity are DSBs, which can be repaired 
by the two most prominent repair mechanisms, non-homologous end joining (NHEJ) and 
homologous recombination (HR). NHEJ is an error-prone repair mechanism that rejoins free 
ends of DSBs without requiring homologous bases at the end of the breaks. Therefore, NHEJ 
is often accompanied with deletion and loss of genetic information. Since NHEJ does not use 
homologous sister chromatids for repair, it is the most prominent repair mechanism in the G1 
and early S phases of the cell cycle. HR instead is an error-free repair mechanism. This repair 
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mechanism uses the homologous sister chromatid as a template for repair and therefore 
operates in the late S and G2 phases of the cell cycle [58]. The main DNA damage in normal 
tissue is repaired within 6 hours after irradiation, therefore fractionated irradiation could be 
applied in a smaller window than the conventional 1 fraction/day. Different studies compared 
hyperfractionated irradiation with 2 smaller fractions/day with the conventional irradiation 
schedule of 1 fraction/day. Hyperfractionated irradiation achieved in cancer cases of advanced 
stages a better local control than the conventional irradiation regimen [59,60]. 
Radiobiologists have defined a set of specific factors that comprise cellular and tissue 
response to irradiation. Considering these biological response mechanism factors, 
radiotherapists can minimize the normal tissue toxicity while increasing the radiation response 
of a tumor. The first of the so-called 4 R’s of radiotherapy is the above-described Repair, 
which leads to the restoration of the damaged macromolecules and especially DNA. The 
second R of radiotherapy is Redistribution/Reassortment, describing the cellular response on 
the level of the cell cycle. The cellular sensitivity towards ionizing radiation differs depending 
on the cell cycle. The most sensitive phase of the cell cycle is the M phase. The obtained 
DNA damage is passed over to daughter cells, leading to mitotic catastrophe and cell death. 
The G2 phase is considered as a radiosensitive phase as well, whereas G1 and especially late S 
phase are the most radioresistant phases. IR induces cell death in the radiosensitive cell cycle 
phases, whereas cells in the radioresistent phases will consequently progress to a more 
sensitive phase after DNA repair. Fractionated irradiation therefore leads to synchronization 
of the surviving cells sensitizing them to the next treatment fraction.   
The Repopulation of the surviving fraction of tumor cells after IR is one of the major 
challenges in radiotherapy. Tumor cells might repopulate even after a fractionated treatment 
regime, starting to reform the tumor. Therefore, a fractionated treatment regimen should be 
conducted without unnecessary interruptions. Treatment with IR can lead to an increase in 
cell proliferation in some tumors like head and neck squamous cell carcinoma [61]. Therefore, 
molecular-targeted agents are used to reduce repopulation during radiotherapy. The most 
prominent target is the epidermal growth factor receptor (EGFR) which is often 
overexpressed in tumors. The use of specific therapies targeting EGFR in a combined 
treatment modality with IR will be described later in the introduction. Another example is the 
aurora kinase B inhibitor AZD1152-HQPA, which inhibited the repopulation of two different 
non small cell lung carcinoma cell lines in vitro when combined with fractionated irradiation. 
The aurora kinases control the cellular mitotic progression and their activity is frequently 
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upregulated in cancer cells [62]. Aurora inhibitors might therefore be a promising agent for 
the control of repopulation in a concomitant treatment regimen with IR.   
The last R of radiotherapy is the Reoxygenation of the surviving tumor cells after treatment. 
Radiosensitivity decrease with increasing hypoxia, leading to a two to three times higher 
radiation resistance of hypoxia cells compared to well-oxygenated tumor cells. Irradiation 
induces cell death in oxygenated tumor cells, subsequently leading to improved oxygenation 
of the hypoxic surviving tumor cells. The reoxygenated cells are afterwards more 
radiosensitive to the next dose of irradiation in a fractionated radiation set-up. Reoxygenation 
and Reassortment are therefore beneficial for radiotherapy, whereas Repair and Repopulation 
hamper radiotherapy [63].  
Of major concern in the field of radiotherapy are the cancer stem cells, which exhibit high 
levels of radioresistance. Cancer stem cells escape the damage by irradiation by various 
mechanisms. They are in a quiescent state of the cell cycle and therefore not cycling into a 
radiosensitive phase. Cancer stem cells further exhibit an enhanced repair of DNA by 
increased activation of the NHEJ repair mechanism through ATM signaling compared to non-
tumoral stem cells. Additionally, cell cycle control mechanism to arrest the cell cycle in order 
to allow DNA repair are upregulated. Furthermore, cancer stem cells contain a higher activity 
of ROS-scavenging enzymes therefore minimizing the induced DNA damage [64]. Different 
strategies to overcome these radiation mechanisms are currently under investigation. 
Targeting specific signaling pathways of the cancer stem cells [65] or the use of radiation 
therapy with heavy particles like carbon ions might be more indicated for cancer stem cells 
than classic irradiation with photons [66]. 
Both, the R’s of radiotherapy as well as the hallmarks of cancer describe factors related to the 
phenotype and the treatment response of a tumor. While the R’s of radiotherapy derive from 
perspectives of “Clinical Radiation Biology and Radiotherapy”, the Hallmarks of Cancer 
derive from “Molecular Oncology”. It is a challenge to “reconcile” these two different worlds, 
but eventually a chance to identify novel treatment regimens and molecular processes as 
targets for a combined treatment modality of ionizing radiation with antisignaling agents. 
 
1.3.2. Tumor hypoxia in radiotherapy 
Tumor hypoxia hinders effective radiotherapy in several ways. Radiotherapy induces free 
radicals, including ones in close proximity to DNA. Oxygen fixes the damage by oxidizing 
DNA radicals, therefore inducing a permanent damage. Under hypoxic conditions, DNA 
radicals are reduced by components containing SH groups, which repair the DNA damage to 
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its original form [31]. Therefore, radiosensitivity is progressively reduced when the pO2 in a 
tumor is below 15-20 mmHg resulting in a two to three fold higher radioresistance of hypoxic 
tumors. A low partial pressure (< 5-10 mmHg) determined with invasive pO2 electrodes prior 
treatment revealed a strong correlation with poor locoregional control in non-small cell lung 
and uterine cervix carcinoma [38,39]. Therefore, tumor hypoxia can in some cases be used as 
surrogate marker or treatment outcome after radiotherapy. 
The cellular radioresistance under hypoxia is mediated by the HIF-1 protein and is described 
as follows. Radiation of a solid tumor activates HIF-1, which in turn leads to the expression of 
VEGF. VEGF protects endothelial cells from further damage by radiation, allowing vessels to 
continue providing tumor cells with nutrients and oxygen. This model is supported by the fact 
that the supernatant of irradiated tumor cells protects endothelial cells from irradiation 
[31,67]. Moreover, data by Harada et al. demonstrated that the concomitant treatment 
modality of IR with the HIF-1 inhibitor YC-1 impaired the post-irradiation induced 
upregulation of HIF-1, consequently leading to a decrease in microvessel density in a 
xenograft model. The concomitant treatment regimen further resulted in a stronger tumor 
growth delay when compared to the treatment with IR alone [52]. 
After irradiation, HIF-1 distribution changes dramatically due to the induced changes in the 
microenvironment. Oxygenation of hypoxic regions in the tumor improves due to death of the 
well-oxygenated tumor cells. It was shown that HIF-1 activity decreases in the first hours 
after IR and increases again afterwards [52]. The later increase in HIF-1 can be explained by 
an increase in secreted nitric oxide (NO) of tumor-associated macrophages caused by the 
reoxygenation of tumor cells after IR. NO in turn leads to S-nitrosylation of HIF-1 at 
cysteine520 in the ODD domain, consequently stabilizing the protein [68]. Furthermore, HIF-
1 stabilization after reoxygenation occurs due to the release of HIF-1 transcripts from 
stress granules, consequent translation of the protein and nuclear accumulation of HIF-1 in 
response to ROS formation [69]. 
Therefore, different approaches have been tried to overcome the treatment resistance caused 
by hypoxia. To overcome the lack of oxygen, investigators tried increasing the level of 
oxygen in the breathing air of patients or increasing the amount of red blood cells [70,71]. 
While these approaches showed promising results in preclinical studies, they did not made it 
into the clinics due to controversial results in clinical trials. To address radioresistance caused 
by HIF-1 the use of specific HIF-1 inhibitors like YC-1 or the regulation of key factors that 
control the expression of HIF-1was employed [52]. The radiosensitizing properties of 
PI3K-Akt-mTOR pathway inhibitors are related, in part, to the inhibition of HIF-1. The 
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specific mTOR inhibitor RAD001 showed a downregulation of the HIF-1 protein and its 
downstream products in a mouse model for prostate cancer [72]. Nevertheless, HIF-1 
inhibitors are still mainly in preclinical studies. 
 
 
1.4. Microtubules as target for cancer therapy 
1.4.1. The microtubule network 
The cytoskeleton is a cytoplasmic system of fibers, which is critical for different cell 
functions like motility, organization of cell contents and cell shape. The different fibers 
forming the cytoskeleton are microfilaments, intermediate filaments and microtubule, which 
are all built up of small protein subunits. Microfilaments and intermediate filaments are 
attached to plasma membrane proteins thereby supporting the shape of the plasma membrane. 
Microfilaments, built up of G-actin monomers to form F-actin polymers, and microtubule are 
responsible for cell movements and cell shape. Motor proteins from the kinesin and dynein 
families are moving along the microtubule or microfilaments to ferry organelles or vessels. 
Many cell movements require, however, cytoskeleton rearrangement, which is reached by 
assembly and reassembly of the cytoskeleton fibers. 
Microtubules are dynamic polymers, which form rope like structures that can grow as long as 
25 micrometers. The  tubulin heterodimer are arranged head-to-tail to form linear 
protofilaments that associate laterally to a hollow like tube with a diameter of 25nm. 
Microtubules are usually formed by 13 protofilaments. Every tubulin heterodimer binds two 
guanosine triphosphates (GTP). The GTP bound to the -subunit is not exchangeable and 
trapped between the -tubulin and the -tubulin. The -tubulin instead binds the GTP 
reversible and hydrolyses it to GDP during polymerization. The GDP bound to the -tubulin 
is not exchanged while the -tubulin remains in the polymer. However, -tubulin exposing 
GDP at the end of a microtubule leads to depolymerisation of the microtubule. The GTP cap 
model describes a layer of -tubulin containing unhydrolyzed GTP, which stabilizes the 
microtubule structure. Microtubules contain a dynamic plus end with an exposed -tubulin 
and a less dynamic minus end characterized by an exposed -tubulin. Microtubule form a 
well organized network in which the minus end is usually anchored at the microtubule-
organizing center (MTOC) like the centrosome whereas the plus pole grows towards specific 
targets [73,74].   
-tubulin exists in 7 isotypes that are expressed in a tissue specific manner. The I- and IV-
tubulins are expressed constitutively in all main cell types, whereas II- and III-tubulins are 
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mainly expressed in neurons. III-tubulins have also been found in different tumors and have 
been associated with aggressiveness and invasiveness. The V-tubulin is mainly expressed in 
the uterus and endometrium, but has also been found in adenocarcinomas. VI-tubulin can be 
found in hepatopoesis-specific cells. 
Further members of the tubulin superfamily include γ, δ, ε, ζ and η-tubulin. The γ-tubulin 
plays an important role in the microtubule nuclearisation, whereas the function and the 
interactions of the other tubulins have been associated with the centrosome or other MTOCs 
[75]. 
Different microtubule-associated proteins organize microtubules and affect their stability. 
Microtubule stabilizing proteins found in most cells are the microtubule associated protein 4 
(MAP4) which is regulating microtubule stability in mitosis and cytoplasmic linker protein of 
170 kDa (CLIP170), which cross-links microtubules to chromosomes. Further proteins 
stabilizing microtubules are MAP1, MAP2 and Tau which are mainly found in dendrites and 
axons. The microtubule binding domain of these proteins contains several repeats of a 
conserved positively charged amino-acid-sequence binding to the negatively charged C-
terminal of tubulin. Due to this binding the charge repulsion of tubulin subunits in a 
microtubule is reduced. Binding of MAPs to the outer wall of a microtubule hinders the 
dissociation of tubulin subunits from the microtubule. MAPs are regulated by reversible 
phosphorylation of MAP kinases or cyclin-dependent kinases (CDKs). Phosphorylation of the 
MAPs impairs binding to microtubule consequently promoting microtubule disassembly [73]. 
Microtubule destabilizing proteins are for example katanin and stathmin. Katanin leads to 
breakage of the internal bonds between tubulin subunits causing the fragmentation of 
microtubules or dissociation from the MTOC. Stathmin instead binds tubulin dimers thereby 
reducing the amount of dimers needed for polymerization [76].  
Microtubules are modified by diverse reversible post-translational modifications such as 
phosphorylation, tyrosination, acetylation, polyglutamylation or polyglycylation. Acetylation 
and deacetylation are involved in the regulation of cell motility by influencing the binding of 
MAPs to microtubule. Polyglutamylation is as well involved in the interaction of microtubule 
and MAPs, but leads further to centriole maturation and stability. However, most of the 
biological functions of these modifications are not yet fully understood [77].  
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1.4.2. The cellular functions of microtubule 
Generation of movements by assembly and disassembly of the microtubule, as well as the 
interaction with motor proteins are highly important to execute the different functions of the 
microtubule network such as the separation of chromosomes during mitosis, organelle 
trafficking or cell motility. Motor proteins of the kinesin and dynein families were found to 
interact with microtubules. Motor proteins utilize the energy of ATP hydrolysis to move 
unidirectly along the microtubule. Most of the kinesins move towards the plus end of a 
microtubule whereas dyneins move in the direction of the minus end. The motor proteins 
usually contain two motor subunits which bind to the microtubule and hydrolyze ATP, and 
regulatory subunits. The cargo is bound to either of the subunits. Cargo of motor proteins 
consists of endosomes moving towards lysosomes, trans-Golgi network-derived vesicles or 
mitochondria. However, motor proteins also transport non-vesicular cargo such as 
cytoplasmic protein complexes, RNA-protein complexes, ribosomes or cytoskeletal polymers. 
Besides their function in cargo transport, motor proteins also play a role in cell signalling. 
Kinesin-1, one of the most prominent motor proteins for anterograde transport in the cell, acts 
also as a scaffolding protein which recruits active kinase complexes to vesicle-associated 
kinesin-1 linkers. Kinesin-4 (KIF4A) instead regulates neuronal survival by the suppression 
of the enzymatic activity of poly (ADP-ribose) polymerase-1 (PARP-1) [78]. 
Another highly important role of microtubules and the associated motor proteins lies in the 
separation of chromosomes during mitosis. Aster microtubules are forming the asters around 
the centrosomes whereas the polar and kinetochore microtubules form the spindle. 
Kinetochore microtubules attach at the kinetochore of the chromosome and transport them by 
forces generated by spindle kinesins as well as by shortening of the microtubule to the 
metaphase plane. Dyneins instead walk along astral microtubules which are attached to the 
plasma membrane thereby pulling the poles outward. The correct attachment of the 
microtubule originated from the two different centromeres to the kinetochore is monitored by 
different proteins. The key regulator ensuring the accuracy of the correct attachment is the 
Aurora B kinase [79]. Aurora B kinase is therefore one of the targets of anti-cancer drugs 
aimed to interfere with cell division.  
Furthermore, microtubules play an important role in cell motility. In order to initiate 
migration the microtubule network gets first polarized with detyrosinated microtubules 
aligning in the direction of the front-rear axis of cells. The microtubule network restricts actin 
polymerization, regulates focal adhesions in cells and locally regulates the activity of Rho 
GTPases which are known to regulate actin cytoskeleton. A good coordination between 
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microtubule, actin and focal adhesions are therefore essential for cell migration. Indanocine, a 
microtubule destabilizing agent led to an increased acetylation of microtubules, defects in cell 
polarization and defects in adhesion disassembly consequently reducing cell migration [80].  
The dynamic instability of the microtubule network is crucial for its proper function in cell 
division, cell shape maintenance, motility and intracellular organelle trafficking, which makes 
microtubules an attractive target in anti-cancer treatment.  
 
1.4.3. Microtubule interfering agents 
Microtubules are one of the most successful targets of anticancer drugs, the so-called 
microtubule interfering agents [81]. Microtubule interfering agents can be divided in two 
classes, microtubule destabilizing and microtubule stabilizing agents. Microtubule 
destabilizing agents inhibit the assembly of tubulin heterodimers into microtubules. Most of 
the microtubule destabilizing agents bind at two distinct domains to the tubulin, the vinca 
domain or the colchicine domain. Substrates binding to the vinca domain are vinca-alkaloids 
(vincristine, vinblastine), dolastatins (eribulin, spongistatin) or cryptophycins. Substrates 
binding to the colchicine domain include colchicine, steganacins and curacins. Vinca 
alkaloids bind mostly to the microtubule ends whereas colchicine binds to soluble dimers 
which are incorporated into the microtubules [74]. The most well-known members of this 
group are vincristine and vinblastine, which have been used in anticancer treatments since the 
1960s. 
Microtubule stabilizing agents (MSA) promote the polymerization of tubulin heterodimers 
into microtubules and stabilize preformed microtubules. Most of the MSAs bind to the same 
or to an overlapping taxoid binding site on the -tubulin located on the inside surface of the 
microtubule. MSAs impair the dynamic instability of the microtubule network, leading to 
defective mitotic spindle formation [82,83] or at lower concentrations to G1-arrest [84] 
followed by apoptosis [85]. The altered microtubule network also leads to a reduction of cell 
invasion and migration [86,87]. MSAs include taxanes, epothilones, discodermolide, 
cyclostreptin, laulimalide, rhazinilam and further substrates.  The first FDA approved agent in 
the group of taxanes was taxol (paclitaxel) in 1992 followed by its related analogue docetaxel 
in 1996. However, treatment with taxanes is often limited by the development of resistance 
towards the drug and taxane-related toxicities [88].  
Therefore, epothilones, a non-taxoid group of MSAs, are gaining more and more interest 
because of their tolerable toxicity profile [89], activity against P-glycoprotein-mediated 
multidrug resistance and better water solubility in comparison to taxanes.  
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Epothilones were initially discovered for their anti-fungal properties in a screen using extracts 
of the myxobacterium Sorangium cellulosum Soce90 [90], and shortly afterwards their ability 
to inhibit tumor cell proliferation was described. Epothilones share the same binding site on 
-tubulin with taxanes, which is in close proximity to residue Thr274 on –tubulin [91]. At 
least seven epothilone-derived agents are in clinical trials for cancer treatment, with the two 
most promising compounds being Ixabepilone and Patupilone (EPO906). Ixabepilone is the 
first FDA approved agent in this group for treatment of metastatic breast cancer [92]. 
Patupilone was tested as a phase III monotherapy agent against ovarian cancer and has passed 
a phase I trial for CNS malignancies with concurrent radiotherapy [93]. 
 
 
Figure 1.6. Chemical structures of MSA agents [94] 
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1.5. Combined treatment modalities 
Besides technical improvements in the field of radiotherapy, radiobiologists aim to enhance 
the tumor growth control of cancer treatment by sensitizing cells to radiotherapy using 
different chemotherapeutic agents. The rationale behind the combined treatment is the use of 
drugs that influence the different features induced by radiotherapy (R’s of radiotherapy) to 
generate a better treatment response. As discussed above, IR results in the strongest inhibition 
of proliferation in cells in specific phases of the cell cycle. It has been shown that the MSA 
Patupilone accumulates cells in the radiosensitive G2/M phase. The combined treatment 
modality of IR and Patupilone led consequently to an additive tumor growth delay in 
xenograft mouse models [95]. A further approach in the combined treatment modality is the 
blockage of repopulation, especially by inhibition of EGFR. Overexpression of EGFR is a 
common feature of head and neck cancer leading to accelerated tumor growth. Activation of 
EGFR by EGF or transforming growth factor  (TGF) triggers the downstream pathways of 
PI3K, Ras/MAP kinase and STAT-3, leading to increased proliferation. It has been shown 
that IR leads to dimerization and therefore activation of EGFR [96]. Combination of IR with 
the clinically relevant anti-EGFR monoclonal antibody C225 (Cetuximab) in a phase III trial 
demonstrated significant locoregional tumor control, minimal tissue toxicity and an increased 
overall survival [97,98]. This overall strong tumor growth control results not only from 
inhibition of repopulation but also from inhibition of DNA damage repair and blockage of 
VEGF and therefore inhibition of angiogenesis by EGFR inhibition [99,100]. 
Modulation of the microenvironment, especially the tumor vasculature, is another target for 
anticancer agents. Blockage of the vasculature will lead to decreased delivery of nutrients, 
growth factors and oxygen and therefore impair tumor growth. Anti-angiogenic agents are 
thought to also decrease metastatic spreading, and the risk of treatment resistance of 
endothelial cells is lower than for tumor cells that have already acquired several mutations.  
Anti-angiogenic agents directly block pro-angiogenic growth factors or their respective 
receptors on endothelial cells, or decrease the secretion of pro-angiogenic factors by tumor 
cells. Another aspect of anti-angiogenic agents, however, is the so-called normalization of the 
tumor vasculature. This phenomenon is caused by destruction of immature vessels and the 
recruitment of pericytes and therefore fortification of intact vessels after treatment with anti-
angiogenic agents [101,102]. Interestingly, the combined treatment of anti-angiogenic agents 
and cytotoxic agents provided improved results over the single treatments alone [103].  The 
concept of the normalization of blood vessels under treatment with anti-angiogenic agents 
renders the combination with ionizing irradiation an attractive strategy for cancer treatment. 
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The oxygenation of tumor cells improves due to vessel normalization leading to a higher 
responsiveness to IR. The combination of anti-VEGFR2 antibodies and IR has been shown to 
significantly enhance the tumor growth retarding properties of IR [104,105]. The same holds 
true for the combined treatment of an anti-VEGF antibody in combination with IR [67,106].  
However, there are still concerns about this combined treatment modality due to the fact that 
both treatments can also induce tumor hypoxia. IR, in fact, possesses both angiogenesis 
promoting and anti-angiogenic properties. The anti-angiogenic effect is caused by the high 
radiosensitivity of endothelial cells, consequently leading to endothelial cell death and an 
increase in hypoxia. The angiogenesis promoting effect is caused by a growth factor-
independent activation of the VEGF receptor on endothelial cells and increased VEGF 
secretion of tumor cells as a stress response towards IR [67]. An approach to overcome these 
restrictions might lie in the scheduling of the different treatments. Treatment schedules with 
an adjuvant application of the anti-angiogenic agent resulted in a prolonged tumor growth 
delay [107], while simultaneous application of the anti-angiogenic agent and IR in a study 
with murine mammary carcinoma also resulted in a prolonged tumor growth delay [105]. 
These results indicate that the combination of IR with anti-angiogenic agents can be 
considered a promising strategy and that further investigations on scheduling could result in 
even better tumor control, paving the way for clinical trials.  
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2. Aims of the study 
 
The combined treatment of ionizing irradiation (IR) and microtubule stabilizing agents (MSA) 
has been shown to be an effective strategy for cancer treatment in preclinical models [95,108]. 
Our group previously demonstrated that the microtubule stabilizing agent patupilone 
combined with IR inhibited tumor cell proliferation in vitro in an additive manner, whereas 
the combined treatment revealed an even supra-additive tumor growth delay effect [95]. 
MSAs sensitize tumor cells towards IR by the accumulation of the cells in a radiosensitive 
cell phase. However, MSAs can also lead to a decrease in the HIF-1 protein level, the major 
transcription factor under hypoxia, in cells treated with high dosages of MSA [109]. MSAs 
might therefore also affect the tumor microenvironment, especially the tumor vasculature, by 
interfering with secretion of pro-angiogenic factors, mostly HIF-1 target genes.  
The first aim of this study was to investigate the effect of patupilone and IR, alone and as part 
of a combined treatment modality, on different tumor cell lines in vitro and on tumor 
xenografts, with a specific focus on the tumor microenvironment. A genetically defined tumor 
cell system was used, which consists of the non-small cell lung carcinoma cell line A549 and 
its patupilone-resistant counterpart A549.EpoB40. This cell pair was used to investigate the 
effect of the combined treatment modality on the tumor cell level as well as on the level of the 
tumor microenvironment. The in vitro studies of different cell lines included the analysis of 
tumor cell proliferation, clonogenicity and cell cycle distribution in response to the different 
treatment modalities. Furthermore, the expression and secretion of HIF-1 target genes were 
analyzed under the different treatment modalities. In vivo experiments of tumor xenografts 
derived from different cell lines aimed to analyze the tumor growth delay induced by the 
different treatment modalities and the impact of the treatments on the tumor vasculature by 
analyzing microvessel density.  
 
DNA-damage is the most relevant damage induced by ionizing radiation. The damage is 
caused by the formation of intracellular reactive oxygen species (ROS) and their interaction 
with the DNA. The reduced oxygen content in hypoxic tumor cells is therefore a major reason 
for a two to three fold increase in radiation resistance. Hypoxic conditions can be caused by 
insufficient angiogenesis due to rapid tumor growth or limited oxygen diffusion or perfusion. 
Furthermore, the oxygen content in a tumor can also be shifted in response to different 
treatment modalities such as inhibitors of angiogenesis. Thus, combined treatment of ionizing 
radiation with compounds affecting the tumor vasculature could create an additional risk for 
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an effective radiotherapy due to treatment-induced hypoxia. Detailed insights into the 
dynamics of tumor hypoxia might contribute to the improvement and adaptation of existing 
therapies to changes in the tumor microenvironment.  
The second aim of this study was therefore to investigate changes of hypoxia, during and in 
response to different treatment modalities in vivo. For this purpose, a bioluminescence-based 
system, leading to the expression of the reporter gene luciferase in response to increasing 
hypoxia, was first developed and validated in vitro. Major requirements were a stable signal 
induction under hypoxia and luciferase expression, which is not perturbed by 
chemotherapeutic agents altering the HIF-1 activity. The in vivo research part was performed 
using a murine xenograft tumor model expressing the developed reporter construct, which 
allowed serial determination of tumor hypoxia. The main focus was to probe the dynamics of 
tumor hypoxia in response to IR, patupilone and the combined treatment modality. This 
system allowed us to evaluate the dynamics of tumor hypoxia as surrogate marker for the 
respective treatment modalities.  
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Abstract 
Tumor hypoxia is one of the most important parameters that determines treatment sensitivity, 
and is mainly due to insufficient tumor angiogenesis. However, the local oxygen 
concentration in a tumor can also be shifted in response to different treatment modalities such 
as cytotoxic agents or ionizing radiation. Thus, combined treatment modalities including 
microtubule stabilizing agents could create an additional challenge for an effective treatment 
response due to treatment-induced shifts in tumor oxygenation. Tumor hypoxia was probed 
over a prolonged observation period in response to treatment with different cytotoxic agents, 
using a non-invasive bioluminescent ODD-Luc reporter system, in which part of the oxygen-
dependent degradation (ODD) domain of HIF-1 is fused to luciferase. As demonstrated in 
vitro, this system not only detects hypoxia at an ambient oxygen concentration of 1% O2, but 
also discriminates low oxygen concentrations in the range from 0.2 to 1% O2. Treatment of 
A549 lung adenocarcinoma-derived tumor xenografts with the microtubule stabilizing agent 
patupilone resulted in a prolonged increase in tumor hypoxia, which could be used as marker 
for its antitumoral treatment response, while irradiation did not induce detectable changes in 
tumor hypoxia. Importantly, despite patupilone-induced hypoxia, the potency of ionizing 
radiation (IR) was not reduced as part of a concomitant or adjuvant combined treatment 
modality.  
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Introduction 
Hypoxia is one of the most important parameters that cause enhanced tumor aggressiveness 
and treatment resistance, and hypoxia is now considered to be an independent prognostic 
indicator of poor outcome for different tumor entities. Alternating periods of hypoxia and 
normoxia in the tumor support the selection of tumor cells with elevated mutation frequency 
with a more stress resistant and aggressive phenotype. Independent of the cellular genotype, 
hypoxic cells are more treatment resistant than normoxic cells, in particular towards ionizing 
radiation (IR). Irradiation of cells leads to the formation of reactive oxygen species (ROS), 
which induce cytotoxic DNA damage. Furthermore the oxygenation fixation theory implies 
that radiation-induced free radical sites in the DNA are chemically derivatized (“fixed”) in the 
presence of oxygen so that they can not be repaired and accumulate, leading to an enhanced 
rate of cell death. Thereby normoxic cells are two- to three-fold more radiation sensitive than 
cells under hypoxia [1,2].  
Tumor hypoxia is mainly caused by insufficient tumor angiogenesis and oxygen supply 
during tumor growth, however, the oxygen content in a tumor can also be shifted in response 
to different treatment modalities such as cytotoxic agents acting on the tumor vasculature. 
Therefore, the combination of cytotoxic agents, provoking an increase in tumor hypoxia, with 
ionizing irradiation may impact treatment efficiency. We previously investigated various 
combined treatment modalities with regard to changes in tumor hypoxia, e.g. VEGF-receptor 
tyrosine kinase inhibitors in combination with IR [3,4]. Furthermore the tumor- and tumor 
vasculature targeting, clinically relevant microtubule stabilizing agent (MSA) patupilone 
(epothilone B) induced an at least additive antitumoral effect when combined with IR [5,6] 
raising the question on the dynamics of patupilone-induced hypoxia and the combination 
scheduling with IR.  
MSAs belong to the most important classes of anti-cancer agents with taxanes being approved 
for a broad range of indications including single treatment for non-small cell lung carcinoma 
or advanced breast cancer [7,8]. The epothilones are nontaxoid macrolide MSAs of bacterial 
origin, which share the same binding site on -tubulin (in close proximity to residue Thr274) 
with taxanes [9,10,11]. Clinically different epothilone derivatives are currently in various 
stages of development as antitumor compounds [12]. Ixabepilone (Ixempra®) is the first 
approved compound in this class and indicated as monotherapy or in combination with 
capecitabine for the treatment of patients with metastatic breast cancer. Apart from a 
manageable safety profile, ixabepilone demonstrates anti-tumor activity after failure and 
resistance towards anthracycline and taxane standard therapy [13]. 
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Epothilone B (patupilone) was tested as a phase III monotherapy agent against ovarian cancer 
and other epothilones are undergoing a wide spectrum of single and combined treatment 
modality in phase II studies (e.g. for recurrent glioblastoma, CNS metastases from breast 
cancer, prostate, cervical, renal cell, gastric and lung tumors, as well as non-Hodgkin’s 
Lymphoma (www.cancer.gov) [13,14,15,16,17]. 
MSAs impair the dynamics of the microtubule network, leading to defective mitotic spindle 
formation and accumulation of cells in the G2/M-phase of the cell cycle [11,18] or at low 
concentrations to transient G1-and S-phase arrest [5,19], followed by apoptosis-induction 
[20]. An MSA-altered microtubule network also reduces the cellular migration and invasion 
capacity [21,22]. Furthermore the potential of MSAs to accumulate cells in the radiosensitive 
G2/M phase renders them potent sensitizers [23] for the combined treatment with ionizing 
radiation [5,6,24]. 
The hypoxia-inducible transcription factor HIF-1 is a heterodimer composed of an oxygen-
sensitive alpha subunit and a constitutively expressed beta subunit. HIF-1 binds to the 
hypoxia response element (HRE) in the promoter region of diverse target genes such as 
VEGF and induces their expression [25]. Under normoxic conditions the alpha subunit is 
hydroxylated on proline402 and proline564 in the oxygen dependent degradation (ODD)-
domain of HIF-1 by prolyl hydroxylase domain (PHD) proteins. Proline hydroxylation leads 
to the recognition by the von Hippel-Lindau tumor suppressor and subsequent ubiquitination 
and proteasomal degradation [26].  
Tumor hypoxia has previously been probed using different luciferase-based bioimaging 
reporter constructs, which are either based on luciferase expression under the control of an 
HRE-based promoter system or on the fusion of extended or shorter ODD-domains to the 
reporter gene [27,28,29]. The HRE-based approach depends on intact HIF-signaling, 
however, several classes of antisignaling agents including microtubule stabilizing agents 
interfere with the activity of HIF-1-upstream elements or the direct expression of HIF-1, 
independent of the pO2 [6,30,31,32,33,34]. We therefore did not use an HRE-based but a 
minimal ODD-based in vivo-bioimaging reporter approach, which demonstrated high 
sensitivity even in the range of low pO2-levels, to serially probe the dynamics of tumor 
hypoxia in response and in relation to the antitumor effect of the microtubule stabilizing agent 
patupilone and ionizing radiation, alone and as part of the combined treatment modality. 
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Materials and Methods 
Cell culture  
The human colon carcinoma cell line HCT116 was obtained from Bert Vogelstein [35] and 
the lung adenocarcinoma cell line A549 from Susan Band Horwitz [36]. All cell lines were 
kept at 37ºC in 5% CO2. The cell line HCT116 was grown in McCoy medium containing 10% 
(v/v) fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin. The cell line A549 
was grown in RPMI 1640 containing 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 100 
μg/ml streptomycin and 2 mM L-glutamine. Patupilone (epothilone B, EPO906) was provided 
by the chemistry department of Novartis Pharma AG (Basel, Switzerland). 
 
Vector construction  
The plasmid SV40-pGl4.27 was obtained by inserting the SV40 promoter of pGl3control 
(Promega Corporation, Madison, WI, USA), cut with the restriction enzymes KpnI and 
HindIII, into the pGl4.27 vector (Promega Corporation) containing the luciferase gene 
including a 3’PEST sequence for rapid degradation and turnover of the luciferase protein. An 
additional NarI restriction site was inserted in the pGL4.27 plasmid at position 174 by site 
directed mutagenesis. The ODD-domain of HIF-1 was amplified by PCR from the pcDHIF 
plasmid (kindly provided by R.Wenger) as described in Safran et al, 2005 [37]. The product 
was cloned into the pGL3 basic vector (by HindIII and NarI) and finally inserted into the 
SV40-pGl4.27 vector, containing the additional NarI-site, to obtain the vector construct 
SV40-ODD-pGl4.27. To obtain the plasmids SV40-pGL4.26 and SV40-ODD-pGL4.26, the 
SV40 promoter or the SV40-ODD sequence was subcloned from the respective pGL4.27 
plasmids cut by KpnI and BsrG1 into the pGL4.26 backbone (Promega Corporation).  
 
Stable transfection, reporter gene assay and Western blot analysis  
HCT116 cells were stably transfected with the SV40-ODD-pGL4.27 plasmid and the A549 
cells were stably transfected with the SV40-ODD-pGL4.26 or the SV40-pGL4.26 plasmid by 
lipofection (Lipofectamine™ 2000 system; Invitrogen, Carlsbad, CA, USA) following the 
manufacturer's instruction. Stable single clones of hygromycin selected pools were selected 
for the highest induction of luciferase activity after 8 hours of hypoxic conditions. The 
reporter gene assay was performed as described by Rohrer Bley et al, 2009 [6]. Hypoxic 
conditions were mimicked by the prolyl hydroxylase inhibitor dimethyloxalylglycine 
(DMOG) (Biomol GmbH, Hamburg, Germany) at a concentration of 0.25 mM or CoCl2 (0.25 
mM). Alternatively, cells were incubated under different pO2 in the hypoxic chamber 
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(Invivo2 400 hypoxia workstation, Biotrace International, Bridgend, UK). Cells were allowed 
to attach for 8-10 hours before addition of patupilone. Hypoxic conditions were applied 24 
hours after patupilone treatment and luciferase activity was determined 8 hours thereafter. 
Western blot analyses were performed as described by Rohrer Bley et al, 2011 [38]. 
 
Hypoxyprobe-1 immunofluorescence  
A549 cells were seeded on glass cover slips and allowed to attach overnight. Medium was 
exchanged and cells were incubated with 150 µM hypoxyprobe-1 (HPI, Burlington, MA, 
USA) for 3.5 hours under normoxic or hypoxic conditions. Culture slides were washed with 
phosphate buffered saline (PBS), fixed in 4% formaldehyde for 10 minutes at RT. Cells were 
washed and permeabilized with 0.2% Triton X-100 buffer on ice for 10 minutes. Cells were 
washed and autofluorescence was quenched with 0.3 M glycin for 5 minutes. After 
preincubation with 3% BSA in PBS at RT for 30 minutes, cells were incubated with the 
fluorescein isothiocyanate (FITC)-labeled monoclonal antiHypoxyprobe-1 monoclonal 
antibody (mAb1) in 3% BSA/PBS, (HPI), at RT in the dark for 1 hour. DNA was 
counterstained with DAPI (1:2500 DAPI stock solution (1 mg/ml) in PBS Sigma) for 15 
minutes at RT. Cells were finally washed with PBS. Images were captured by fluorescence 
microscopy using a CCD camera (Leica DM6000B equipped with Leica CTR6000). 
 
Tumor xenograft in nude mice and application of treatment regimes  
Stably transfected HCT116 cells (4 x 106) and A549 cells (7 x 106) were subcutaneously 
injected on the back of 4- to 8-week old athymic nude mice. Tumors were allowed to expand 
to a volume of 300 mm3 (± 10%) or 200 mm3 (± 10%) before treatment start. Tumor volumes 
were determined as described elsewhere [6]. The group sizes ranged from n = 7-12 for the 
HCT116-xenograft experiments, from n = 3-5 for the A549-Luc only and CoCl2-control 
experiments, and n = 5-16 for all other experiments. Patupilone (dissolved in 30% PEG-300 / 
70% saline) was applied i.v. at a concentration of 2 mg/kg and CoCl2 (45 mg/kg, dissolved in 
saline) i.p after the first IVIS measurement (day 0). Control mice were treated i.v. or i.p. with 
saline. IVIS measurements were performed daily at the indicated time points. Fractionated 
irradiation (3 x 1 Gy on 3 consecutive days) was applied locally using a customized led 
shielding device with a Gulmay 200 kV X-ray unit at 1 Gy/min.  
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Statement of ethical approval 
This study was performed in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the Swiss Cantonal Veterinary Authorities. The 
protocol was approved by the Committee of the Swiss Cantonal Veterinary Authorities 
(Permit Number: 136/2008 and 154/2011). All procedures and measurements were performed 
under isoflurane anesthesia, and every effort was made to minimize suffering. 
 
In vivo bioluminescence imaging and analysis 
Mice were i.p. injected with 150 mg/kg D-luciferin (CaliperLife Sciences, Hopkinton, MA, 
USA) (10 µl/g of a 15 mg/ml stock solution) prior to anesthesia. Sequential measurements of 
light emission were taken approx. 5 minutes after D-luciferin injection with the IVIS200 
(CaliperLife Sciences). The measurement with the highest total flux in the respective region 
of interest (ROI) was used for the longitudinal survey. 
 
 
Results 
Establishment and evaluation of a highly sensitive in vitro and in vivo tumor hypoxia 
reporter system 
To monitor changes in tumor hypoxia in vivo, a reporter gene system was constructed, which 
consists of an oxygen-dependent degradation (ODD)-domain fused 5’ to the luciferase 
reporter gene (ODD-Luc). This construct is constantly expressed in cells under control of a 
minimal, hypoxia-independent, SV40-promoter to be rapidly degraded under normoxic 
conditions, and slightly differs from previously used ODD-based constructs [29,39]. The 
ODD-sequence derives from the originally-identified human oxygen-dependent degradation 
domain (ODD) of HIF-1 but includes only the sequence coding for aa530 to aa652. This 
shorter ODD includes proline564, which is hydroxylated under normoxia and thereby marked 
for ubiquitin-dependent degradation by the VHL-proteasome-pathway, but excludes the NO-
sensitive Cys-residue at amino acid position 520 (corresponding to mouse HIF-1 aa533), 
which could lead to a hypoxia-independent stabilization of the reporter construct in the 
presence of tumor associated macrophages [39]. A luciferase reporter construct without an 
ODD and under control of the same SV40 promoter served as control system (Figure 1A).  
Hypoxia-sensitivity of the ODD-luciferase reporter construct was probed in stably-transfected 
A549 non-small cell lung cancer cells under hypoxia and hypoxia-mimicking conditions 
using the specific prolyl hydroxylase domain (PHD) inhibitor dimethyloxalylglycine 
(DMOG) at non-toxic conditions. Western blot analysis of cell lysates derived from cells 
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incubated under normoxic and hypoxic conditions (0.2% O2) or with DMOG (0.25 mM) 
revealed high hypoxia- and DMOG-dependent protein levels of the ODD-luciferase construct. 
Prolonged expression level of the construct was observed under permanent hypoxic 
conditions but the ODD-luciferase expression level decreased over time in DMOG-treated 
cells (Figure 1B). This might be due to a reduced potency of DMOG to constantly inhibit 
related PHDs. HIF-1 protein stability paralleled ODD-luciferase protein levels under these 
conditions but also decreased over time, most probably due to a previously described 
regulatory feedback mechanism [40]. An in vitro luciferase activity assay also clearly 
demonstrated a strong hypoxia and DMOG-dependent increase in luciferase activity in this 
stably transfected tumor cell line (Fig 1C).   
The kinetics of ODD-luciferase activity was further investigated after cellular treatment with 
DMOG during a 22-hours time course experiment and demonstrated the highest fold-increase 
in ODD-luciferase activity 8-10 hours after PHD-inhibition, with a subsequent slow decrease 
of luciferase activity over time (Figure 1D). Keeping cells under hypoxia for 8 hours followed 
by full reoxygenation to aerated conditions resulted in a rapid decrease of luciferase activity 
within the first 20 minutes, to reach 50% of its activity under hypoxic conditions already 90 
minutes after reoxygenation (Figure 1E). 
To validate this non-invasive ODD-luciferase reporter system in vivo, we used cobalt salt  
CoCl2, which also inhibits PHDs. CoCl2 (0.25 mM) induced a time-dependent increase in 
HIF-1 and ODD-luciferase protein levels in vitro (Figure 2B), and cellular luciferase activity 
peaked 14 hours after addition of CoCl2 (Figure 2A). Mice carrying tumor xenografts, which 
derived from ODD-Luc stably transfected A549 cells, were treated with CoCl2 (45 mg/kg, 
i.p.), and luciferase activity in the tumor xenograft was determined 14, 22 and 38 hours after 
CoCl2-treatment by in vivo bioimaging. Luciferase activity in the tumor xenografts reached a 
maximum of 2.5-fold induction at the 14 hour time point after treatment and returned to basal 
levels 38 hours after treatment start. In comparison, luciferase activity in placebo-treated 
control mice did not change over this 38 hour period (Figure 2C and D).   
To determine the sensitivity of the luciferase reporter system towards different levels of 
hypoxia, stably-transfected A549 cells were incubated for 8 hours at 0.2, 0.5, 1 and 2% O2. 
Interestingly, the luciferase activity constantly increased with cellular incubation at lower 
pO2-levels. An 8-fold increase in luciferase activity from normoxia to 1% O2 and a 2.8-fold 
increase in luciferase activity from 1% to 0.2% O2 was observed, which indicate a high 
sensitivity towards different levels of hypoxia (Figure 3A).  
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Figure 1. Oxygen-sensitive luciferase reporter system. (A) Scheme of luciferase constructs 
for constitutive (Luc) and oxygen-sensitive luciferase expression (ODD-Luc), containing a 
part of the oxygen-dependent degradation (ODD) domain of HIF-1. Both constructs are 
under the control of a minimal SV40 promoter. (B) Protein levels of HIF-1 and ODD-
luciferase in cellular extracts of stably transfected A549 cells, incubated for different time 
periods under normoxia, 0.2% O2 or DMOG. (C) Luciferase activity in stably transfected 
ODD-Luc A549 cells. Cells were incubated for 8 hours under normoxia, DMOG or hypoxia. 
(D) Luciferase activity in DMOG-treated, stably transfected ODD-Luc A549 cells over a 22 
hour period. (E) Luciferase activity in stably transfected ODD-Luc A549 cells kept for 8 
hours under hypoxia and reoxygenated (time point 0 minutes) thereafter. 
 
The bioreductive hypoxia marker pimonidazole forms stable adducts with thiol (sulphydryl) 
groups in proteins below the threshold of 10 mmHg pO2, corresponding to approx. 1.5-2% O2. 
To analyze whether different low levels of pO2 can be distinguished from each other by an 
increased cellular accumulation of pimonidazole, A549 cells were incubated with 
pimonidazole (150 μM) under normoxia and various concentrations of pO2 (0.2, 0.5, 1, 2 and 
5% O2) for 3.5 hours and stained with an FITC-labelled anti-pimonidazole antibody. The 
staining intensity of pimonidazole increased in a dose dependent way from normoxia to 2% 
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O2, however no difference in the staining intensity could be detected below 1% O2 (Figure 
3B). 
Overall these in vitro and in vivo results obtained with the non-invasive ODD-Luc-reporter 
approach demonstrate the high practicability and sensitivity to monitor dynamic changes in 
tumor hypoxia in vitro and in vivo. 
 
Figure 2. CoCl2 increases luciferase activity in A549 ODD-Luc cells in vitro and in vivo.  
(A,B) Luciferase-activity (A) and HIF-1, and ODD-luciferase protein levels (B) of CoCl2 
(0.25 mM)-treated, stably transfected ODD-Luc A549 cells, determined at the indicated time 
points. (C) Luciferase activity of A549 ODD-Luc-derived tumor xenografts in mice injected 
with CoCl2 (45 mg/kg) at time point 0 hour and at the indicated time points thereafter. (D) 
Representative in vivo bioimages of untreated and CoCl2-treated mice.  
 
Changes in tumor hypoxia as marker for treatment response to cytotoxic agents  
Using logistically-demanding non-invasive small animal positron emission tomography and 
classic invasive immunohistochemical approaches, we previously demonstrated that 
cytotoxic, anti-signaling and anti-angiogenic agents affect the tumor microenvironment and 
thereby tumor hypoxia [3]. In the intracellular signaling-based bioluminescence reporter 
system used in this report, which has been designed to investigate the dynamics of tumor 
hypoxia under different treatment modalities, the level of reporter gene expression and 
activity must be virtually independent of direct interference with the agent of interest (see 
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introduction). To control for such a putative, detrimental interference, luciferase activity in the 
human A549 lung adenocarcinoma and the human HCT116 colon adenocarcinoma cell line, 
both stably transfected with the ODD-Luc-construct, was determined in vitro on treatment 
with increasing concentrations of patupilone under normoxic and hypoxic conditions. 
Hypoxia strongly increased luciferase activity in both cells lines but cellular treatment with 
increasing concentrations of patupilone did not perturb luciferase activity significantly neither 
under normoxic nor hypoxic conditions (Figure 4A). 
Having in hand a sensitive system to probe tumor hypoxia in vivo, the dynamics of tumor 
hypoxia in response to patupilone treatment was monitored over a prolonged observation 
period. Stably-transfected A549 ODD-Luc cells were subcutaneously injected on the back of 
nude mice and tumors were allowed to grow until a volume of 200 mm3 +/-10 %. Mice were 
then treated with patupilone as a single dose (2 mg/kg, i.v.) and luciferase activity in control 
and patupilone-treated mice was determined over 10 days by in vivo bioimaging. The basal 
level of luciferase activity in A549 ODD-Luc xenografts was measured prior to patupilone 
injection and treatment-dependent changes in luciferase activity were further corrected for 
treatment-dependent changes in the tumor volume (see Material and Methods). A significant 
increase in luciferase activity already occurred on day 4 in tumor xenografts of mice treated 
with patupilone in comparison to placebo-treated mice and reached a maximal induction of 
luciferase activity at day 10 after treatment (5.2-fold versus 0.8-fold in control tumors) 
(Figure 4B). Patupilone-treatment also significantly inhibited tumor growth during this 
observation period (Figure 4B). Relative luciferase activity declined approximately 20 days 
after treatment, in mice probed over a prolonged time period (data not shown).  
No substantial patupilone-induced tumor growth delay was observed in three patupilone-
treated xenografted mice, and likewise, luciferase activity did not increase in these tumor 
xenografts. We could not explain the lack of responsiveness in these three mice, but more 
importantly they illustrate the correlation between the anti-tumoral effect of patupilone and 
the increase in intratumoral hypoxia in response to patupilone treatment (Figure 4C). Thus, 
increase in tumor hypoxia in response to patupilone treatment might serve as immediate 
surrogate marker for treatment sensitivity.  
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Figure 3. Differential sensitivity for low levels of pO2 by ODD-luciferase and 
pimonidazole. (A) Luciferase activity in A549 ODD-Luc cells was determined after cellular 
incubation for 8 hours at different levels of hypoxia and normoxia. (B) Detection of 
pimonidazole accumulation in A549 cells incubated at different levels of hypoxia and 
normoxia. Images display immunocytochemistry staining of pimonidazole and DAPI for 
nuclear staining (magnification, x 300). 
 
Control experiments were performed with tumor xenografts derived from A549 cells, which 
were stably-transfected with intact ODD-luciferase construct or a luciferase construct lacking 
an ODD-domain (Luc-only). With the latter construct, interference of patupilone with the 
SV40 promoter or with D-luciferin uptake and diffusion could be excluded. Tumors were 
allowed to grow until a volume of 200 mm3 +/-10%, and mice were treated with either 
placebo or patupilone (2 mg/kg). Growth rate was similar for both A549 ODD-Luc and A549 
Luc-only-derived tumor xenografts, and patupilone induced a comparable tumor growth delay 
for both tumor types. In contrast luciferase activity only increased after patupilone treatment 
in tumors derived from the ODD-Luc expressing A549 cells. These results further corroborate 
the specificity of the hypoxia-reporter construct to monitor treatment-related changes in vivo 
(Figure 4D).  
To test for patupilone-increased tumor hypoxia in other tumor cell systems, the human 
colorectal adenocarcinoma cell line HCT116 was stably transfected with the ODD-Luc-
construct and xenotransplanted in nude mice. HCT116 ODD-Luc derived tumors were 
allowed to grow to a volume of 300 mm3, and mice were treated with placebo or a single dose 
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of patupilone (2 mg/kg). Tumor growth was strongly inhibited and luciferase activity also 
increased in this tumor model in response to patupilone treatment. However increase in 
luciferase activity already peaked on day 7 after patupilone treatment, though to a lesser 
extent in comparison to the A549-derived tumor system (Figure 4E). Histologic-morphologic 
analysis revealed a high percentage of necrosis (> 50%) in this tumor model, thus 
complicating tumor volume standardization. Therefore, further experiments were only 
performed with the A549-derived tumor model with a low level of tumor necrosis.   
Tumor hypoxia is an important parameter for tumor radiosensitivity, and fluctuation of tumor 
hypoxia may influence the treatment response to radiotherapy. Short-term fractionated 
irradiation was therefore used as a second cytotoxic treatment modality to probe the dynamics 
of tumor hypoxia under treatment (Figure 5). A549 ODD-Luc-derived tumor xenografts with 
a small or a large tumor volume (200 mm3 and 400 mm3, respectively) were irradiated with a 
minimally fractionated treatment regimen of 3 x 1 Gy on 3 consecutive days and luciferase 
activity was determined during treatment and seven follow-up days. In the two control groups 
covering small and large tumor volumes, tumors steadily increased in size and volume-
corrected luciferase activity did not change over time (Figure 5B and D). The minimal 
irradiation regimen suppressed tumor growth until day 8 after treatment start in the group of 
small tumors, and during the entire observation period in the group with large tumors (Figure 
5A and C).  Irradiation induced a slight increase in luciferase activity in both groups (1.5 to 
1.7-fold), which remained stable in the group of large tumors but again decreased to basal 
level in the group of small tumors towards the end of the observation period. Interestingly, 
this drop of volume-corrected luciferase activity coincided with resumed tumor growth and 
remained at basal levels during subsequent tumor growth (data not shown). 
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Figure 4. Patupilone-dependent increase in tumor hypoxia in vivo. (A) Stably-transfected 
A549 ODD-Luc and HCT116 ODD-Luc cells were treated with increasing concentrations of 
patupilone for 24 hours before incubation under normoxia and hypoxia (0.2% O2). Luciferase 
activity was determined after 8 hours of hypoxia. (B) Luciferase activity (left side) and tumor 
growth (right side) of A549 ODD-Luc-derived tumor xenografts in mice treated with 
patupilone (2 mg/kg). (C) Equal treatment as in (B) of mice not responding to patupilone 
treatment. (D) Luciferase activity and tumor growth of A549 ODD-Luc and A549 Luc-only-
derived xenografts in mice treated with patupilone (2 mg/kg). (E) Luciferase activity and 
tumor growth of HCT116 ODD-Luc-derived xenografts in mice treated with patupilone (2 
mg/kg).  
 
Patupilone-induced hypoxia does not impair the radiation response 
We previously investigated the combined treatment modality of patupilone and ionizing 
radiation and determined an at least additive treatment response on concurrent treatment on 
A549, SW480 colon carcinoma and D425Med medulloblastoma xenografts [5,6,41]. We now 
aimed to investigate the dynamics of tumor hypoxia, as indicated by changes in luciferase 
activity, in response to this combined treatment modality and to determine a putative 
counteractive effect of patupilone-induced tumor hypoxia on the radiation response. 
Therefore, A549 ODD-Luc-derived tumor xenografts were treated with different treatment 
schedules and luciferase-activity was monitored.   
First, A549 ODD-Luc xenotransplanted mice at a small tumor volume (200 m3) were treated 
with patupilone (2 mg/kg) and ionizing radiation (3 x 1 Gy) as part of a concomitant treatment 
regimen. In comparison to the intermediate treatment response to IR and patupilone alone (see 
above), the combined, concomitant treatment modality induced an additive tumor growth 
delay over the entire observation period. Interestingly, induction of luciferase activity in 
response to the combined treatment modality was similar to the increase in luciferase activity 
after patupilone-treatment alone and thus dominated over the effect on luciferase activity after 
irradiation (Figure 6A).  
Next, A549-ODD-Luc xenotransplants were treated with placebo or patupilone alone (2 
mg/kg) at a small tumor volume (200 mm3) and were adjuvantly irradiated once the tumors 
reached a volume of 400 mm3 +/- 10% (in control and patupilone-pretreated mice, which 
corresponds to the day of highest patupilone-induced luciferase activity). Irradiation of 
placebo-treated mice only resulted in a slight induction of luciferase-activity, while irradiation 
of patupilone-pretreated mice further enhanced the already elevated luciferase-activity 
twofold. Interestingly though, the IR-induced tumor growth delay was similar in the placebo- 
and the patupilone-pretreated mice, despite the elevated hypoxic status in the patupilone-
pretreated tumors at the time point of irradiation (Figure 6B). 
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Figure 5. Minimal effect of ionizing irradiation on tumor hypoxia. Luciferase activity and 
tumor volume of A549 ODD-Luc-derived xenografts in control (B, D) and irradiated mice (A, 
C, 3 x 1 Gy) at a small (A, B, 200 mm3) and at a large (C, D 400 mm3) tumor volume at the 
day of treatment start. Fold induction of luciferase activity per tumor volume (solid line) and 
relative tumor volume (dotted line) were set to 1 at day 0. 
 
 
Discussion 
Radiosensitivity is progressively reduced when the pO2 in a tumor is below 15-20 mmHg. 
pO2 determination with invasive pO2 electrodes revealed a strong correlation between low 
pO2 (< 5-10 mmHg) prior treatment and locoregional control after radiotherapy in squamous 
cell cancer of the head and neck, uterine cervix and non-small cell lung carcinoma 
[42,43,44,45,46]. However, the dynamics of tumor microenvironmental parameters like 
hypoxia during treatment might even represent the better prognostic factor with regard to 
clinical outcome [47]. Furthermore tumor microenvironment-interfering agents might also 
negatively change tumor oxygenation and the hypoxic tumor fraction by itself, thereby 
affecting the treatment response to irradiation. Thus, a combined treatment modality might be 
challenged by new potential hazards created by the combination itself [3,6]. To address and 
investigate these processes and endpoints, non-invasive methods are required that allow serial 
determination of tumor hypoxia. 
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Here we established a non-invasive luciferase-based reporter system to serially probe tumor 
hypoxia, and determined the course of treatment-induced changes in tumor hypoxia in 
response to ionizing radiation and the clinically relevant microtubule stabilizing agent 
patupilone. The fusion construct luciferase linked to a minimal ODD-domain was stably 
expressed in tumor cells but rapidly degraded under normoxic conditions by the oxygen-
sensing prolyl hydroxylases. This hypoxia-sensing approach was previously developed in 
mouse models, which express this fusion protein ubiquitously and even as an ODD-luciferase 
transgene in a spontaneous murine mammary carcinoma model [37,48]. Here we demonstrate 
that this approach could also be easily adapted to tumor xenografts in order to probe the effect 
of clinically relevant antitumor treatment modalities on tumor hypoxia. In contrast to HRE-
based-luciferase hypoxia-reporting systems, the ODD-luciferase system with a minimal 
ODD-domain has the advantage to be robust against putative interference of agents of interest 
with the signaling cascade upstream of HIF-1, thereby avoiding false positive or negative 
readouts. Control experiments on the expression level of prolyl hydroxylase 2 and 3 in the 
A549 tumor cell line and in histological A549 ODD-Luc cell-derived tumor sections did not 
reveal treatment-induced changes, which might have influenced the reporter system (data not 
shown).     
Our in vitro experiments revealed that the ODD-luciferase hypoxia reporter systems can be 
used to sense and differentiate decreasing pO2-levels even as low as 0.2% O2. Thus, this 
approach is more sensitive than pO2-measurements with the hypoxia marker pimonidazole, 
which did not discriminate hypoxic milieus below 1.5% O2, corresponding to 10 mmHg, or 
more sensitive than 18F-fluoromisonidazole (FMISO), which is used as hypoxia tracer for 
positron emission tomography in experimental tumor models and which has similar chemical 
properties as pimonidazole [49]. While the ODD-luciferase reporter system is highly sensitive 
to detect tumor hypoxia, unfortunately, the resolution of the in vivo bioimaging system is 
rather low. Therefore, only collective luminescence derived from the luciferase activity in the 
whole tumor could be determined, representing the mean tumor oxygenation status in the 
whole tumor. Thus, we could not distinguish between tumor areas with high or low tumor 
hypoxia and could not identify tumor-sections that are specifically prone to treatment-induced 
changes in tumor hypoxia. Future in vivo bioimaging approaches with improved resolution 
are required to overcome these drawbacks.  
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Figure 6. Tumor hypoxia in response to the combination of patupilone and ionizing 
radiation. (A) Luciferase activity and tumor growth of A549 ODD-Luc-derived xenografts in 
response to patupilone (2 mg/kg) and ionizing radiation (3 x 1 Gy) alone and in combination, 
treated at a tumor volume of 200 mm3. (B) Luciferase activity and tumor growth of A549 
ODD-Luc-derived xenografts in control and patupilone-pretreated mice irradiated at a tumor 
volume of 400 mm3 (control) or 10 days after patupilone-pretreatment.  
 
The dynamics of tumor hypoxia in tumor xenografts were probed in response to minimal 
fractionated irradiation and the microtubule stabilizing agent patupilone. Independent of the 
initial tumor volume, irradiation resulted in a transient tumor growth arrest with a slight 
increase in the hypoxic fraction (volume-corrected luciferase activity). A drop in the hypoxic 
tumor fraction 5 days after treatment end in tumors treated at a small tumor volume coincided 
with resumed tumor growth, which could be due to the recovery or normalization of the tumor 
vasculature. We previously demonstrated that the hypoxic fraction in response to low dose, 
fractionated irradiation changes only minimally, but that the tumor vasculature nevertheless 
may undergo structural changes (e.g. switch to intussusceptive angiogenesis) with full 
recovery only after extended tumor regrowth [3,50].  
Single treatment with patupilone resulted in extended tumor growth arrest in both tumor 
models (A549, HCT116) and a strong, prolonged increase in the hypoxic tumor fraction. This 
correlation was accidentally confirmed in patupilone-non-responding animals on the level of 
tumor growth and tumor hypoxia. Thus, an increase in tumor hypoxia could represent an early 
surrogate marker for treatment sensitivity towards patupilone and likewise towards other 
microtubule stabilizing agents. However, we have only limited mechanistic insights how 
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patupilone affects tumor hypoxia. Patupilone has anti-angiogenic and vascular disruptive 
activity leading to reduced tumor blood volume, which finally could translate into enhanced 
tumor hypoxia [51]. Patupilone directly interferes with HIF-signaling, which eventually 
results in a diminished tumor hypoxia stress response. Using a genetically defined patupilone-
sensitive and -resistant tumor model, we previously demonstrated that the major cytotoxic 
insult occurs on the tumor cell level, and that the anti-angiogenic effect of patupilone required 
patupilone-dependent blockage of pro-angiogenic cytokine expression and secretion from the 
targeted, patupilone-sensitive tumor cell, such as VEGF [6,38]. Here, histologic analysis of 
patupilone-treated tumors did not reveal a significant additional increase in pimonidazole-
staining in comparison to the already intense pimonidazole-level for the A549 control tumors. 
This might be due to lack of correlation between HRE- or ODD-based bioimaging readouts 
and pimonidazole-staining, as already observed by others [27,52], or the already low pO2-
levels present in the control tumors, which does not allow anymore the use of pimonidazole to 
differentiate between treatment-dependent changes in pO2-levels (see above).  
Own studies revealed a supra-additive antitumoral effect of patupilone in combination with 
ionizing radiation, against tumor xenografts derived from different tumor cell lines [5,6,41]. 
We previously demonstrated that ionizing radiation counteracted an inhibitor-of-
angiogenesis-induced increase in tumor hypoxia in tumor xenografts when used as part of a 
combined treatment modality and thereby counteracted the potential risk of enhanced 
radiation resistance by the inhibitor of angiogenesis [3]. Concomitant treatment of patupilone 
with ionizing radiation did not reduce the patupilone-dependent increase in tumor hypoxia. 
Nevertheless, combined treatment resulted in an enhanced tumor growth delay, which could 
be due to a synergistic insult to the tumor cell compartment and tumor vasculature.  
Interestingly, the hypoxic fraction in the patupilone-pretreated xenografts even increased after 
adjuvant irradiation, which might derive from persistent fragility of the tumor vasculature in 
patupilone-pretreated xenografts and subsequent further damage on irradiation. Nevertheless 
and despite the presence of an enhanced hypoxic tumor fraction in the patupilone pretreated 
xenografts, irradiation still induced a similar antitumoral effect in patupilone-pretreated 
xenografts as in naive xenografts with a lower hypoxic tumor fraction. However, we cannot 
rule out that a low, radiosensitizing level of patupilone might still be present at the timepoint 
of irradiation.  
Overall, our results obtained with the two anticancer agents patupilone and ionizing radiation 
demonstrate, that the ODD-luciferase reporter system is a highly convenient, non-invasive 
approach to serially probe the dynamics of tumor hypoxia in murine tumor xenograft models. 
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Patupilone-induced increase in tumor hypoxia might be used as marker for patupilone 
sensitivity. Furthermore, scheduling-experiments of the treatment modality of patupilone in 
combination with ionizing radiation reveal that patupilone-induced tumor hypoxia does not 
enhance radiation resistance as part of a concomitant or neo-adjuvant treatment regimen.  
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Role of theMicroenvironment for Radiosensitization by Patupilone
Carla Rohrer Bley,1,3 WolframJochum,2 Katrin Orlowski,1Polina Furmanova,1Van Vuong,1
Paul M.J. McSheehy,4 andMartin Pruschy1
Abstract Purpose:The combined treatment modality of ionizing radiation (IR) and the clinically relevant
microtubule-stabilizing compound patupilone (epothilone B, EPO906) is a promising approach
for anticancer therapy. Here, we investigated the role of the tumor microenvironment for the
supra-additive in vivo response in tumor xenografts derived from patupilone-sensitive and patu-
pilone-resistant non-small cell lung cancer cells.
Experimental Design:The treatment response to a combined regimenof patupilone and IRwas
investigated in vitro and in tumor xenografts derived from wild-type A549 and A549.EpoB40
cells, which are resistant to patupilone due to a h-tubulin mutation.
Results: In both A549 and A549.EpoB40 cells, proliferative activity and clonogenicity were
reduced in response to IR, whereas patupilone, as expected, inhibited proliferation of the mutant
cell line with reduced potency. Combined treatment with patupilone and IR induced a cytotoxic
effect in vitro in an additiveway in A549 cells but not in the tubulin-mutated, patupilone-resistant
A549.EpoB40 cells. A supra-additive tumor growth delay was inducedby combined treatment in
xenografts derived from A549 cells but not in xenografts derived from A549.EpoB40 cells. His-
tologic analysis revealed a significant decrease in tumor cell proliferation (Ki-67) andmicrovessel
density and a treatment-dependent change of tumor hypoxia in A549 but not A549.EpoB40
xenografts.
Conclusions: Using a genetically defined patupilone-sensitive and patupilone-resistant tumor
model, we here showed that the major cytotoxic effect of the combined treatment modality of
IR and patupilone is directed against the tumor cell compartment. The induced antiangiogenic
effect derives indirectly from the tumor cell.
Interference with microtubule function is a promising strategy
for anticancer therapy (1). This approach has been extensively
validated by the use of taxanes (microtubule stabilizers) for the
treatment of a wide variety of human malignancies. The
suppression of microtubule dynamics interferes with mitotic
spindle formation, leading to cell cycle arrest in M phase and
eventually to apoptosis or postmitotic cell death. The primary
mechanism of microtubule-stabilizing agents (MSA) at the
biochemical level is well investigated, but the signaling
consequences relevant for their cytotoxic effect are far from
clear. Furthermore, treatment with taxanes (paclitaxel and
docetaxel) is limited by taxane-related toxicities and the
development of multidrug resistance. This has prompted an
ongoing worldwide search for novel microtubule-targeting
compounds. One new class of MSAs are the epothilones,
which are structurally distinct from the taxanes and may
overcome some of their limitations, suggesting a promising
new treatment approach for cancer (2–4).
Epothilones are nontaxoidMSA of bacterial origin, which share
the same binding site on h-tubulin with taxanes (5, 6). One of the
epothilones, patupilone (epothilone B, EPO906), is currently in
phase II clinical development in several different solid tumors
and is in phase III clinical trials for ovarian cancers in patients
refractory to carboplatin-taxane treatment. Patupilone retains
activity against P-glycoprotein-expressingmultidrug-resistant cells
both in vitro and in vivo (5) and shows different clinical toxicities
to the taxanes (6, 7). Apart from the direct tumor-cytotoxic action,
patupilone has also shown antivascular (8) and antiangiogenic
(9) effects. The antiangiogenic effect might be linked to different
mechanisms either directly targeting endothelial cells (10) or
indirectly interfering with the secretion of proangiogenic agents
from tumor cells (11, 12).
The accumulation of cells in the most radiosensitive G2-M
phase of the cell cycle represents the current rationale to
combine MSAs with ionizing radiation (IR) and promises a
strong radiosensitizing effect in combination with IR (2, 13,
14). Our own previous in vitro and in vivo experiments done
with patupilone in combination with IR showed an at least
additive cytotoxic effect in various cancer cell types in vitro and
strong supra-additivity of the combined treatment regimen
against tumor xenografts in vivo. Interestingly, also a S-phase
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progression-related mechanism for radiosensitization was
observed (15).
The observed in vivo supra-additive response to patupilone in
combination with IR points to an additional mechanism of
sensitization, which is not limited to the tumor cell but may
also be due to effects on the microenvironment within the solid
tumor (15).
Here, we investigated the different treatment modalities of
patupilone and IR alone and in combination in vitro and in vivo
using a patupilone-sensitive A549 cell line and the mutant
derivative cell line (A549.EpoB40), which is strongly resistant to
patupilone in vitro because it contains a defined h-tubulin
mutation (3, 11, 16, 17). In this manner, we aimed to distinguish
between a tumor cell and/or tumor microenvironment-directed
effect of the different treatment modalities. Our results show a
major tumor cell-directed effect with a subsequent indirect
antiangiogenic effect especially by the combined treatment
modality of patupilone in combination with IR.
Materials andMethods
Patupilone (epothilone B, EPO906) was provided by the Chemistry
Department of Novartis Pharma. The human cell line pair A549 and
A549.EpoB40 was obtained from the laboratory of Dr. Susan Band
Horwitz.
Cell cultures, drug preparation, and irradiation. The human non-
small cell lung cancer lines A549 and A549.EpoB40 were grown in
RPMI 1640 containing 10% (v/v) fetal bovine serum, 1% (v/v)
penicillin-streptomycin, and 1% (v/v) L-glutamine at 37jC in 5%
CO2. A549.EpoB40 is derived from A549 by stepwise selection with
patupilone and contains a point mutation in class 1 h-tubulin (h292
from Gln to Glu), which is associated with f95-fold resistance to
patupilone (3). The A549.EpoB40 cell line was grown and maintained
in medium containing 10 nmol/L patupilone. For in vitro experiments,
patupilone was dissolved in DMSO (1 mmol/L stock solution) and
further diluted with medium containing 10% FCS.
Irradiation of cell cultures was carried out using a Pantak Therapax
300 kV X-ray unit at 70 cGy/min at room temperature. For combined
treatment, the cells were pretreated with patupilone 18 h before
irradiation.
Cell proliferation and clonogenic survival assays. The proliferative
activity of tumor cells was assessed in 96-well plates with the
colorimetric alamarBlue assay, which is based on detection of
metabolite activity according to the protocol of the manufacturer
(Biosource International). Absorption was measured at 570 and
630 nm using a Tecan GENios spectrophotometer. Experiments were
carried out under normoxic as well as hypoxic conditions. To render
cells hypoxic, cells were grown in a hypoxic incubator at 1% pO2.
Clonogenic survival was determined by the ability of single cells to
form colonies in vitro . The number of plated cells was adjusted to
obtainf100 colonies per cell culture dish with a given treatment. After
treatment with different regimes, the dishes were maintained at 37jC
in 5% CO2 and allowed to grow for 12 days before fixation in
methanol/acetic acid (3:1) and staining with crystal violet. Colonies
with >50 cells/colony were counted manually. All assays were repeated
as independent experiments at least thrice.
Tumor xenograft in nude mice and application of treatment
regimes. A549 or A549.EpoB40 cells (4  106) were injected
subcutaneously on the back of 4- to 8-week-old athymic nude mice.
Tumor volumes were determined from caliper measurements of tumor
length (L) and width (l) according to the formula: (L  l2) / 2. Tumors
were allowed to expand to a volume of 200 mm3 (F10%) before
treatment start. Using a customized shielding device, mice were given a
strictly locoregional radiotherapy of 4  3 or 3  1 Gy at 4 or
3 consecutive days using a Pantak Therapax 300 kV X-ray unit at
0.7 Gy/min. Patupilone (dissolved in 30% PEG-300/70% saline) was
applied intravenously 24 h before the first treatment with IR (at day 0
of the treatment). Tumor growth was monitored at least thrice and
body weight once weekly.
Histology and immunohistochemistry. Tissues were immersion fixed
in 4% PBS-buffered formalin and embedded in paraffin. Sections (3 Am
thick) were mounted on glass slides (SuperFrost Plus; Menzel),
deparaffinized, rehydrated, and stained with H&E using standard
histologic techniques. In addition, CC1 (antigen retrieval solution;
Ventana Medical Systems)-pretreated sections were immunostained for
Ki-67 (rabbit clone SP6; dilution 1:100; NeoMarkers), CD31 (rabbit
polyclonal, ab28364; dilution 1:50; Abcam), and GLUT1 (rabbit
polyclonal, MYM AB 1351; dilution 1:1,000; Chemicon International)
using a Discovery immunohistochemistry staining system (Ventana
Medical Systems). Detection of primary antibody was done with a
biotinylated anti-rabbit IgG antibody (Jackson ImmunoResearch) and
the iView DAB kit (Ventana Medical Systems). For hypoxia detection,
pimonidazole hydrochloride (60-80 mg/kg) was applied intravenously
45 min before sacrifice. CC1-pretreated sections were incubated with
Hypoxyprobe-1 MAb1 (mouse IgG1; dilution 1:300; Chemicon
International) conjugated with FITC. Detection of primary antibody
was done with a biotinylated mouse anti-FITC antibody (Jackson
ImmunoResearch) and the iView DAB kit. All immunostains were
counterstained with hematoxylin.
To determine proliferative activity, Ki-67-positive tumor cells were
counted in 5 to 10 randomly chosen visual fields (magnification 200)
in each xenogaft (n = 4 for each group). The mean Ki-67-positive cell
count from these fields was determined. Microvessel density (MVD) was
determined in 5 to 10 randomly chosen visual fields (high-power
fields) in each of three equally treated vital tumor tissues at 100
magnification (0.3 mm2 visual field size). Hypoxia staining was
quantified by manual counting using a grid of 1,200 points in two
photographs per tumor, which displayed the whole tumor section.
Transfections and reporter gene assay. Both cell lines were stably
transfected with a vector construct containing two copies of the
Transferrin promoter hypoxia response element (HRE) and SV40
promoter in front of the firefly luciferase gene. Stably transfected,
hygromycin-selected A549 and A549.EpoB40 cell lines were tested
for luciferase enzymatic activity with a commercial kit (Bright-Glo
luciferase assay; Promega) using a GloMax 20/20 luminometer. Hypoxic
conditions were mimicked using dimethyloxaloylglycine (Biomol),
a prolyl-4-hydroxylase inhibitor, which prevents hypoxia-inducible
Translational Relevance
Patupilone is a novel microtubule inhibitor with known
antitumor and antiangiogenic/vascular activity currently in
phase II/III clinical trials. Herein, we present first comple-
mentary in vitro and in vivo results investigating the role of
the tumor microenvironment in the treatment response to
the combination of ionizing radiation (IR) and patupilone.
Using a genetically defined patupilone-sensitive and patu-
pilone-resistant human non-small cell lung cancer tumor
model system, we show that the major cytotoxic effect of
the combined treatment modality of IR and patupilone is
directed against the tumor cell compartment and that the
induced antiangiogenic effect, which contributes to the
synergistic treatment response of this combined treatment
modality, derives indirectly from the tumor cell. These pre-
clinical experiments are of relevance for clinical strategies
that target the microtubule cytoskeleton and hypoxia-
inducible factor dysregulation in combinationwith IR.
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factor (HIF) degradation at prior tested nontoxic concentrations of
0.25 and 1 mmol/L, respectively. To discriminate between treatment-
induced cell death and treatment-interfered HIF signaling, cells were
transiently cotransfected with a Renilla luciferase-expressing control
vector. Patupilone was applied 24 h after transient transfection.
Dimethyloxaloylglycine treatment was started 24 h and irradiation
(5 Gy) 28 h after patupilone treatment. Luciferase activity was deter-
mined 14 h after treatment with dimethyloxaloylglycine.
Statistical analysis. Statistical analysis of the in vivo tumor growth
data was done with the Mann-Whitney U test. The absolute tumor
growth delay was defined as the time for tumor volume in the treated
groups to triplicate the initial treatment size minus the time in the
untreated control group to reach the same size. Kruskal-Wallis one-way
ANOVA was used to test for significant differences of Ki-67, CD31, and
hypoxia following the various treatments. Treatments effects (difference
between control and treatments) were analyzed using the Mann-
Whitney U test. The level of significance was set at 0.05. The
calculations were all done using the StatView program (SAS Institute)
version 5.0.1.
Results
Antiproliferative effect of patupilone under normoxic and
hypoxic conditions. The antiproliferative effect of patupilone
was tested over 72 h in the A549 wild-type and A549.EpoB40
mutant cell lines under normoxic and hypoxic conditions. A
dose-dependent decrease of the proliferative activity was
observed in the A549 tumor cells (IC50f0.2 nmol/L), whereas
a >100-fold higher concentration (>20 nmol/L) was required to
obtain the same antiproliferative effect in the mutant
A549.EpoB40 cell line. No difference with regard to the
antiproliferative effect by patupilone was observed under
normoxia and under hypoxia (1% pO2; Fig. 1A and B).
Antiproliferative and clonogenic cell death-inducing effect
by combined treatment with patupilone and IR. The antiproli-
ferative effect of patupilone in combination with IR was tested
using increasing concentrations of patupilone and doses of IR.
In the patupilone-sensitive A549 cell line, an additive anti-
proliferative effect was induced with 5 Gy, a dose that shows
<50% inhibition of proliferation over 72 h in response to
irradiation alone (Fig. 2A and B). No radiosensitizing effect
could be detected in the drug-resistant A549.EpoB40 cell line
at various doses of patupilone and IR. Interestingly, these
cells were also slightly more radioresistant than the wild-type
counterpart cell line (Fig. 2C and D). Patupilone was also
highly potent against human umbilical vein endothelial cells.
Picomolar concentrations of patupilone were sufficient to
inhibit endothelial cell proliferation and cell viability alone
and in combination with IR (data not shown). Clonogenic
survival assays were done with both cell lines and increasing
concentrations of patupilone and IR. Clonogenicity was
reduced in an at least additive way in the A549 cell population.
In contrast, the mutant cell line A549.EpoB40 was refractory to
patupilone alone up to 10 nmol/L, and patupilone did not
sensitize for IR (Fig. 2E and F).
Effect of combined treatment with patupilone and IR on growth
of tumor xenografts. We previously observed a supra-additive
effect of a combined patupilone/IR treatment on tumor growth
delay in xenografts derived from radioresistant SW480 human
colon adenocarcinoma cells (15). In the tumor xenografts
derived from the wild-type A549 cell line, a small growth delay
was induced by 3  1 Gy irradiation compared with untreated
control tumors. Growth was significantly inhibited by patupi-
lone (1  2 mg/kg) treatment alone (P = 0.022). In response to
the combined treatment modality, a supra-additive tumor
growth delay was observed. Tumor growth in the combined
treatment group was significantly inhibited compared with
IR- or patupilone-treated groups (P = 0.010 and 0.013; Fig. 3A).
The absolute growth delay to triple the initial tumor volume at
the start of treatment (200 mm2 F 10%) was most enhanced
with the combined treatment modality when compared with
the absolute tumor growth delay in response to patupilone or
IR alone [26 days (patupilone + IR) versus 6 days (patupilone)
and 2 days (IR)], respectively (data not shown). In contrast, no
tumor growth delay was induced by the same dose of
patupilone in tumors derived from the drug-resistant
A549.EpoB40 cells, indicating that the tumor growth suppres-
sion effect of patupilone primarily derives from tumor cell-
directed cytotoxicity (Fig. 3B). The tumors derived from the
mutated cell line were also more radiation-resistant than the
wild-type counterparts. Nevertheless, a treatment regimen of
4  3 Gy alone induced a significant growth delay in tumors
derived from these cells (P = 0.004). On the other hand,
combined treatment did not further increase the antitumor
effect, and even a slightly diminished absolute tumor growth
delay was observed after combined treatment versus treatment
Fig. 1. Antiproliferative effect of patupilone under normoxia and hypoxia. Lung
adenocarcinoma cells A549 (A) andmutant cells A549.EpoB40 (B) were exposed
to increasing concentrations of patupilone and grown in normoxic or hypoxic
conditions (1%) for 72 h. Data were pooled from three independent experiments.
Columns, mean; bars, SE.
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with IR alone [14 days (IR) versus 9 days (patupilone + IR); data
not shown]. These results indicate that the major antitumor
effect of the investigated treatment modality derives from tumor
cell-directed cytotoxicity. A direct antiangiogenic effect of
patupilone alone or in combination with irradiation is unlikely
to contribute to the observed tumor growth delay. Determination
of body weight changes only revealed a minor patupilone-
dependent transient weight loss over 48 h after treatment
Fig. 2. Antiproliferative effect of patupilone alone and in combinationwith IR (5 Gy). Lung adenocarcinoma cells A549 (A andB) andmutant cells A549.EpoB40 (C andD)
were exposed to increasing concentrations of patupilone and IR. Clonogenic survival after treatment with patupilone and IR was determined forA549 cells (E) and mutant
A549.EpoB40 cells (F) treated with patupilone18 h before irradiation.
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www.aacrjournals.orgClin Cancer Res 2009;15(4) February15, 2009 1338
 American Association for Cancer Research Copyright © 2009 
 on June 1, 2012clincancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/1078-0432.CCR-08-0969
initiation. No skin changes or tissue damage were observed in the
coirradiated healthy tissue area around the tumor.
Histologic analysis of treatment-induced effects in tumor
xenografts. To investigate a putative antiangiogenic effect of
the different treatment modalities, MVD, tumor hypoxia, and
proliferative status were determined in tumor sections of
treated mice, which were collected 84 h after treatment with
patupilone (2 mg/kg) or vehicle alone, after fractionated
irradiation (3  1 or 3  3 Gy, respectively) or the combined
treatment modality. Histologic analysis was first done on
xenografts without any treatment to compare baseline charac-
teristics of A549 and A549.EpoB40 xenografts. Xenografts of
both A549 and A549.EpoB40 cells showed solid growth of
carcinoma cells with areas of necrosis and thin stromal septa.
Tumor cell proliferation was determined using immunohis-
tochemistry for the Ki-67 protein, which is expressed during all
phases of the cell cycle, except G0. In the tumors derived from
the drug-sensitive A549 cell line, the proliferative activity was
reduced by 32% 84 h after treatment with patupilone alone,
whereas irradiation and the combined treatment reduced
the proliferative activity by 54% and 71%, respectively
(P < 0.0001). No change in the proliferative activity could be
detected in A549.EpoB40-derived tumor sections after patupi-
lone treatment. Irradiation reduced the proliferative activity by
22% (P < 0.0001), without any further effect in the combined
treatment group (Fig. 4A and B). To examine the effect of the
different treatment modalities on the tumor vasculature, MVD
was determined by CD31 immunohistochemistry. Patupilone
reduced the MVD in the drug-sensitive tumors by 25% at the
84 h time point when compared with control tumors
(P = 0.0003). Irradiation and combined treatment reduced
the MVD by 37% and 47%, respectively (P < 0.0001). In the
drug-resistant tumors, a tendency in MVD reduction was only
observed in the irradiated group (P = 0.074; Fig. 4C and D).
Treatment-induced changes of the tumor vasculature may
also affect the pO2 in the tumor tissue. We therefore
determined treatment-dependent changes of tumor oxygena-
tion by injection of the hypoxia probe pimonidazole, which
specifically accumulates in hypoxic tissue areas. Treatment-
dependent changes of hypoxic areas were determined in
histologic sections 84 h after treatment. A significant increase
of pimonidazole accumulation was determined in A549-
derived tumors after treatment with patupilone (P = 0.0019),
whereas the amount of hypoxic, pimonidazole-positive areas
was reduced in the irradiated group (P = 0.0045). Interestingly,
the amount of hypoxic areas was similar to untreated tumors
after treatment with patupilone in combination with IR
(P = 0.747). No change of pimonidazole accumulation was
observed in any of the treatment groups in A549.EpoB40-
derived tumor sections (Fig. 4E and F). These results indicate
that changes in the tumor microenvironment in response to the
different treatment modalities mainly derive from the treatment
effect directed against the tumor cells (see below).
Treatment-interfered expression of hypoxia-induced gene
expression. The HIF represents the major determinant in
tumor cells for hypoxia-regulated expression of proangiogenic
factors and patupilone reduced the level of the hypoxia-
sensitive HIF-1a subunit under hypoxic conditions in the
patupilone-sensitive A549 cell line as determined by Western
blotting (data not shown). Using a reporter gene assay where
luciferase expression is under the control of multiple HREs, the
treatment response of patupilone and IR alone and in
combination was quantitatively assessed in the patupilone-
sensitive and patupilone-resistant cell lines. To normalize for
transfection efficacy and cell numbers, cells were cotransfected
with the Renilla luciferase-expressing vector system. To mimic
hypoxic conditions, cells were incubated in dimethyloxaloyl-
glycine, thereby up-regulating the endogenous HIF level and
inducing luciferase expression 8.5-fold over control conditions
(data not shown). Treatment of the patupilone-sensitive A549
cells with increasing doses of the MSA significantly reduced
luciferase expression already at subnanomolar concentrations
(P = 0.010). Of note, the A549.EpoB40 cells were resistant up
to low nanomolar concentrations of patupilone (20 nmol/L),
indicating a role of microtubule interference in HIF-1a-regulated
gene expression (Fig. 5A). Treatment of cells with increasing
doses of irradiation only minimally affected luciferase expres-
sion (data not shown). Treatment with increasing doses of
patupilone in combination with IR (5 Gy) additionally
Fig. 3. Effect of patupilone and IR alone or in combination on the growth of
A549-derived (A) and A549.EpoB40-derived (B) xenografts in nude mice. Mice
were treated with patupilone (2 mg/kg once) and IR (3  1or 4  3 Gy on
consecutive days) alone and in combination, with administration of patupilone or
the vehicle 24 h before the first fraction of IR.Horizontal column, days of treatment.
MeanF SE tumor volume per group.
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decreased luciferase expression (P = 0.018) in the A549 cell
line, indicating a increased stress response on the level of
hypoxia-regulated gene expression (Fig. 5B).
Discussion
Here, we investigated the treatment response of tumor
xenografts derived from MSA-sensitive and MSA-resistant lung
adenocarcinoma cell lines to treatment with patupilone and IR
alone or in combination. We previously identified a strong
treatment response to this combined treatment modality
in vivo in the SW480 human colon xenograft model, which
strongly exceeded the additive cytotoxic effect of the treatment
combination in vitro (15). By means of this genetically defined
tumor model, we now were able to differentiate between a
direct tumor cell-directed and a microenvironment-directed
Fig. 4. Tumor cell proliferation, MVD, and changes in tumor hypoxia in response to treatment. Mice with A549-derived (A, C, and E) and A549.EpoB40-derived (B, D, and
F) xenografts were treated with vehicle, patupilone (2 mg/kg), IR (3  1and 3  3 Gy, respectively), or a combination of patupilone and IR. Mice were sacrificed 84 h after
treatment and tumors were harvested, formalin fixed, and stained for the Ki-67 (A and B), CD31as marker of tumor cell proliferation and MVD (C and D), and antibodies
against the exogenous hypoxia marker pimonidazole hydrochloride for the immunohistochemical detection of tumor hypoxia (E and F), respectively. MeanF SE value per
group. *, P < 0.01; **, P < 0.001.
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cytotoxic in vivo effect in response to the different treatment
modalities.
We observed a cytotoxic and tumor growth delay effect in the
tumors derived from the MSA-sensitive adenocarcinoma cell
line A549 in response to irradiation and patupilone alone and a
supra-additive response to combined treatment. As expected,
patupilone reduced the proliferative activity of the MSA-
resistant cell line A549.EpoB40 in vitro only at >100-fold the
concentration necessary for the wild-type cell line (3, 18). As
determined here in this report, no tumor growth delay could be
observed in vivo with treatment of patupilone alone and no
enhancement of an IR effect was induced on combined
treatment in tumors derived from the MSA-resistant cell line.
Of note, patupilone induced an antiangiogenic response with
reduced MVD and enhanced hypoxia in the wild-type but not
MSA-resistant tumors.
The wild-type A549 cell line was also more sensitive to
treatment with increasing doses of IR than A549.EpoB40 cells,
which carry a specific Gln-to-Glu mutation at residue 292 in
the M loop of h-tubulin and which changes the affinity of
h-tubulin to the MSA (3). We cannot exclude that additional
mutations are present in the patupilone-resistant cells, but most
likely the known h-tubulin mutation not only reduces the
affinity to patupilone but also affects microtubule dynamics,
which may subsequently render the cells more radiation
resistant. Importantly, the proliferative activity and growth
kinetics of untreated cells or tumors derived from the two
different cell lines were similar. An increased radiation
resistance was present in the patupilone-resistant tumor cells
and not in the sensitive ones and thus still enabled to
investigate the involvement of the tumor microenvironment
in response to the combined treatment modality of IR with
patupilone.
The potent antiangiogenic activity of MSAs was proposed to
be a major mechanism leading to the successful anticancer
activity of this class of compounds (9, 11, 19, 20). Patupilone
has an antiproliferative and apoptosis-inducing effect in
microvascular and macrovascular endothelial cells (9) and
our own in vitro experiments done with primary human
umbilical vein endothelial cells confirmed the high potency of
patupilone against this cell type (data not shown). Patupilone
also induces vascular disruption leading to reduced tumor
blood volume (8). We showed previously an at least additive
antitumor effect by the combined treatment of IR with different
inhibitors of angiogenesis, such as the VEGF receptor tyrosine
kinase inhibitor PTK787 or the dual receptor tyrosine kinase
inhibitor AEE788 (21, 22). Based on the putative direct
antiangiogenic property of patupilone, a partial tumor growth
delay effect was expected on treatment with patupilone alone or
in combination with IR even in tumors derived from the
patupilone-resistant tumor cells (A549.Epo40). However,
treatment with neither patupilone alone nor in combination
with IR reduced tumor growth or increased tumor growth
delay, respectively, in A549.Epo40-derived tumors.
A strong reduction in MVD and change in tumor hypoxia on
treatment with patupilone alone was only detected in tumors
derived from the A549 wild-type cells and not in tumors
derived from the patupilone-resistant tumor cells. Despite
direct in vitro cytotoxicity against endothelial cells (9), our
results indicate that the antiangiogenic effect of patupilone
in vivo is indirectly induced by interference on the level of the
tumor cellular stress response. Our in vitro experiments done
with the hypoxia-regulated reporter gene assay clearly showed
that patupilone reduces the expression of the HIF-1 ‘‘tran-
scriptome’’ such as VEGF and other genes involved in
angiogenesis and hypoxic adaptation but only in patupilone-
sensitive tumor cells, thereby leading to an indirect tumor
cell-mediated antiangiogenic effect of patupilone. Patupilone
might also directly target the microtubule system in the tumor
endothelial cell compartment but might be less cytotoxic in
presence of sufficient VEGF and other survival factors secreted
from the tumor cells. The radiosensitivity of the tumor vascular
network codetermines the tumor response to IR (23). There-
fore, pharmacologic approaches, which interfere with the
survival signaling of endothelial cells, render these cells more
radiosensitive and subsequently enhance the tumor response
to IR.
Fig. 5. Patupilone reduces HRE-dependent luciferase expression. A549 and
A549.EpoB40 cells stably transfected with a pGL4.27 HRE vector (3 HRE-VEGF
promoter for firefly-luciferase expression) and the pRL SV40 vector (Renilla
luciferase) were treated with increasing doses of patupilone (A) and in combination
with IR (5 Gy; B) under normal and hypoxia mimicking conditions.The cells were
tested for luciferase reporter activity 24 h after patupilone treatment. MeanF SE
value per group. *, P < 0.01; **, P < 0.001.
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A major obstacle for the successful tumor response to IR is
tumor hypoxia, which renders tumor cells two or three times
more radioresistant than under normoxic conditions. Of note,
our in vitro experiments revealed that patupilone is as potent
against tumor cells under normoxic as under hypoxic con-
ditions. Thus, a combined treatment modality of patupilone in
combination with IR also bears promise against tumors with an
increased hypoxic fraction. Here, we observed an increase of
tumor hypoxia induced by patupilone alone presumably
through this antiangiogenic, indirect MVD-reducing effect. We
investigated previously the dynamics of tumor hypoxia in
response to inhibitors of angiogenesis alone and in combina-
tion with IR and observed that irradiation counteracts the risk
of treatment-induced hypoxia by the inhibition of angiogenesis
(21, 22). Although treatment with the VEGF receptor/tyrosine
kinase inhibitor PTK787/ZK222584 also increased overall and
local tumor hypoxia, combined treatment with IR resulted in
extended tumor growth delay and tumor cell apoptosis but no
increase in tumor hypoxia (22). As the radiosensitivity of the
tumor vascular network codetermines the tumor response to IR
(23), pharmacologic approaches, which interfere with the
survival signaling of endothelial cells, render these cells more
radiosensitive and subsequently enhance the tumor response to
IR. The reduction of survival factors secreted by the tumor cells,
after treatment with patupilone, leaves the endothelial cells
more vulnerable to direct irradiation. Nevertheless, combined
treatment of patupilone with radiation did not enhance tumor
hypoxia relative to untreated tumors as if radiation antagonizes
the patupilone-induced increase of tumor hypoxia. The
mechanisms underlying this antagonistic effect is unclear, but
it is conceivable that enhanced cell death together with reduced
proliferation of tumor cells may reduce the intratumoral
oxygen demand to a level that can still be met by the damaged
tumor vasculature and thereby avoid a hypoxic state in the
allograft (24, 25). This mechanism might be relevant for the
combined treatment of irradiation with direct and indirect
inhibitors of angiogenesis.
In summary, our results using in vivo tumor models derived
from patupilone-sensitive and patupilone-resistant variants of
the non-small cell lung cancer cell line A549 strongly suggest
that the major antitumor effect of patupilone and a combined
patupilone/IR treatment is mainly due to directed effects on the
tumor cell compartment and that patupilone may induce an
antiangiogenic effect in an indirect way through tumor cell
targeting. Overall, these preclinical experiments are of strong
relevance for a clinical strategy and further support the
promising treatment modality of patupilone alone and in
combination with IR.
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a  b  s  t  r  a  c  t
The  use  of  microtubule  stabilizing  agents  (MSAs)  is  a  promising  strategy  for anti-cancer  therapy  alone
and as  part  of  combined  treatment  modalities  with  ionizing  radiation.  However  MSA-provoked  molec-
ular and  cellular  processes  including  the  regulation  of intercellular,  paracrine  signaling  pathways  are
far  from  clear.  Here  we  investigated  the  interference  of  the  novel,  clinically  relevant  MSA  patupilone
(epothilone  B)  with  the  tumor-cell  derived  vascular  endothelial  growth  factor  (VEGF),  which  is most  rele-
vant for  tumor  angiogenesis.  Low-dose,  sub-nanomolar  concentrations  of  patupilone  speciﬁcally  reduced
hypoxia-driven  stabilization  of the  transcription  factor  HIF-1  in  the  patupilone-sensitive  lung  adenocar-
cinoma  cell  line A549,  but not  in  the  mutant  derivative  cell  line  A549.EpoB40.  Patupilone  further  reduced
hypoxia-induced  VEGF  expression  and  secretion  but  only  in  the  A549  wildtype  cell  line. In  the  wildtype
cell  line,  ionizing  radiation  alone  induced  hypoxia-dependent  VEGF-expression  but  a strong  dominant
counteracting  effect  of  patupilone  was  always  observed  when  ionizing  radiation  was  combined  with
patupilone,  on the  level  of HIF-1  protein  stability,  VEGF-expression  and  VEGF-secretion.  These  results
demonstrate  that  patupilone  and  ionizing  radiation  dysregulate  hypoxia-induced  stress  responses,  which
might contribute  to  the  potency  of  this  promising,  combined  treatment  modality.
© 2011 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Interference with microtubule function leads to defective
mitotic spindle formation, cell cycle arrest in M-phase, and eventu-
ally to apoptosis or post-mitotic cell death. The use of microtubule
interfering agents is therefore a promising strategy for anti-cancer
therapy alone and as part of combined treatment modalities with
cytotoxic agents [1].  The effects of microtubule interfering agents at
the biochemical level are well investigated, but additional cytotoxic
effects due to signaling interference have been identiﬁed, which
merit further investigation [2–5].
We previously investigated the combined treatment modal-
ity of ionizing radiation (IR) with the novel, clinically relevant
microtubule stabilizing agent patupilone (Epothilone B), and inter-
estingly, the combination of patupilone with IR resulted in vitro
only in an additive cytotoxic effect (against various cancer cell
types) but in a supra-additive tumor growth delay against tumor
xenografts derived from the same tumor cells [2,4]. The accumula-
tion of tumor cells in the most radiosensitive G2-M phase of the cell
cycle represents the major rationale for the sensitization to IR [6–9],
∗ Corresponding author. Tel.: +41 44 255 8549; fax: +41 44 255 4435.
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though other S-phase progression-related mechanisms have been
observed as well [4].  Additional anti-vascular and anti-angiogenic
effects might contribute to the supra-additive tumor growth delay
observed in vivo, and indeed, direct targeting of endothelial cells
[10–12] and indirect, anti-angiogenic interference with the secre-
tion of pro-angiogenic factors from tumor cells have been proposed
[2,13]. Microtubule stabilizing and destabilizing agents block the
nuclear translocation and correct assembly of the hypoxia inducible
factor (HIF) by disrupting the structural organization of the micro-
tubule cytoskeleton. In consequence, the downstream signaling of
HIF-1 target genes in response to hypoxia is compromised [2,3,5].
A reduction of pro-angiogenic (and cytoprotective) cytokine secre-
tion by patupilone via inhibition of HIF could contribute to this
mechanism [14,15]. However, such a link between microtubule-
interfering agents and HIF-signaling has only been investigated at
high-dose concentrations of these agents.
The group of microtubule stabilizing agents (MSAs) are amongst
the most promising chemotherapeutic agents for the treatment
of non-small cell lung cancer. The MSA  docetaxel is the only
chemotherapeutic agent currently approved for ﬁrst- and second-
line treatment of advanced non-small cell lung cancer. Although
single agent docetaxel as well as combined treatments with
platinum-based agents have led to signiﬁcant progress in the treat-
ment of lung cancer, its use often results in strong side-effects
0169-5002/$ – see front matter ©  2011 Elsevier Ireland Ltd. All rights reserved.
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[16–18].  In order to overcome such limitations, new MSA  with
fewer side-effects, superior pharmacological and anticancer activ-
ity are under investigation in order to maximize the induced
beneﬁts for lung cancer patients. At the same time and based on
the immense technological improvements of current radiotherapy
with regard to treatment conformality and accuracy radiotherapy
is becoming standard of care for the management of lung cancer. As
such, combined radiochemotherapy treatment modalities are also
of high interest for this tumor entity.
Here we investigated the treatment response of low-dose, sub-
nanomolar concentrations of patupilone alone and in combination
with IR speciﬁcally on hypoxia-driven VEGF expression and secre-
tion in the patupilone-sensitive lung adenocarcinoma cell line A549
and the mutant derivative A549.EpoB40, which is strongly resis-
tant to patupilone due to a genetically deﬁned -tubulin-mutation
[3,19–21]. Thereby we aim to further explore the interference of
patupilone with the tumor-cell derived growth factor most relevant
for tumor angiogenesis.
2. Materials and methods
2.1. Drugs and cell lines
Patupilone (epothilone B, EPO906) was provided by Novartis
Pharma AG (Basel, Switzerland). The human cell line pair A549 and
A549.EpoB40 was obtained from the laboratory of Dr. S.B. Horwitz.
2.2. Cell cultures, drug preparation and irradiation
The human non-small cell lung cancer lines A549 and
A549.EpoB40 were grown in RPMI 1640 containing 10% (v/v) fetal
bovine serum, 1% (v/v) penicillin–streptomycin and 1% (v/v) l-
glutamine at 37 ◦C in 5% CO2. A549.EpoB40 is derived from A549 by
stepwise selection with patupilone and contains a point mutation
in class 1 -tubulin (292 from Gln to Glu) which is associated with
a ∼95-fold resistance to patupilone [20]. The A549.EpoB40 cell line
was grown and maintained in medium containing 10 nM patupi-
lone. For in vitro experiments, patupilone was dissolved in DMSO
(1 mM stock solution) and further diluted with media containing
10% FCS.
Irradiation of cell cultures was carried out using a Gulmay
200 kV X-ray unit at 100 cGy/min at room temperature. For com-
bined treatment and hypoxia experiments, cells were pretreated
with patupilone 24 h before applying hypoxia or hypoxia mimick-
ing conditions. Cells were irradiated 4 h thereafter.
2.3. Cultivation of cells under hypoxia
Hypoxia experiments with A549 and A549.EpoB40 were per-
formed for various time spans at 0.2% or 1% oxygen using a Invivo2
400 hypoxia workstation (Biotrace International). Cells were prein-
cubated with patupilone for 24 h under normoxic conditions,
followed by incubation in the hypoxia chamber or under hypoxia-
mimicking conditions, using Dimethyloxaloylglycine (DMOG)
(Biomol GmbH, Hamburg, Germany), a prolyl-4-hydroxylase
inhibitor (0.25 and 1 mM,  respectively) [2].
2.4. Western blot analysis
A549 and A549.EpoB40 were cultivated in 6-well dishes, washed
twice with ice cold PBS, and whole cell extracts were obtained
by scraping cells with 150 l of pre-cooled hypotonic lysis buffer
(Laemmli-buffer (4% SDS, 15% glycerol, 0.125 M Tris–HCl) and 2×
SDS-buffer (20% glycerol, 0.100 M Tris, 0.1% bromphenol blue; 10%
-mercaptoethanol) 1:1) and immediately heated for 5 min  at 95 ◦C
on a heating block. Hypoxic probes were retrieved under hypoxic
conditions. Proteins were resolved by 10% SDS–PAGE, followed by
western blotting onto polyvinylidene diﬂuoride membranes. Mem-
branes were probed with the HIF-1 antibody (HIF-1  (H-206),
Santa Cruz Biotechnology, Inc.). Antibody detection was achieved
by enhanced chemoluminescence (Amersham, Piscataway, NJ)
according to the protocol of the manufacturer. All experiments
were carried out independently at least thrice.
2.5. Isolation and analysis of RNA
Total RNA was isolated using the Quiagen RNeasy Plus Mini
Kit (Qiagen, Hombrechtikon, Switzerland). First-strand cDNA syn-
thesis was performed with 1–5 mg  total RNA using reverse
transcriptase enzyme, and mRNA levels were measured by real-
time quantitative PCR using a SybrGreen qPCR reagent kit (Applied
Biosystems) in combination with a 7900 HT TaqMan rtPCR system
(Applied Biosystems) and SDS manager 2.3, patch 3-software. Real-
time PCR was carried out as recommended by the manufacturer. To
verify equal input levels, -actin was  used as a housekeeping gene
and the data were expressed as ratios relative to -actin levels.
The primers (Microsynth, Balgach, Switzerland) used for RT-PCR
of VEGF-A mRNA were as follows: (a) forward primer, 5′-ATG AAC
TTT CTG CTG TCT TGG GT-3′ and (b) reverse primer: 5′-TCA CCG
CCT CGG CTT GTC AC-3′ [22]. The forward primer sequence for -
actin mRNA (internal control) quantiﬁcation was 5′-GTC CTC TCC
CAA GTC CTC ACA-3′; the reverse primer sequence was 5′-AAT TTA
CAC GAA AGC AAT CCT ATC AC-3′.
2.6. ELISA
Supernatants of cultured cells were centrifuged at 10,000 × g
to remove debris and stored at −80 ◦C. Cell numbers were manu-
ally counted after trypsination to allow correction to cell number.
Total protein content of supernatant was measured with a Nano-
drop spectrophotometer (Witec AG, Switzerland) at an absorbance
of 280 nm.  The concentration of VEGF-levels in the supernatant
was  determined using the commercially available Quantikine®
Human VEGF Immunoassay kit (R&D Systems GmbH, Wiesbaden-
Nordenstadt, Germany), following the manufacturer’s description.
2.7. Statistical analysis
Experiments presented in the ﬁgures are representative of three
or more different repetitions if not otherwise indicated. Statis-
tical analysis was performed using GraphPad Prism5 software
(GraphPad Software Inc.). Student’s t-test was used to evaluate the
differences between normoxic and hypoxic and between drug and
IR treated samples. The level of signiﬁcance was  set at 0.05.
3. Results
3.1. Stabilization of microtubules leads to inhibition of the HIF
pathway
The hypoxia-stabilized HIF-1-subunit of the transcription fac-
tor HIF represents a major determinant for hypoxia-regulated
expression of pro-angiogenic growth factors. To determine
hypoxia-dependent HIF-1  stabilization on patupilone treatment,
patupilone-sensitive lung adenocarcinoma A549 wildtype and
patupilone-resistant A549.EpoB40 cells were pretreated for 24 h
with increasing concentrations of patupilone (0–1 nM) followed
by incubation in 0.2% pO2 or addition of the hypoxia-mimicking
agent DMOG (0.25 and 1 mM,  respectively). Maximum stabiliza-
tion of the HIF-1 subunit under hypoxic conditions was  observed
at 4 h of hypoxic exposure and in hypoxia-mimicking conditions
(Fig. 1) and was  reduced again to background levels at the 24 h
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Fig. 1. Patupilone reduces HIF-1 levels under hypoxia. (a) A549 wildtype and (b) A549.EpoB40 cells were treated for 24 h with increasing concentrations of patupilone and
then  subjected to hypoxia or hypoxia mimicking conditions (0.2% pO2 or DMOG, respectively), for additional 4 h. HIF-1 protein levels were determined by western blotting.
Band  intensities of two independent experiments were quantiﬁed, pooled and are plotted.
time point in both cell lines (data not shown). In the A549 wild-
type cells HIF-1 stabilization was abrogated by patupilone in
a dose-dependent way, while HIF-1 protein levels were not
reduced in the A549.EpoB40 cells on patupilone treatment (Fig. 1).
HIF-1 stabilization in the A549.EpoB40 cells was  only affected
at approximately 100-fold higher concentrations of patupilone,
which correlates to the 100-fold-reduced afﬁnity of mutant -
tubulin to patupilone in these cells (data not shown).
We previously observed an at least additive reduction of
microvessel density in tumor xenografts derived from A549-
adenocarcinoma tumor cells on combined treatment with
patupilone and IR [2].  This might be due to a combined effect on
the HIF-1 -dependent expression or secretion of pro-angiogenic
factors such as the vascular endothelial growth factor (VEGF).
Irradiation of cells alone did not affect HIF-1-level but syner-
gized with patupilone. When A549 wildtype cells were pretreated
with low dose patupilone (0.2 nM and 0.5 nM;  with only a minor
effect on HIF-1 stability alone), followed by incubation with
DMOG and irradiation 2 h thereafter, HIF-1-protein levels were
even further reduced than after treatment with patupilone alone.
No downregulation of HIF-1 was observed in the -tubulin-
mutated counterpart cells after treatment with either condition
(Fig. 2).
3.2. Downstream signaling of HIF at the level of VEGF mRNA is
affected by treatment with patupilone
To determine the consequence of deregulated HIF-1 stability
on the expression of the major pro-angiogenic factor VEGF, VEGF
mRNA levels were quantiﬁed by real-time PCR. Incubation of cells
for 24 h under hypoxic (0.2% pO2) or hypoxia mimicking condi-
tions (DMOG) resulted in a 6- and 4-fold upregulation of VEGF
mRNA levels, in A549 wildtype and A549EpoB40 mutated lung
adenocarcinoma cells, respectively (Fig. 3). Similar to the effect on
HIF-1-stability, pretreatment with patupilone (0.5 nM)  resulted
in diminished VEGF mRNA upregulation in the A549 cells by 43%
(p = 0.002), but not in the patupilone-resistant A549.EpoB40 cells,
when treated under hypoxic or hypoxia mimicking conditions.
Under hypoxia-mimicking conditions irradiation alone (4 h after
start of DMOG-treatment) resulted in enhanced VEGF expres-
sion in the A549 wildtype cells but not in the A549EpoB40 cells,
which are more radiation resistant [2].  The discrepancy between
IR-downregulated HIF-1-levels (see above) and IR-enhanced
VEGF-mRNA levels might be due to the different time points of
data collection. However and more important, the relative down-
regulation of VEGF mRNA levels in patupilone-pretreated cells was
observed to a similar extent in irradiated as in unirradiated A549
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Fig. 1. (Continued.)
wildtype cells (reduction by 45% of initial values (p = 0.006)), while
patupilone treatment did not downregulate VEGF expression in
irradiated A549.EpoB40 cells.
3.3. VEGF protein secretion with drug pretreatment is inhibited in
A549
To determine the amount of secreted VEGF in response to
treatment with IR and patupilone, cells were preincubated with
patupilone for 24 h, incubated under hypoxia mimicking condi-
tions (for 30 h) and irradiated at the 4 h time point following
DMOG-addition. Supernatants were collected during a 12 h interval
of incubation under hypoxia-mimicking conditions (18–30 h time
period) and were analyzed for VEGF protein levels by ELISA.
As expected from the real time PCR results, secreted VEGF lev-
els in supernatants derived from DMOG-treated cells were 3–4-fold
enhanced in both A549 wildtype and A549.EpoB40 mutated cells in
comparison to supernatants derived from cells kept in normoxia.
Of note, while irradiation enhanced VEGF mRNA levels in A549 cells
kept under hypoxia-mimicking conditions (see above), no further
increased VEGF protein level could be detected in supernatants
derived from these cells. Interestingly, in response to patupi-
lone treatment (0.5 nM)  a signiﬁcant reduction in VEGF-secretion
under normoxic (31%, p = 0.008) as well as DMOG conditions (34%,
p < 0.001) was determined in the patupilone-sensitive cell line
A549 (Fig. 4) but not in the patupilone-resistant cell line. Similar
results were determined when cells were kept under hypoxia (1%)
instead of DMOG-treatment or in supernatants collected over a
48 h-interval from cells treated under the same conditions (data
not shown). Of note, prior results demonstrated that the anti-
proliferative effect of patupilone under normoxic and hypoxic (pO2
of 1%) conditions remains the same (data not shown [2]). Thus
combined treatment modality of low doses of patupilone in com-
bination with ionizing radiation also bears promise against tumors
with an increased hypoxic fraction.
Overall our results demonstrate that low-dose treatment of
tumor cells with patupilone antagonizes a major pro-angiogenic
signaling axis on the level of the hypoxia-inducible factor
HIF-1,  thereby reducing hypoxia-enhanced expression and sub-
sequent secretion of the vascular endothelial growth factor
VEGF.
4. Discussion
Here, we  investigated the regulation of the hypoxia-inducible
factor HIF-1 and its downstream target VEGF by the novel, clin-
ically relevant microtubule stabilizing agent patupilone alone and
in combination with ionizing radiation. The effect of patupilone
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Fig. 2. Enhanced reduction of HIF-1 levels on combined treatment with patupilone and ionizing radiation: A549 wildtype and A549.EpoB40 cells were treated for 24 h
with  increasing concentrations of patupilone, subjected to hypoxia mimicking conditions, irradiated after 2 h and analyzed for HIF-1a protein levels 4 h after start of DMOG
incubation. Band intensities of three independent experiments were quantiﬁed, pooled and are plotted: columns: mean; bars: ±SE.
was speciﬁcally tested in the lung adenocarcinoma cell line A549
at subnanomolar concentrations, which do not induce the classic
MSA-dependent M-phase arrest and have only minimal cytotoxic
activity. Under hypoxia HIF-1-protein levels were reduced by
low-dose treatment with patupilone. Subsequently VEGF mRNA
transcription was diminished, and reduced levels of secreted VEGF-
protein were detected in cell supernatants. Furthermore patupilone
repressed IR-induced VEGF mRNA expression. The speciﬁcity of
patupilone and the involvement of the microtubular system were
evidenced by the lack of a treatment response in the mutated A549
cell line derivative harboring a speciﬁc -tubulin mutation, which
abrogates patupilone-binding.
A variety of microtubule targeting drugs has previously been
described to exhibit anti-HIF properties in tumor cells exposed
to hypoxia [3,5]. 2-Methoxyestradiol and classic microtubule
stabilizing (taxanes) and microtubule destabilizing (vincristine,
discodermolide) agents downregulated HIF-1 at the posttran-
scriptional level resulting in reduced HIF-1 protein synthesis
and subsequent reduced nuclear accumulation and transcriptional
activity. Microtubule stabilizing agents may  interfere with a regu-
lated HIF-1  mRNA-microtubule association and guided nuclear
import of the HIF-1 subunit into the nucleus [3,5]. However
these experiments were performed at concentrations of the respec-
tive compounds that strongly induced microtubule stabilization
and destabilization, respectively and treatment-dependent cell
cycle redistribution into G2-M phase. Here we demonstrate that
low-dose concentrations of patupilone (epothilone B) strongly
reduce HIF-1  protein levels and subsequent downregulation of
the major downstream target VEGF at up to 100-fold lower concen-
trations, which do not result in microtubule interference-related
G2-M cell cycle redistribution, and that patupilone counteracts
a potential pro-angiogenic stress response [23]. Furthermore
these low concentrations of patupilone are still -tubulin-speciﬁc,
without any effect in the A549-mutated cell line and are suf-
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Fig. 3. Regulation of hypoxia-driven VEGF-mRNA-expression by patupilone and IR. (a) A549 wildtype and A549.EpoB40 cells were treated for 24 h with patupilone (0.5 nM)
and  subjected to hypoxia or hypoxia mimicking conditions (0.2% pO2 or DMOG, respectively) for 24 h. (b) A549 wildtype and A549.EpoB40 cells were treated for 24 h with
patupilone (0.5 nM), subjected to hypoxia mimicking conditions and irradiated after 4 h. VEGF mRNA was determined 24 h after start of DMOG incubation by real time PCR
and  normalized to -action mRNA expression. Data were pooled from three independent experiments, columns: mean; bars: ±SE.
ﬁcient to sensitize for ionizing radiation ([2,4], and data not
shown).
Despite direct in vitro cytotoxicity against endothelial cells
[11], our prior results allocate part of the anti-angiogenic effect of
patupilone to interference with the tumor cellular stress response.
In vitro experiments performed with a hypoxia-regulated reporter
gene assay demonstrated that patupilone reduces the expres-
sion of the HIF-1 “transcriptome” but only in patupilone sensitive
tumor cells, thereby abrogating the paracrine, tumor cell-mediated
protection of the tumor endothelium [2]. Here we  speciﬁcally
determine downregulation of VEGF expression and subsequent
secretion of the HIF-1 downstream target and major endothelial
growth and survival factor VEGF on cellular treatment with patupi-
lone. Similar to patupilone in this study, the MSA  paclitaxel also
downregulates VEGF-gene expression and VEGF-protein secretion,
however only at high cytotoxic doses of paclitaxel as demonstrated
in MKN45 and HT29 gastrointestinal carcinoma cell lines (≥0.1 M)
[24,25].
Regulation of HIF-1 in response to irradiation is com-
plex and dependent on multiple factors including hypoxia and
reoxygenation-enhanced generation of reactive oxygen species
[14,15]. Furthermore the treatment response in vitro might not
reﬂect the in vivo situation with its dynamic adaptation to
microenvironmental changes in response to radiotherapy. Here we
determined multiple endpoints in response to IR alone and in com-
bination with patupilone in the two related adenocarcinoma cell
lines (HIF-1protein levels, VEGF expression and secretion). In part
they are difﬁcult to be reconciled. For example IR enhanced VEGF
expression under hypoxic condition, but no enhanced HIF-1 pro-
tein levels could be detected in irradiated cells. This might be due
to undetected posttranslational modiﬁcations, which increases the
transcriptional activity of HIF-1, but might also be due to incom-
plete analysis of HIF-1  due to technical limitations. In this study,
patupilone-reduced VEGF-mRNA expression was normalized to -
actin-housekeeping gene expression and is therefore not affected
by a small reduction of cell viability at patupilone-concentrations
used (20% at 0.5 nM,  data not shown). However we  cannot exclude
that patupilone-reduced VEGF-secretion might in part derive from
patupilone-affected cell viability at a later time point. On the other
hand MSA  may  also interfere with the secretion of vesicles and
proteases required for VEGF-release along a dynamic microtubu-
lar system [26], which is currently investigated as part of ongoing
studies.
However and more important a strong dominant counteracting
effect was always observed when IR was  combined with patupi-
lone, on the level of HIF-1 protein stability, VEGF-expression and
VEGF-secretion.
Overall, we  demonstrate that low dose, subnanomolar treat-
ment of lung carcinoma cells with the clinically relevant
microtubule stabilizing agent patupilone interferes with the major
hypoxic signaling axes. This effect is most probably linked to micro-
tubules interference, as indicated by the negative results in the
-tubulin-mutated drug-resistant A549.EpoB40 cell line. Patupi-
lone treatment results in reduced VEGF expression and secretion
under hypoxic conditions and subsequent lack of paracrine pro-
tection of the tumor vasculature. Thus besides its direct cytotoxic
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Fig. 4. Regulation of hypoxia-driven VEGF-secretion by patupilone and IR. A549
wildtype and A549.EpoB40 cells were treated for 24 h with patupilone (0.5 nM),
subjected to hypoxia mimicking conditions for 30 h (a) and irradiated at the 4 h
time point following DMOG-addition (b). Supernatants were collected during a 12 h
interval of incubation under hypoxia-mimicking conditions (18–30 h time period)
and  analyzed for VEGF protein levels by ELISA. Data presented are derived from
three independent experiments, columns: mean; bars: ±SE.
and radiosensitizing effect on the tumor cell level, patupilone might
concomitantly render endothelial cells more vulnerable to ionizing
radiation. This eventually contributes to the strong supra-additive
treatment response observed in vivo in response to the combined
treatment modality of IR with patupilone [2,4] and will also be
of future clinical interest [27]. Thus a pharmacological approach
which interferes with the hypoxic signaling of neoplastic cells ren-
ders these cells more radiosensitive and subsequently enhances the
tumor response to ionizing radiation.
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Concurrent radiochemotherapy for medulloblastoma
includes the microtubule disrupting agent vincristine;
however, vincristine alone or as part of a combined treat-
ment regimen is highly toxic. A major goal is therefore to
replace vincristine with novel potent chemotherapeutic
agents—in particular, with microtubule stabilizing and
destabilizing compounds—with a larger therapeutic
window. Here, we investigated the antiproliferative,
cytotoxic and radiosensitizing effect of patupilone
(epothilone B [EPO906]), a novel, non–taxane-related
and nonneurotoxic microtubule-stabilizing agent in
human medulloblastoma cell lines. The antiproliferative
and cytotoxic effects of patupilone alone and in combi-
nation with ionizing radiation was determined in the 3
representative human medulloblastoma cell lines
D341Med, D425Med, and DAOY. Patupilone alone
effectively reduced the proliferative activity and clono-
genicity of all medulloblastoma cell lines tested at pico-
molar concentrations (50–200 pM) and resulted in an
at least additive anticlonogenic effect in combination
with clinically relevant doses of ionizing radiation (2 or
5 Gy). Cell-cycle analysis revealed a sequential G2-M
arrest and sub-G1 accumulation in a dose- and treat-
ment-dependent manner after exposure to patupilone.
In tumor xenografts derived from D425Med cells, a
minimal treatment regimen with patupilone and fractio-
nated irradiation (1 3 2 mg/kg plus 3 3 3 Gy) resulted
in an extended tumor growth delay for the 2 single treat-
ment modalities alone and a supra-additive treatment
response for the combined treatment modality, with com-
plete tumor regressions. These results demonstrate the
potent efficacy of patupilone against medulloblastoma
cell lines and indicate that patupilone represents a prom-
ising candidate to replace vincristine as part of a com-
bined treatment strategy with ionizing radiation.
Keywords: apoptosis, autophagy, ionizing radiation,
medulloblastoma, patupilone.
M
edulloblastoma is the most common malig-
nant brain tumor of childhood.1 Standard
therapy for medulloblastoma comprises neuro-
surgical resection, radiotherapy, and chemotherapy.
However, nearly one-half of all patients die of progressive
disease, and survivors experience considerable adverse
effects,2–4 including radiation-dependent reduction of
neurocognitive performance.5–8 Medulloblastoma is a
relatively radiation sensitive tumor entity. Concurrent
radiochemotherapy for medulloblastoma often includes
the microtubule-disrupting agent vincristine. However,
use of vincristine alone or as part of a combined treatment
regimen is highly toxic;3,9 therefore, treatment modifi-
cations have been reported frequently.10–12 Of note,
excellent outcomes were reported in a multi-institution
phase II trial in which patients with average- and high-
risk medulloblastoma were treated with risk-adapted cra-
niospinal radiotherapy without concurrent vincristine
therapy. In this trial, vincristine was only part of the
dose-intensive postirradiation treatment (cyclophospha-
mide, cisplatin, and vincristine), challenging the value
of concomitant vincristine treatment during radiother-
apy.13 Therefore, a major goal is to replace vincristine,
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as part of multimodality treatment regimens, with novel
potent chemotherapeutic agents, such as carboplatin,
which is under clinical investigation, either a) together
with vincristine during craniospinal radiotherapy—as in
the COG 99701 trial (ClinicalTrials.gov number
NCT00003203) for patients with metastatic medullo-
blastoma14— b) with the aim of substituting vincristine
during craniospinal radiotherapy—as in the future
SIOP-Europe PNET 6 medulloblastoma study for
“standard-risk” patients with medulloblastoma—or c)
with other promising microtubule-stabilizing and -desta-
bilizing agents, which have been investigated thoroughly
in the preclinical setting and which show promising
activity against a panel of xenograft-derived embryonal
tumors.15
Patupilone (epothilone B [EPO906]), which is cur-
rently being tested in phase III clinical trials,16 is a novel
microtubule-targeting cytotoxic agent that is structurally
unrelated to paclitaxel and docetaxel. Patupilone is 3–20
times more potent than the taxanes in vitro and has
shown a safe toxicity profile in adults.17 Patupilone
stabilizes preformed microtubules and leads to aberrant
spindle formation during mitosis. Patupilone has been
shown to induce regression of various types of human
tumors in vivo, including glioma, lung, colon, breast,
prostate, and ovarian carcinomas. Of note and in contrast
to paclitaxel, patupilone is equally cytotoxic to
paclitaxel-susceptible and paclitaxel-resistant cells that
display a multidrug-resistance phenotype due to overex-
pression of the P-glycoprotein (P-gp) efflux pump.17
The combined treatment with patupilone and ionizing
irradiation showed a supra-additive effect in vitro and
in vivo in lung and colon carcinoma models.18,19
Combination of ionizing radiation and patupilone
has also been tested in a phase I trial involving brain
tumors.20
We investigated the efficacy of patupilone alone and
in combination with ionizing radiation in different
human medulloblastoma cell lines. We showed that
patupilone alone is extremely potent at picomolar con-
centrations in medulloblastoma cell lines, and combined
treatment with clinically relevant doses of ionizing radi-
ation results in an at least additive anticlonogenic effect
in vitro and induces a strong supra-additive treatment
response in vivo.
Materials and Methods
Cell Cultures, Reagents, and Irradiation
Patupilone was kindly provided by Novartis Pharma.
D425Med human medulloblastoma cells were pur-
chased from the American Type Culture Collection.
D341Med and D425Med human medulloblastoma
cells were the kind gift of Dr Henry Friedman (Duke
University). All medulloblastoma cells were cultured in
Richter’s zinc option medium supplemented with 10%
fetal bovine serum (nonessential amino acids were
added to the medium of D341Med and D425Med cells
to a final concentration of 1%). All cell cultures were
maintained at 378C in a humidified atmosphere with
5% CO2.
For in vitro assays, a stock solution (1 mM) of
patupilone was prepared in DMSO and further diluted
with water/DMSO- and serum-containing media.
Irradiation was performed at room temperature, using
a Pantak Therapax 300 kV X-ray unit at 0.7 Gy/min.
3-Methyladenine (Sigma) was prepared in water at a
stock solution of 100 mM and further diluted in serum-
containing media. Bafilomycin-1 (Sigma) was prepared
in DMSO at a stock solution of 100 mM and further
diluted in serum-containing media. The broad-range
caspase inhibitor z-VAD-FMK (Calbiochem; Merck
Chemicals) was prepared in DMSO at a concentration
of 10 mM and further diluted in serum-containing media.
Cell Proliferation, Clonogenic Cell Survival,
and Cell Viability Assay
Proliferative activity was assessed in 96-well F-plates
using the Alamar Blue (Biosource International) and
MTS assays (Promega). Absorption was measured at
570 and 630 nm (Alamar blue) using a GenTec spec-
trophotometer or at 490 nm (MTS) using a microplate
spectrophotometer (Molecular Devices).19,30,31 The
half-maximal inhibitory concentration (IC50) values
were calculated from the regression curve using
GraphPad Prism software, version 4 (GraphPad
Software).30 Each experiment was performed at least
in triplicate. For the cell viability assay, 400 000 or
500 000 cells were seeded and treated 24 h thereafter.
Cell viability was determined 72 h after treatment
began using the trypan blue exclusion assay. Each
experiment was performed at least in duplicate. To
determine clonogenic cell survival, the number of
single-seeded cells was adjusted to obtain 100 colo-
nies per cell culture dish with a given treatment.
After treatment with different regimens, cells were
maintained at 378C in a humidified atmosphere con-
taining 5% CO2 and allowed to grow for 14 days
before fixation in methanol/acetic acid (ratio,
75%:25%) and staining with crystal violet. Only
colonies with .50 cells/colony were counted. For
combined treatment, cells were pre-incubated with
patupilone or control solution 1 h before irradiation.
Clonogenic cell survival assays were repeated as
independent experiments at least twice.
Cell-Cycle Analysis
For cell-cycle analysis, medulloblastoma cells were
treated with patupilone for 6, 12, and 24 h,
respectively. Both floating and adherent cells were
collected. After washing twice in phosphate-buffered
saline (PBS), cells were stained with propidium
iodide (50 mg/mL) (Becton-Dickinson) in PBS contain-
ing 100 U/mL RNase A (Qiagen) for 30 min at room
temperature. The percentage of cells in the different
phases of the cell cycle was determined by evaluating
DNA content, as described elsewhere.30,31
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Caspase-3 Activity Assay
Asp-Glu-Val-Asp (DEVD)ase activity was determined in
cytosolic cell extracts. Cells were treated with increasing
concentrations of patupilone for 6, 12, 24, and 48 h.
Cells were harvested thereafter by trypsin/EDTA, centri-
fuged, and washed with precooled PBS. The cell pellet
was suspended in 5 volumes of precooled buffer A
(20 mM HEPES-KOH [pH 7.5], 10 mM KCl, 1.5 mM
MgCl2, 1 mM sodium EDTA, 1 mM sodium EGTA,
1 mM dithiothreitol [DDT], 250 mM sucrose, and
0.1 mM phenylmethylsulfonyl fluoride [PMSF] sup-
plemented with protease inhibitors [5 mg/mL pepstatin
A, 10 mg/mL leupeptin, 2 mg/mL aprotinin, 2 mg/mL
DTT, and 1 mM of PMSF]). After incubation on ice
for 15 min, the cells were disrupted by freezing and
thawing. Cell lysates were centrifuged at 1000 g for
10 min at 48C, and the supernatant was further centri-
fuged at 100 000 g for 30 min. The resulting supernatant
(S-100 fraction) was stored at 2808C. To determine
caspase 3-like activity, 75 mg of protein from the S-100
fraction was incubated at 378C with the colorimetric
caspase 3 substrate N-acetyl-Asp-Glu-Val-Asp p-
nitroanilide (100 mM; Ac-DEVD-pNA; Calbiochem)
and 1 mM dATP in a final volume of 120 mL.
Cleavage of the caspase substrate was monitored at
405 nm using a GenTec spectrophotometer.
Detection and Quantification of Acidic Vesicular
Organelles (AVOs) with Acridine Orange
To detect and quantify AVOs, cellular vital staining
with acridine orange was performed. In acridine
orange-stained cells, the cytoplasm and nucleolus fluor-
esce bright green and dim red, whereas the acidic com-
partments fluoresce bright red.32 The intensity of the
red fluorescence isproportional to the degree of acidity
and/or the volume of the cellular acidic compartment
and was measured 6, 12, 24, and 48 hafter exposure to
patupilone alone or 48 h after treatment with patupilone
combined with ionizing radiation. After treatment with
patupilone alone or in combination with irradiation,
both adherent and suspended cells were stained at the
indicated time points with acridine orange (1 mg/mL)
for a period of 15 min, harvested by trypsin/EDTA,
and collected in PBS. As a negative control, 0.5 mM bafi-
lomycin A1 (Sigma) was added 30 min before acridine
orange staining. Green (510–530 nm) and red (465 nm)
fluorescence emission from 5 × 105 cells illuminated
with blue (488 nm) excitation light was measured with
a FACS Calibur from Becton Dickinson using CellQuest
software. The ratio of red to green fluorescence was deter-
mined in control and treated cells and normalized in
relation to untreated cells.
Tumor Xenograft in Nude Mice and Application
of Treatment Regimes
D425Med cells (6× 106) were injected subcutaneously on
the backs of 4–6-week-old athymic nude mice. Tumor
volumes were determined from caliper measurements of
tumor length (L) and width (l ) according to the formula
(L x l2)/2. Tumors were allowed to expand to a volume
of 200 mm3 (+10%) before treatment start. With the
use of a customized shielding device, mice were given
strictly loco regional radiotherapy of 3 × 3 Gy on 3 con-
secutive days using a Gulmay 200 kV X-ray unit at
100 cGy/min at room temperature. Patupilone (2 mg/
kg; dissolved in 30% PEG-300/70% saline) was applied
intravenously 24 h before the first treatment with ionizing
radiation (at day 0 of the treatment; n ¼ 5 per group).
Tumor growth was monitored daily.
Results
Patupilone Strongly Reduces Proliferation and Viability
in Human p53wt and p53mt Medulloblastoma Cell
Lines
The antiproliferative effect of the microtubule-
stabilizing agent patupilone was tested in the 3 represen-
tative human medulloblastoma cell lines D341Med,
D425Med, and DAOY. Patupilone reduced the prolif-
erative activity in the D341 cell line, with an IC50 of
0.53 nM (95% confidence interval [CI], 0.45–0.62)
(Fig. 1A); in the D425Med cell line, with an IC50 of
0.37 nM (95% CI, 0.14–0.96) (Fig. 1B); and in the
DAOY cell line, with an IC50 of 0.19 nM (95% CI,
0.12–0.29) (Fig. 1C). Likewise, cell viability, as detected
by trypan blue exclusion, was reduced to 50% when
treated with subnanomolar concentrations of patupilone
(D341Med, 0.25 nM; D425Med and DAOY, 0.1 nM)
(Fig. 1D–F). Of note, up to 10-fold higher IC50 values
were obtained when the different cell lines were treated
with the microtubule-destabilizing agent vincristine
(Supplement 1).
Next, clonogenic cell survival was determined in the 3
cell lines after treatment with increasing concentrations
of patupilone. In the D341Med cell line, the effect of
patupilone on clonogenic survival was at dose range of
patupilone similar to the level of proliferative activity
and viability (IC50, 0.50–0.75 nM). However, the clo-
nogenicity of D425Med and DAOY cells was already
strongly reduced at a 10-fold lower concentration of
patupilone (IC50, 30 pM) (Fig. 1G, H). These results
overall demonstrate that patupilone is highly potent
against different medulloblastoma cell lines. These
medulloblastoma cell lines differ in the expression of
and mutations in specific genes (eg, p53, c-myc).
However, a differential treatment sensitivity so far
cannot be attributed to a specific genetic background.21
Patupilone Sequentially Induces a G2-M-Phase Arrest
and Apoptosis in Medulloblastoma Cell Lines
To investigate patupilone-induced alterations of cell cycle
progression, we determined the cell-cycle distribution
over time in the 3 medulloblastoma cell lines following
treatment with low and high concentrations of patupi-
lone (0.1–1 nM). Low-dose treatment with patupilone
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resulted in minor changes in cell-cycle distribution in all 3
cell lines but also in a small accumulation of cells in a
sub-G1-peak in the D341Med and D425Med cell popu-
lation, which is indicative of apoptosis. On the other
hand, exposure to increased concentrations of patupilone
resulted in extended G2-M-phase accumulation in all 3
medullobastoma cell lines (D341Med and DAOY cell
lines, 1 nM; D425Med cell line, 0.5 nM patupilone)
(Fig. 2). Twelve hours after patupilone exposure,
33.3% (D341Med), 40.6% (D425Med), and 46.2%
(DAOY) of cells were accumulated in the G2-M
phase, compared with 16.5% (D341Med), 26.3%
(D425Med), and 17.5% (DAOY) of the untreated cell
populations (see Table I). Accumulation of cells in the
G2-M phase was most prominent in the DAOY cell
line, probably because of an inactive G1 checkpoint.
After the patupilone-induced G2-M-phase redistribu-
tion, extended accumulation of cells in a subG1-peak
was observed in the D341Med and DAOY cells after
treatment with 1 nM patupilone and in the D425Med
cells after treatment with 0.5 nM of patupilone, again
indicative of patupilone-induced, late apoptosis. These
results demonstrate a dose-dependent sequential antipro-
liferative and cytotoxic effect of patupilone in the medul-
loblastoma cell lines.
Patupilone Induces Apoptosis and Autophagy
in Medulloblastoma Cell Lines
To further investigate patupilone-induced apoptosis,
caspase-3 activity was assessed in the 3 medulloblastoma
cell lines treated with the same concentrations as used
for FACS analysis (see above). Caspase-3 activity was
increased over time in the D425Med and the DAOY
cell lines (Fig. 3B and 3C) and, to a smaller extent, in
Fig. 1. Antiproliferative and cytotoxic effects of patupilone in human medulloblastoma cell lines. A–C, D341Med (A), D425Med (B), and
DAOY (C) human medulloblastoma cells were treated with increasing doses of patupilone, and the antiproliferative activity was determined
after 72 h of exposure. D–F, D341Med (D), D425Med (E), and DAOY (F) human medulloblastoma cells were treated with increasing doses
of patupilone, and cell viability was determined by trypan blue exclusion after 72 h of exposure. (G) Clonogenicity of the D341Med cells
after treatment with increasing doses of patupilone. (H) Clonogenicity of the D425Med and DAOY cells after treatment with increasing
doses of patupilone. Results of a representative experiment are shown (n ¼ 3).
Table 1. Cell-cycle analysis following treatment with high doses
of patupilone.
Cell line 0 h (%) 12 h (%) 24 h (%)
D341 G0-1 53 30.22 42.53
G2-M 17 33.26 12.55
S 30 36.52 44.92
sub-G1 0.6 16.85 26.03
D425 G0-1 39.7 15.36 21.52
G2-M 26 40.65 21.74
S 34 44 56
sub-G1 2 22.47 38.32
DAOY G0-1 35 25.2 44.87
G2-M 17.5 46.21 25.05
S 47 28.6 30.08
sub-G1 1 16.6 14.79
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the D341Med cell line, reflecting the outcome of
subG1-accumulation, as obtained by FACS analysis
(Fig. 3A). Of note, pretreatment with the broad-range
caspase inhibitor z-VAD-FMK did not rescue
D425Med or DAOY cell lines from undergoing cell
death, as assessed by the trypan blue viability assay
(data not shown).
Comparable treatment sensitivity but a reduced
amount of apoptosis in the D341Med cell line suggested
another form of cell death induced by patupilone in this
cell line. As a marker for autophagy, the fractional
volume of acidic vesicular organelles (AVO) in control
and patupilone-treated cells was quantified. A time-
dependent increase in the amount of AVOs was exclu-
sively observed in the D341Med (Fig. 3D) but not in
the D425Med and DAOY medulloblastoma cell lines
(Fig. 3E and 3F). To inhibit the autophagic process
induced by patupilone, cells were pretreated with bafilo-
mycin A1, which prevents the fusion of autophagosomes
with lysosomes. High concentrations of bafilomycin A1
alone (100 nM) were not toxic to the D341Med cells,
but interestingly, pretreatment with bafilomycin A1
strongly sensitized D341Med cells to patupilone
(0.5 nM), resulting in nearly 100% dead cells
(Supplementary Fig. S1). To determine a putative switch
to apoptotic cell death after inhibition of autophagy,
caspase-3 activity was assessed in cells pretreated with
bafilomycin A1. No additional increase in caspase-3
activity could be detected after patupilone treatment
(data not shown). These results suggest that after a
G2-M-phase arrest, patupilone induces late apoptosis
in the medulloblastoma cell lines D425Med and
DAOY. On the other hand, D341Med cells are apopto-
sis resistant, and patupilone-induced autophagy might
initially protect these cells from undergoing cell death
not related to apoptosis.
Patupilone Sensitizes Medulloblastoma Cell Lines
to Ionizing Radiation
Patupilone is a promising agent for combined treatment
with ionizing radiation. We therefore investigated its
antitumor effect in these 3 medulloblastoma cell lines
in combination with increasing doses of ionizing radi-
ation. The D341Med cell line was clearly more radiosen-
sitive than the D425Med and DAOY cell lines with
regard to the level of proliferative activity, viability,
and clonogenic survival (Fig. 4A–C). On the level of
the short-term end points (ie, proliferative capacity and
viability), the combined treatment modality induced an
additive effect in the D341Med cell line but not in the
D425Med and DAOY cell lines (Fig. 4A–F). More
Fig. 2. Cell-cycle analysis after treatment with patupilone. Human medulloblastoma cell lines D341Med (top row), D425Med (middle row),
and DAOY (bottom row) were treated with patupilone at low concentrations (D425Med and DAOY, 0.1 nM; D341Med, 0.25 nM) or high
concentrations (D425Med, 0.5 nM; D341Med and DAOY, 1 nM) and subjected to cell-cycle determination by propidium iodide staining and
FACS analysis at the indicated time points.
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important, combined treatment reduced clonogenicity in
all cell lines in an at least additive and comparable
extent. As expected from the response to patupilone
alone (see above), the D425Med and DAOY cell lines
were sensitized to ionizing radiation at a 10-fold lower
concentration of patupilone, compared with the
D341Med cells (Fig. 4G–I). On the basis of the additive
effects of combined treatment on the level of cell viabi-
lity and clonogenicity, caspase-3 activity and the frac-
tional volume of acidic vesicular organelles were
determined in response to treatment. Caspase-3 activity
in response to irradiation was least induced in the
DAOY cells; however, no additive caspase-3 activation
could be observed in all 3 cell lines in response to com-
bined treatment with ionizing radiation (Fig. 5A–C).
The autophagy-related end point was most prominently
induced in the D341Med cell line in response to
irradiation (Fig. 5D–F); however, a minor additive
effect could only be detected in the D425Med cell line
in response to the combined treatment modality.
Overall, these data demonstrate that patupilone
enhances the effect of ionizing radiation in human
medulloblastoma cell lines with regard to viability and
clonogenicity. However, combined treatment of these
meduloblastoma cell lines does not result in enhanced
amounts of apoptosis or autophagy in these cell lines.
Radiosensitizing Effect of Patupilone on Tumor
Xenografts
To determine an at least additive effect of the combined
treatment modality in vivo, a combined treatment
regimen with patupilone and ionizing radiation
Fig. 3. Caspase-3 activity and formation of acidic vesicular organelles (AVOs) after treatment with patupilone. Caspase-3 activity in
patupilone-treated medulloblastoma cells (D341Med [A], D425Med [B], and DAOY [C]) was determined at the indicated time points.
(D–F) AVO formation was determined in patupilone-treated medulloblastoma cells ([D] D341Med, 1 nM; [E] D425Med, 0.5 nM; [F]
DAOY, 1 nM). Green (510–530 nm) and red (465 nm) fluorescence emission from 5 × 105 cells illuminated with blue (488 nm)
excitation light was measured with a FACSCalibur at the indicated time points.
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was tested against xenografts derived from human
D425Med medulloblastoma cells, which were subcu-
taneously injected into the backs of nude mice.
Treatment was started when tumors reached a minimal
size of 200 mm3+10% (on days 20–27 after cell injec-
tion). In vivo studies were performed with loco regional
application of ionizing radiation using a shielding device
and a minimal fractionated treatment regimen of 3 Gy on
3 consecutive days. This daily dose is applied when frac-
tionated radiotherapy is used for the treatment of human
malignancies. For practical reasons only 3 fractions were
chosen as the treatment regimen, but the response to such
a regimen was previously found to be useful for treat-
ment evaluation.19 Fig. 6 summarizes the effect of
tumor treatment with patupilone alone (2 mg/kg patupi-
lone once), ionizing radiation alone (vehicle combined
with 3 × 3 Gy), and patupilone and ionizing radiation
in combination (2 mg/kg once combined with 3 ×
3 Gy), compared with a vehicle alone–treated control
group. Patupilone was applied 24 h before the first of 3
fractions of irradiation applied on 3 consecutive days.
Determination of treatment-related body weight
changes did not reveal a patupilone-dependent transient
weight loss after patupilone application (data not
shown), and no skin changes or tissue damage were
observed in the co-irradiated healthy tissue area around
the tumor during the follow-up period of tumor
growth. Treatment with patupilone or ionizing radiation
alone resulted in a partial tumor growth suppression over
10 days, whereas combined treatment exerted a strong
supra-additive tumor growth control, with complete
tumor regression in the follow-up period (P, .005, for
ionizing radiation or patupilone alone vs combined treat-
ment) (Fig. 6). Interestingly, tumors only slowly
regressed after the end of treatment, coinciding with
the in vitro results that treatment-induced apoptosis
might only play a minor role for the treatment response
of these medulloblastoma cells to ionizing radiation
and patupilone. Complete visible tumor regression was
observed in all mice treated with the combined treatment
modality. In 2 of 5 mice, slow-growing tumor recur-
rences could be observed 25–30 days after the start of
treatment. No recurrences at all occurred in the remain-
ing cohort of mice treated with the combined treatment
modality (data not shown). Overall, these results demon-
strate that patupilone might be a promising alternative
for a combined treatment regimen using microtubule
inhibitors and ionizing radiation.
Fig. 4. Antiproliferative and cytotoxic effect of patupilone in combination with ionizing radiation. (A–C) Human medulloblastoma cell lines
D341Med (A), D425Med (B), and DAOY (C) were treated with patupilone alone or in combination with clinically relevant doses of ionizing
radiation (2–5 Gy). Patupilone was added 30–60 min before irradiation. The antiproliferative activity was determined after 72 h of exposure.
(D–F) Human medulloblastoma cell lines D341Med (D), D425Med (E) and DAOY (F) were treated with patupilone at low (D425Med and
DAOY, 0.1 nM; D341Med, 0.25 nM) or high (D425Med, 0.5 nM; D341Med and DAOY, 1 nM) concentrations, alone or in combination
with ionizing radiation (5 Gy), and cell viability was determined by trypan blue exclusion after 72 h of exposure. (G–H) Clonogenicity of
human medulloblastoma cells after treatment with increasing doses of patupilone or in combination with ionizing radiation.
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Discussion
Vincristine-associated side effects in medulloblastoma
have led to an intense search for novel microtubule-
interfering agents with radiosensitizing potential and
devoid of toxicities. Here, we investigated the effect
of the novel clinically relevant microtubule inhibitor
patupilone alone and in combination with ionizing
radiation on 3 human medulloblastoma cell lines and
determined a strong cytotoxic potency of patupilone
at picomolar concentrations. Importantly, patupilone
was 10-fold more potent than vincristine at inhibiting
proliferation at subnanomolar concentrations (IC50 for
patupilone, 0.1–0.25 nM; IC50 for vincristine, 1–
1.4 nM) in all medulloblastoma cell lines tested.
Cell-cycle analysis revealed that patupilone sequen-
tially induced a strong G2-M-phase arrest in all cell
lines, followed by signs of apoptosis in the 2 medullo-
blastoma cell lines D425Med and DAOY. In combi-
nation with ionizing radiation, an at least additive
cytotoxic effect against both radiation-susceptible
and radiation-resistant medulloblastoma tumor cell
lines was observed. These results demonstrate a
potent cytotoxic effect of patupilone alone and in
combination with ionizing radiation, and they
suggest that such a combined treatment modality qua-
lifies for additional preclinical and clinical testing in
medulloblastoma. Patupilone and other epothilone-
derivatives are currently being tested in clinical phase
II/III trials in adults, and there is an ongoing phase
Fig. 5. Apoptosis and autophagy after combined treatment with patupilone and ionizing radiation. (A–C) Human medulloblastoma cell lines
D341Med (A), D425Med (B), and DAOY (C) were treated with patupilone at low (D425Med and DAOY, 0.1 nM; D341Med, 0.25 nM) or
high (D425, 0.5 nM; D341Med and DAOY, 1 nM) concentrations, alone or in combination with ionizing radiation. Caspase-3 activity was
determined after 48 h. (D–F) Human medulloblastoma cell lines D341Med (D), D425Med (E), and DAOY (F) were treated with patupilone
at low (D425Med and DAOY, 0.1 nM; D341Med, 0.25 nM) or high (D425Med, 0.5 nM; D341Med and DAOY, 1 nM) concentrations, alone
or in combination with ionizing radiation. Green (510–530 nm) and red (465 nm) fluorescence emission from 5 × 105 cells illuminated with
blue (488 nm) excitation light was measured with a FACSCalibur at the indicated time points or after 48 h.
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I/II trial of combined treatment with patupilone and
radiotherapy in brain tumors.
We previously investigated the cytotoxic effect of
patupilone alone or as part of a combined treatment
modality with ionizing radiation against tumor cells
derived from different tumor entities. Interestingly, the
combination of patupilone with ionizing radiation
resulted only in an additive cytotoxic effect against
various cancer cell types only in vitro, but it resulted in
a supra-additive tumor growth delay when tested
against tumor xenografts derived from the same tumor
cells as those tested in vitro.18,19 To the same extent, we
could also now demonstrate an at least additive effect
on combined treatment in the medulloblastoma cell
lines in vitro and, more important, a strong
supra-additive treatment response, including complete
tumor regressions in tumor xenografts treated with a
minimal combined treatment regimen in vivo. The
accumulation of tumor cells in the most radiosensitive
G2-M phase of the cell cycle represents the major rational
for the sensitization to ionizing radiation,22–24 although
other, S-phase progression-related mechanisms have also
been observed.19 Additional anti-vascular and anti-
angiogenic effects might contribute to the supra-additive
tumor growth delay observed in vivo, and in fact, direct
targeting of endothelial cells25–27 and indirect, anti-
angiogenic interference with the secretion of
pro-angiogenic factors from tumor cells have been
proposed.
Interestingly, the semisynthetic epithilone B deriva-
tive ixabepilone has previously been investigated
against several pediatric cancer models and revealed
broad-spectrum activity.15 To our knowledge, this is
the first report to have investigated the potency of patu-
pilone alone and in combination with ionizing radiation
in medulloblastoma cell lines and tumor xenografts, and
we observed a differential cell line–dependent response
with regard to the patupilone-induced mode of cell
death. A strong G2-M-phase arrest was induced in all
cell lines by patupilone 6 and 12 h after the commence-
ment of treatment with low subnanomolar concen-
trations (0.1–1 nM). However, we also observed an
initial longer-lasting accumulation of cells in the radiore-
sistant S-phase in D425Med and D341 cell lines (data
not shown), as previously manifested in other tumor
cells in response to low-dose treatment with patupi-
lone.19 The combined treatment with ionizing radiation
in all cell lines resulted in an at least additive cytotoxic
effect. After G2-M-phase arrest, patupilone potently
induced apoptosis in the D425Med and the DAOY
medulloblastoma cell lines, as indicated by caspase-3
activation and the occurrence of a subG1-peak cell
population by flow cytometry. The D341Med medullo-
blastoma cell line was less susceptible to patupilone in
terms of proliferation, clonogenic cell survival, and the
apoptosis level, with an IC50 of patupilone 10-fold
higher than the IC50 for the 2 other medulloblastoma
cell lines. Interestingly, the fractional volume of
patupilone-induced acidic vesicular organelles was
increased in this cell line versus the other 2 cell lines,
indicating an enhanced patupilone-dependent autopha-
gic process. These medulloblastoma cell lines differ in
their expression level and mutations of specific genes;
however, a differential treatment sensitivity thus far
could not be attributed to a specific genetic
background.21
In addition to apoptosis, several additional cell death
pathways exist, such as autophagy, necrosis, senescence,
and mitotic catastrophe. Autophagy, which is also called
self-cannibalism, includes the degradation and recycling
of intracellular proteins and small organelles.
Autophagy may protect cells under the condition of
environmental stress but may also lead to cell death.
Patupilone only induced autophagy-related acidic
vacuolar organelles in the D341Med cells, which were
also less susceptible to patupilone, compared with the
2 other medulloblastoma cell lines. Interestingly, inter-
ference with autophagy sensitized cells to patupilone-
induced cell death, indicating that autophagy acts as a
cell-protective rather than a cell death–related response
to patupilone in these cells. However, how microtubule-
stabilizing agents promote autophagy on the molecular
level is far from clear. Only recently, a novel functional
link has been suggested between autophagy and micro-
tubules that is relevant for the cellular redistribution of
the autophagy related LC3-protein and coordinated
fusion of lysosomes and autophagosomes.28
Microtubule inhibitors and ionizing radiation also
induce mitotic catastrophe as a mode of cell death,29
because they result in aberrant chromosomal segregation
and failed mitosis. Treatment with patupilone led to a
strong accumulation of cells in G2-M and multinuclea-
tion, as indicators for mitotic catastrophe, which has
been identified in all 3 medulloblastoma cell lines (data
Fig. 6. The effect of patupilone and ionizing radiation alone or in
combination on the growth of D425Med-derived xenografts in
nude mice. Mice were treated with patupilone (2 mg/kg once)
and ionizing radiation (3 × 3 Gy on consecutive days), alone and
in combination, with administration of patupilone or the vehicle
24 h prior to the first fraction of ionizing radiation. The horizontal
bar indicates days of treatment. Each curve represents the mean
tumor volume per group+ standard error.
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not shown). Treatment-induced mitotic catastrophe can
also trigger other late cell death end points, including
apoptosis and independent of the original cytotoxic
insult. Thus, we cannot exclude that patupilone-induced
apoptosis in the medulloblastoma cells is a secondary
end point and that the cells have already undergone
mitotic catastrophe. Because pretreatment of cells
with the broad-range caspase inhibitor did not
reduce patupilone-induced cell viability, activation of
apoptosis-related end points might indeed represent a
secondary mode of cell death.
Overall, we demonstrated that patupilone is a very
potent cytotoxic agent against several medulloblastoma
cells lines, strongly reduces clonogenic survival alone and
in combination with ionizing radiation, and induces differ-
ent modes of cell death in a cell-line-dependent way. The
strong treatment response also determined in vivo
against tumor xenografts suggests that patupilone is a
promising agent for combined treatment modality
instead of vincristine and merits further preclinical
investigation and eventually clinical evaluation.
Supplementary Material
Supplementary material is available online at Neuro-
Oncology (http://neuro-oncology.oxfordjournals.org/).
Acknowledgments
Patupilone was kindly provided by Novartis Pharma
(Basel, Switzerland). We thank Paul McSheehy for his
continuous support of our patupilone-related research
program and Oralea Buechi for her technical support
with the flow cytometry experiments.
Conflict of interest. The authors declare no conflict of
interest.
Funding
We acknowledge the following sources of funding:
Oncosuisse, the Radiumfonds, the Swiss National
Foundations (to C.O. and M.P.); the Swiss National
Fonds, the Swiss Research Foundation Child and
Cancer (to A.O.v.B., M.A.G.); German Children‘s
Cancer Foundation/Deutsche Kinderkrebsstiftung (to
A.O.v.B., S.R.); and Fonds fu¨r Medizinische
Forschung UZH (to A.B.-T.)
References
1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification
of tumours of the central nervous system. Acta Neuropathol (Berl).
2007;114(2):97–109.
2. Kuhl J. Modern treatment strategies in medulloblastoma. Childs Nerv
Syst. 1998;14(1-2):2–5.
3. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with
medulloblastomas with reduced-dose craniospinal radiation therapy and
adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin
Oncol. 1999;17(7):2127–2136.
4. Reeves CB, Palmer SL, Reddick WE, et al. Attention and memory func-
tioning among pediatric patients with medulloblastoma. J Pediatr
Psychol. 2006;31(3):272–280.
5. Radcliffe J, Packer RJ, Atkins TE, et al. Three- and four-year cognitive
outcome in children with noncortical brain tumors treated with whole-
brain radiotherapy. Ann Neurol. 1992;32(4):551–554.
6. Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and
decline in intelligence: the influence of dose and age on IQ score.
J Clin Oncol. 1992;10(9):1390–1396.
7. Chapman CA, Waber DP, Bernstein JH, et al. Neurobehavioral and
neurologic outcome in long-term survivors of posterior fossa brain
tumors: role of age and perioperative factors. J Child Neurol.
1995;10(3):209–212.
8. Dennis M, Spiegler BJ, Hetherington CR, Greenberg ML.
Neuropsychological sequelae of the treatment of children with medullo-
blastoma. J Neurooncol. 1996;29(1):91–101.
9. Packer RJ, Sutton LN, Goldwein JW, et al. Improved survival with the
use of adjuvant chemotherapy in the treatment of medulloblastoma.
J Neurosurg. 1991;74(3):433–440.
10. Greenberg HS, Chamberlain MC, Glantz MJ, Wang S. Adult medullo-
blastoma: multiagent chemotherapy. Neuro Oncol. 2001;3(1):29–34.
11. von Bueren AO, von Hoff K, Benesch M, Rutkowski S. Dose reductions
of vincristine in children with medulloblastoma treated in the mainten-
ance arm of the prospective multicenter trial HIT’91. Klin Padiatr.
2009;221(6):396–397.
12. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant
treatment, and residual tumor are prognostic factors for medullo-
blastoma in children: conclusions from the Children’s Cancer
Group 921 randomized phase III study. J Clin Oncol. 1999;17(3):
832–845.
13. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal
radiotherapy followed by high-dose chemotherapy and stem-cell rescue
in children with newly diagnosed medulloblastoma (St Jude
Medulloblastoma-96): long-term results from a prospective, multicentre
trial. Lancet Oncol. 2006;7(10):813–820.
14. Jakacki RBP, Zhou T, Holmes E, Packer RJ, Goldwein J, et al. Outcome
for metastatic (M+) medulloblastoma (MB) treated with carboplatin
during craniospinal radiotherapy (CSRT) followed by cyclophospha-
mide (CPM) and vincristine (VCR): Preliminary results of COG
99701. ASCO Annual Meeting Proceedings Part I, Journal of
Clinical Oncology 2007.
15. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone
(BMS247550), a novel epothilone B derivative, against pediatric cancer
models. Clin Cancer Res. 2005;11(19 Pt 1):6950–6958.
16. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al. Safety and effi-
cacy of patupilone in patients with advanced ovarian, primary fallopian,
or primary peritoneal cancer: a phase I, open-label, dose-escalation
study. J Clin Oncol. 2009;27(19):3097–3103.
17. Rothermel J, Wartmann M, Chen T, Hohneker J. EPO906 (epothilone B):
a promising novel microtubule stabilizer. Semin Oncol. 2003;30(3 Suppl
6):51–55.
Oehler et al.: Cytotoxicity of patupilone in medulloblastoma
NEURO-ONCOLOGY † S E P T E M B E R 2 0 1 1 1009
 at U
niversitaet Zuerich on June 1, 2012
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
18. Bley CR, Jochum W, Orlowski K, et al. Role of the microenvironment
for radiosensitization by patupilone. Clin Cancer Res. 2009;15(4):
1335–1342.
19. Hofstetter B, Vuong V, Broggini-Tenzer A, et al. Patupilone acts as
radiosensitizing agent in multidrug-resistant cancer cells in vitro and in
vivo. Clin Cancer Res. 2005;11(4):1588–1596.
20. Fogh S, Machtay M, Werner-Wasik M, et al. Phase I Trial Using
Patupilone (Epothilone B) and Concurrent Radiotherapy for Central
Nervous System Malignancies. Int J Radiat Oncol Biol Phys.
2010;77(4):1009–1016.
21. Saylors RL, 3rd, Sidransky D, Friedman HS, et al. Infrequent p53 gene
mutations in medulloblastomas. Cancer Res. 1991;51(17):4721–4723.
22. Altmann KH, Wartmann M, O’Reilly T. Epothilones and related
structures–a new class of microtubule inhibitors with potent in vivo
antitumor activity. Biochim Biophys Acta. 2000;1470(3):M79–91.
23. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to
radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928–942.
24. Sinclair WK. Cyclic x-ray responses in mammalian cells in vitro. Radiat
Res. 1968;33(3):620–643.
25. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human
endothelial cell proliferation and survival in vitro reveal a selective anti-
angiogenic window for various chemotherapeutic drugs. Cancer Res.
2002;62(23):6938–6943.
26. Ferretti S, Allegrini PR, O’Reilly T, et al. Patupilone induced vascular
disruption in orthotopic rodent tumor models detected by magnetic
resonance imaging and interstitial fluid pressure. Clin Cancer Res.
2005;11(21):7773–7784.
27. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin
Cancer Res. 2004;10(2):415–427.
28. Shen S, Kepp O, Martins I, et al. Defective autophagy associated with
LC3 puncta in epothilone-resistant cancer cells. Cell Cycle.
2010;9(2):377–383.
29. Demidenko ZN, Kalurupalle S, Hanko C, Lim CU, Broude E, Blagosklonny
MV. Mechanism of G1-like arrest by low concentrations of paclitaxel:
next cell cycle p53-dependent arrest with sub G1 DNA content mediated
by prolonged mitosis. Oncogene. 2008;27(32):4402–4410.
30. von Bueren AO, Shalaby T, Oehler-Janne C, et al. RNA interference-
mediated c-MYC inhibition prevents cell growth and decreases sensi-
tivity to radio- and chemotherapy in childhood medulloblastoma cells.
BMC Cancer. 2009;9:10.
31. von Bueren AO, Shalaby T, Rajtarova J, et al. Anti-proliferative activity
of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC
Cancer. 2007;7:19.
32. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of
autophagy in temozolomide-induced cytotoxicity for malignant glioma
cells. Cell Death Differ. 2004;11(4):448–457.
Oehler et al.: Cytotoxicity of patupilone in medulloblastoma
1010 NEURO-ONCOLOGY † S E P T E M B E R 2 0 1 1
 at U
niversitaet Zuerich on June 1, 2012
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
 91
3.5. Microtubule Stabilizing Agents and Ionizing Radiation:  
Multiple Exploitable Mechanisms for Combined Treatment  
 
Carla Rohrer Bleya,b;, Polina Furmanovaa, Katrin Orlowskia, Nicole Grossea,  
Angela Broggini-Tenzera, Paul MJ. McSheehyc, Martin Pruschya  
 
aDepartment of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland 
bDivision of Radiation Oncology, Vetsuisse Faculty, University of Zurich, Zurich,  
Switzerland 
cNovartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland 
 
 
Status of the manuscript: Accepted for publication in the European Journal of Cancer 
 
Author contribution K. Orlowski: 
Concepts and data of this PhD thesis were also recapitulated in this review. 
 
 
 
 
Short title: Microtubule Stabilizing Agents and Ionizing Radiation 
 
Conflict of interest statement: No potential conflicts of interest were disclosed. 
 
Grant Support: Swiss Cancer League, Vontobel-Stiftung, Swiss National Science 
Foundation 
 92
Abstract 
Combined radiochemotherapy treatment modalities are in use for many indications and 
therefore of high interest. Even though a combined modality in clinical use is often driven by 
pragmatic aspects, mechanistic preclinical-based concepts of interaction are of importance in 
order to translate and implement an optimal combination and scheduling of two modalities 
into the clinics. The use of microtubule stabilizing agents is a promising strategy for anti-
cancer therapy as a part of combined treatment modality with ionizing radiation. 
Traditionally, microtubule targeting agents are classified as cytotoxic chemotherapeutics and 
are mostly used in a maximally tolerated dose regimen. Apart from direct cytotoxicity and 
similar to mechanisms of molecular targeting agents, microtubule stabilizing agents interfere 
with multiple cellular processes, which can be exploited as part of combined treatment 
modalities. Recent preclinical investigations on the combination of ionizing radiation and 
microtubule stabilizing agents reveal new mechanistic interactions on the cellular and tumor 
level and elucidate the supra-additive tumor response observed particularly in vivo. The major 
focus on the mechanism of interaction was primarily based on radiosensitization due to cell 
cycle arrest in the most radiosensitive G2/M-phase of the cell cycle. However, other 
mechanisms of interaction such as reoxygenation and direct as well as indirect endothelial 
damage have also been identified. In this review we summarize and allocate additive and 
synergistic effects induced by the combined treatment of clinically relevant microtubule 
stabilizing agents and ionizing radiation along a described radiobiological framework 
encompassing distinct mechanisms relevant for exploiting the combination of drugs and 
ionizing radiation.  
 
 
Keywords: Ionizing Radiation, Microtubule Stabilizing Agents, Radiochemotherapy, 
Epothilones, Taxanes 
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Introduction: Microtubule Stabilizing Agents  
Microtubule targeting agents belong to the most important classes of anti-cancer agents and 
are subdivided in two groups, according to their mode of action. While microtubule 
destabilizers prevent the assembly of tubulin heterodimers, microtubule stabilizing agents 
(MSA) prevent the shortening of microtubules resulting in the accumulation of polymerized 
microtubule bundles and the interference of the mitotic spindle function.(1-4) Experimental 
evidence concerning the kinetics and mechanism of tubulin-binding as well as the ability to 
actively promote microtubule function by paclitaxel mimetics has been recently provided 
using biochemical and NMR techniques.(5) Eventually both classes of microtubule targeting 
agents alter spindle-microtubule dynamics, which results in a transient or permanent M-phase 
arrest and the induction of apoptotic cell death or mitotic catastrophe (Figure 1).(6) In this 
review we will specifically focus on the mode of interaction between MSA and ionizing 
radiation as part of a combined treatment modality. 
Taxanes and epothilones are the clinically most relevant microtubule stabilizing agents. The 
taxanes (paclitaxel and docetaxel) have been approved for a broad range of indications, 
including advanced breast cancer after failure of combination chemotherapy or at early 
relapse,(7) high grade ovarian cancer in combination with platinum compounds, and primary 
treatment of non-small cell lung cancer in combination with cisplatin.(8) Furthermore 
paclitaxel is used in an “off-label manner” for other tumor types, such as cancer of unknown 
origin, bladder, esophagus, gastric, head and neck, and cervical cancers (reviewed in (9)). 
Paclitaxel has also been evaluated clinically for its radiosensitizing properties for various 
tumors(10-14) and drug plasma concentrations in patients. Low concentrations with 
prolonged exposure during long parts of the course of radiation therapy have been found 
feasible and tolerated in patients.(12-18) Docetaxel is used as first-line chemotherapy for 
locally advanced or metastatic breast cancer,(19) nonresectable, advanced or metastatic non-
small cell lung cancer after failure of cisplatin-based therapy, hormone-refractory metastatic 
prostate cancer in combination with prednisone,(20) gastric adenocarcinoma in combination 
with cisplatin and 5-fluorouracil,(21) and inoperable advanced squamous cell cancer of the 
head and neck in combination with cisplatin and 5-fluorouracil. Both of the approved taxane 
derivates are hydrophobic and require organic solvents for administration (cremophor EL / 
ethanol, polysorbate / ethanol), which by themselves can cause unwanted side effects.(22) 
The epothilones are nontaxoid macrolide MSA of bacterial origin, which share the same 
binding site on beta-tubulin (in close proximity to residue Thr274) with taxanes,(23) albeit 
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with different affinities.(1, 24-26) Clinically different epothilone derivatives are currently in 
various stages of development as antitumor compounds. Several properties like increased 
water solubility, low susceptibility to common mechanisms of resistance and the more 
tolerable toxicity profile, favor their development. Ixabepilone (Ixempra®) is the first 
approved compound in this class and indicated as monotherapy or in combination with 
capecitabine for the treatment of patients with metastatic breast cancer. Apart from a 
manageable safety profile, ixabepilone demonstrates activity after failure and resistance 
towards anthracycline and taxane standard therapy.(27) Epothilone B (patupilone) was tested 
as a phase III  monotherapy agent against ovarian cancer and other epothilones are 
undergoing a wide spectrum of single and combined treatment modality in phase II studies 
(e.g. for recurrent glioblastoma, CNS metastases from breast cancer, prostate, cervical, renal 
cell, gastric and lung tumor, as well as non-Hodgkin’s Lymphoma (www.cancer.gov).(15, 28-
31) 
Both, taxanes and epothilones, have been extensively tested at the preclinical level in 
combination with ionizing radiation, demonstrating a strong supra-additive treatment 
response. Here, we will outline classic rationales for the combined treatment modality of 
ionizing radiation with microtubule stabilizing agents and discuss novel mechanistic 
preclinical-based concepts of interaction between these two modalities.  
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Fig. 1. A: Chemical structure: The MSA compounds are of complex structure and high 
chemical diversity. The complex structure of these compounds explains the difficulty for 
chemical synthesis. 
B: Binding site: Microtubules are dynamic structures of α- and β-tubulin molecules arranged 
in tubular form. The microtubule-stabilizing agents of the taxane and epothilone groups bind 
along the interior surface of the microtubules to the same or an overlapping taxoid-binding 
site on β-tubulin. Thereby microtubular polymerization is enhanced and microtubular 
dynamics reduced. 
C: Microtubules interact with various intracellular organelles: In the mitotic spindle, proper 
alignment and separation of the chromosomes during cellular division is provided by the 
normal microtubular function. Furthermore cellular structure and motion as well as vesicular 
transport take place by and along tubular structures. 
 
Rationale for the Combined Use of Irradiation and Cytotoxic Agents  
The rationale for a combined treatment with ionizing radiation (IR) and chemotherapy is to 
increase survival by improving locoregional tumor control and decrease the probability of 
distant disease, with concurrent organ and function preservation.(32, 33) Recently, a new 
framework encompassing five distinct mechanisms relevant for exploiting the combination of 
drugs and ionizing radiation has been proposed.(34) While for some of the mechanisms direct 
drug-radiation interactions at the tumor-cellular level is not required (e.g. in spatial 
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cooperation, normal tissue protection), other mechanisms are fundamentally based on their 
mutual interaction (e.g. cytotoxic enhancement, biological cooperation, temporal 
modulation). With regard to microtubule stabilizing agents, IR-MSA interactions can be 
allocated to several of these mechanisms.  Interestingly these mechanisms even complement 
each other on several levels thereby further enhancing the potency of this promising 
combined treatment modality. 
The main rationale to exploit spatial cooperation, combining a drug with efficacy against 
systemic disease with radiotherapy against locoregional disease, is to achieve local and 
systemic control by full doses of both treatment modalities, often applied in sequence.(20) For 
the mechanisms involving a direct drug-radiation interaction at the cellular level (cytotoxic 
enhancement, biological cooperation and temporal modulation), the strategies aim mainly at 
enhancing cell killing, interfering with repair mechanisms, targeting distinct cell populations 
(e.g. hypoxic cells) and microenvironmental structures within the tumor.  
 
Interactions between Ionizing Radiation and MSA (Figure 2) 
Cell cycle specific enhancement (cytotoxic enhancement). MSAs induce mitotic arrest in most 
tumor cells. Depending on the dose applied and/or the genetic background and inherent 
cellular sensitivity of the tumor cells, MSA-induced mitotic arrest will lead to transient cell 
cycle arrest or apoptosis. Therefore only a poor correlation exists between MSA-induced 
mitotic arrest and tumor control, as mitotically arrested cells in some tumors are capable of 
continued survival (35, 36). In paclitaxel- and docetaxel-resistant tumors, the radioenhancing 
mechanism is primarily based on the transient accumulation of cells in this cell cycle 
phase.(36, 37) 
The cell cycle phases of late G2 and mitosis are most sensitive to ionizing radiation.(38, 39) 
Ionizing radiation produces different types and quantities of chromosomal aberrations at 
various stages of the cell cycle. The frequency of IR-induced chromosomal aberrations is 
higher for cells in G2- and M-phase than for cells irradiated in the G1- and S-phase of the cell 
cycle.(40) In addition, cells in late G2/M-phase already passed the G2-checkpoint to repair 
their DNA damage, and thus the frequency of residual, detrimental chromosomal aberrations 
in cells entering mitosis is also increased. As mitotic cells with double strand breaks will lose 
genetic material following cell division, irradiation of MSA-treated, transiently arrested late 
G2-/M-phase-cells will result in genomic instability and eventually mitotic catastrophe.(35, 
41-45)  
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Fig. 2. Multifaceted interaction of MSA and ionizing radiation on the tumor and endothelial 
cell level: 1. High doses of MSA and IR lead to reassortment of cells in the cell cycle, cell 
loss and subsequent tumor reoxygenation. Massive tumoral cell loss will directly decrease the 
metastatic potential. 2. MSAs counteract the pro-angiogenic IR-induced stress response. 3. 
MSAs counteract IR-induced secretion of survival and pro-metastatic factors thereby 
sensitizing the tumor to the combined treatment modality.  
 
This implies that the therapeutic efficacy of the combined treatment modality strongly 
depends on the innate cellular drug sensitivity and in particular on the combination 
scheduling. Indeed, effects ranging from supra-additive interactions (Figure 3), to additive, 
and even sub-additive effects are documented.(43, 46-50) The radiosensitizing effect of MSA 
is most prominent between 8-12 hours after start of drug exposure at the time of accumulation 
of cells in G2/M-phase (Figure 4).(42, 43, 49, 50) In contrary, the cytotoxic M-phase-related 
potency of paclitaxel added after irradiation was lost and did not increase IR-induced cell 
death due to the strong IR- induced G1- and G2- cell cycle arrest and subsequent sublethal 
damage repair.(49, 51) In vivo, multiple doses of taxanes given during the course of 
fractionated irradiation maximized the exposure for cells to ionizing radiation even in drug 
resistant tumors.(52) However, with intermittent multiple high doses of taxanes, the 
therapeutic gain was in part limited by side effects in acutely responding tissues such as 
jejunal mucosa, skin and connective tissues as observed in murine tumor models.(52-54) 
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Moderate concentrations of MSA, which are sufficient to induce a G2-M cell cycle arrest are 
optimal for radioenhancement.(43, 47-50) Interestingly, low dose MSA-treatment may also 
induce an additional G2/M-phase independent mode of radiosensitization. Low doses of 
patupilone induced a transient accumulation of cells in S phase, but only on combined 
treatment with ionizing radiation.(55) Combined treatment did not result in the accumulation 
of cells in the radiosensitive G2/M-phase and radiosensitization was rather due to an S-phase-
related process. A similar effect has also been described for synchronized HeLa cells, in 
which docetaxel resulted in a S-phase specific (and hence radioresistant) cell killing.(56, 57) 
 
 
Fig. 3. (Adapted from Hofstetter et al.,(55)). Effect of Patupilone and IR alone or in 
combination on the growth of SW480-derived xenografts in nude mice: Mice were treated 
with Patupilone (2 mg/kg, once) and IR (4 × 3 Gy, on 4 consecutive days), alone and in 
combination. Patupilone or the vehicle was administered 24 hours before the first fraction of 
IR. Combined treatment exerted a strong, supra-additive tumor growth control during 
treatment and the follow-up period. The human colon adenocarcinoma cell line SW480 is a p-
glycoprotein (MDR1)-overexpressing tumor. Patupilone is a promising alternative in 
multidrug-resistant tumors for a combined treatment regimen using microtubule inhibitors and 
IR.  
 
Reoxygenation theory (biological cooperation, temporal modulation). The enhanced radiation 
response of combined treatment with microtubule stabilizing agents and ionizing radiation has 
also been attributed to “tumor cell reoxygenation”. Massive cell loss due to MSA-induced 
apoptosis or necrosis might lead to a shortening of the tumor cell-vascular distance and a 
decrease of the intratumoral fluid pressure (IFP) with a subsequently increased blood delivery 
to hypoxic tumor regions as well as a decreased overall oxygen consumption rate. Eventually 
this results in increased tumor oxygenation, and subsequently increased radiation sensitivity 
(Figure 4).(35, 37, 52, 54, 58, 59) For example, paclitaxel in combination with ionizing 
radiation significantly reduced tumor hypoxia in MCA-4 xenograft tumors, especially in a 
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drug-radiation interval of 3 days.(59) Due to the high concentration of the administered drug, 
this effect was mostly attributed to extensive cytotoxicity caused by paclitaxel.   
 
Endothelial theory (biological cooperation, temporal modulation). As the radiosensitivity of 
the tumor vascular network codetermines the tumor response to IR, enhanced tumor 
radiosensitivity can be attributed to the effect of microtubule agents on the tumor endothelial 
system.(60) Microtubule stabilizing agents have anti-angiogenic properties at high and at low, 
non-tumor cytotoxic doses.(61) These properties are on one hand based on direct anti-
endothelial cell activity, but also on the indirect tumor-cell mediated anti-angiogenic effect, 
by inhibition and subsequent down-regulation of proteins and genes involved in angiogenesis 
and hypoxic adaptation.(62, 63) High doses of microtubule stabilizing agents act in a 
cytotoxic manner via mitotic block and activation of the mitochondrial apoptotic pathway, 
while on the other hand, low doses decelerate overall cell cycle progression and inhibit 
migration and proliferation,(64, 65) which results in reduced capillary-like tube 
formation.(61, 66) Similar to the radiosensitizing effect on the tumor cell level, prolonged 
metaphase-to-anaphase transition in endothelial cells can also provoke an increase of the 
radiation response on the tumor vasculature level by temporal modulation in the classic 
radiobiological framework of cell cycle redistribution (see above).(34) In addition to the anti-
angiogenic effects, MSA such as epothilone B also exert vascular disruptive effects. Drug 
administration led to a rapid destruction of blood vessels (observable at day two) associated 
with a decrease in tumor IFP.(67) This direct destruction of blood vessels and decrease of IFP 
might also lead to a subsequent reorganization of the vasculature, thereby temporarily 
decreasing the hostility of tumor microenvironment by also changing oxygenation and pH-
status of the tumor.(67, 68) Enhanced tumor oxygenation could also be attributed to the 
proposed concept of tumor vasculature normalization, caused by a transient decrease of 
VEGF signaling and thereby reduction of vessel abnormalities such as tortuosity and leakage 
of the impaired tumor vasculature. Addition of radiation therapy during this “window of 
normalization” would in principle enhance radiation response.(68, 69) 
However, reduction of tumor hypoxia on MSA-treatment is not a prerequisite for a supra-
additive anti-tumor effect when combined with ionizing radiation. Early results indicated that 
paclitaxel suppresses the expression of VEGF in murine breast cancer cells in vivo and in 
vitro.(70) Our own experiments performed with patupilone in a genetically defined MSA-
sensitive and MSA-resistant tumor model revealed that the anti-angiogenic and 
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radiosensitizing effect on the level of the tumor vasculature of MSA is strongly promoted in 
an indirect tumor-cell mediated way.  A significant reduction in microvessel density and 
initial increase of tumor hypoxia on treatment with epothilone B (patupilone) alone was only 
detected in tumors derived from the MSA-sensitive A549 wild-type cells but not in the MSA-
resistant cell line. These results indicate that the anti-angiogenic effect of patupilone in vivo is 
indirectly induced by interference at the level of the tumor cellular stress response.(62, 71) 
MSA interfere with the expression and transcriptional activity of the hypoxia-inducible factor 
1α (HIF-1α) and subsequent reduction of the downstream pro-angiogenic HIF-transcriptome, 
including VEGF and other genes involved in angiogenesis, endothelial cell survival and 
hypoxic adaptation.(62, 63, 71) Vascular disruption as well as a decrease of the 
radioprotective effect of endothelial cells by VEGF and other survival factors will thereby 
enhance the radiation response, which is attributed to biological cooperation.(34, 60, 72)  
 
Antimetastatic properties of MSAs (spatial cooperation). There is currently an ongoing 
discussion on the impact of ionizing radiation on tumor cell dissemination. Enhanced cell 
invasion and metastatic spread was observed in selected preclinical experiments in response 
to irradiation.(73-77) This effect is most probably due to IR-induced expression and secretion 
of matrix metalloproteinases (MMPs) required for cell invasion.(78-81) Interestingly the 
secretion of MMPs and related tissue inhibitors of metalloproteinases are also regulated by 
MSAs, as they are at least partially dependent on the dynamic functional MT system.(82, 83) 
At low doses, paclitaxel impairs the secretion of MMP-2 and MMP-9 by human melanoma 
and prostate cancer cells, thereby inhibiting cell invasion(84, 85) and this may be relevant 
mechanistically for the promising anti-metastatic effect of MSA. Furthermore, taxanes and 
epothilones can reduce migration of non-neoplastic smooth muscle and endothelial cells,(86-
88) as well as neoplastic tumor cells (e.g. ovarian and colon carcinoma).(89, 90) The anti-
metastatic properties of paclitaxel and epothilones were also demonstrated in tumor-bearing 
mice (for lung, prostate and breast tumors).(91-94) 
Our own studies are currently investigating the combined treatment modality of epothilones 
and IR on MMP function. Interestingly, epothilones specifically counteract IR-induced MMP 
activity and IR-induced cell invasion of human fibrosarcoma and glioma cell lines.(95) This 
might represent an additional cause for the supra-additive tumor growth delay observed on 
combined treatment in preclinical in vivo experiments and is an interesting rational for a 
combined treatment modality in the clinical setting. 
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Fig. 4. Dose dependent consequences of MSA via initial G2/M-phase block: cytostatic, low 
doses of MSA lead to cellular reassortment into the most radiosensitive phase of the cell 
cycle, while cytotoxic high doses of MSA radiosensitize the tumor by tumor reoxygenation.  
 
The combined treatment modality of ionizing radiation with microtubule stabilizing agents 
fulfill the classic rationales of cell cycle specific enhancement, biological cooperation, 
temporal modulation and, in part, spatial cooperation. By causing cell cycle arrest in the most 
radiosensitive phase of the cell cycle, reducing the hypoxic fraction within the cellular 
population and thereby redistributing and reoxygenating the remaining tumor cells, and by 
interference with angiogenic signaling and endothelial cells, the interaction between 
microtubule stabilizing agents and ionizing radiation has a promising potential to increase the 
potency of this treatment combination. It is not only the additive effect of each of these 
mechanisms, which contribute to radiosensitization by MSAs, interestingly these mechanisms 
even complement each other on several levels thereby further enhancing the potency of this 
promising combined treatment modality. 
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4. Discussion 
 
4.1. Combined treatment modality of patupilone and ionizing irradiation  
Cancer therapy using the MSA patupilone has been extensively studied in vitro and in vivo 
using several different preclinical models [1,2].  Patupilone acts through several mechanisms 
to serve as an anti-cancer agent: by stabilizing microtubules it impairs mitosis, which results 
in an accumulation of cells in the G2/M-phase of the cell cycle and inhibition of proliferation. 
However, microtubule dynamics not only play an important role in cell division but also in 
intracellular trafficking of cell organelles, vesicles and proteins as well as in cell motility. 
Treatment with patupilone leads to inhibition of invasion, vascular disruption, and 
deregulation of the HIF-1 protein [2-4]. Clinical trials using patupilone (EPO906) 
demonstrated promising results for metastatic castration-resistant prostate cancer in a phase II 
trial [5] and for previously treated advanced metastatic colon carcinoma in a phase I trial [6]. 
Patupilone was also evaluated in phase I and II trials for small cell lung carcinoma; its 
strongest indications are for breast, lung and prostate cancer [7]. Patupilone has also been 
studied as part of combined treatment modalities: a phase Ib clinical trial in combination with 
carboplatin [8] and a phase I trial in combination with gemcitabine [9] revealed anti-tumor 
activity and tolerable toxicity. Despite the radiosensitizing properties of patupilone, so far 
only one phase I clinical trial has been reported for the combination with concurrent IR, 
applied to central nervous system malignancies [10], with another trial combining patupilone 
with IR for head and neck cancer currently ongoing (clinicaltrials.gov). However, the future 
of patupilone as a clinical anti-cancer agent is uncertain.  While combined treatments with IR 
seemed promising, a phase III trial investigating single agent patupilone for ovarian cancer in 
2010 failed to show an increase in overall survival in comparison to doxorubicin.  Therefore, 
Novartis International AG decided not to proceed with regulatory filings for patupilone 
(www.novartis.com). Nevertheless, characterizing and analyzing the radiosensitizing 
properties of epothilones - with patupilone as a model compound - is of high clinical 
relevance.  
 
In this study we demonstrated a very strong radiosensitizing effect of patupilone in a 
concurrent treatment scheme with IR in vitro and especially in vivo (Bley et al, 2009). Tumor 
xenografts derived from A549 cells revealed an at least additive tumor growth delay in 
response to the combined treatment regimen, whereas tumors derived from the patupilone-
resistant tumor cell line A549.EpoB40 did not exhibit an enhanced response to combined 
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treatment. Therefore, we concluded that the radiosensitizing effect of patupilone on the A549-
derived xenografts must result from the cytotoxic effect on the tumor cell compartment.  
 
However, combined treatment modalities are often effective because they simultaneously 
target both the tumor cell compartment and the tumor microenvironment. Here we showed 
that the tumor growth delay caused by the combined treatment modality of patupilone and IR 
on the A549-derived xenografts was further enhanced by interference with tumor VEGF 
secretion (Rohrer Bley et al., 2011).  As VEGF secreted from tumor cells protects endothelial 
cells from treatment with IR [11], this resulted in sensitization of the endothelial cells 
supporting the tumor, as shown by a reduction in microvessel density. We demonstrated a 
decrease of both VEGF mRNA and VEGF secretion levels under patupilone treatment in the 
patupilone-sensitive cell line, whereas no difference was detected in the resistant 
A549.EpoB40 cell line in vitro. Reduced VEGF mRNA and secretion most probably resulted 
from interference of patupilone with HIF-1protein functions. We and others have shown 
that microtubule interfering agents lead to a reduction of the HIF-1 protein level [12]; 
moreover, Carbonaro and colleagues demonstrated an accumulation of HIF-1 mRNA in 
cytoplasmic P-bodies under taxol treatment [13]. However, an additional mechanism leading 
to reduced VEGF secretion could be impaired microtubule trafficking of vesicles containing 
VEGF as a result of patupilone interference with microtubule stability.  
 
The additive tumor growth inhibition of the combined treatment modality might therefore 
derive from two complementary mechanisms: first, from the accumulation of tumor cells in 
the radiosensitive G2/M-phase of the cell cycle, and second, from reduced secretion of growth 
factors leading to decreased protection of endothelial cells. This work focused primarily on 
the secretion of the pro-angiogenic cytokine VEGF and the general HIF-1 “transcriptome” by 
the luciferase assay in the A549 cell line in response to the different treatment modalities. To 
extend this work, it would be of interest to determine whether patupilone also impairs VEGF 
secretion in other cell lines. This paracrine regulatory mechanism could be tested in a co-
cultivation assay analyzing radiosensitivity of endothelial cells when co-cultivated with 
patupilone-treated versus untreated A549 cells. Furthermore, altered levels of other cytokines 
besides VEGF could also be responsible for the decrease in microvessel density and 
consequent increase in tumor hypoxia after patupilone treatment. We aimed to identify 
cytokines differentially regulated under hypoxic conditions upon patupilone treatment using a 
human angiogenesis array. This analysis demonstrated small but statistically insignificant 
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differences in angiogenin, interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-1) and 
placental growth factor (PIGF) (data not shown). Surprisingly, the patupilone-resistant 
A549.EpoB40 cells exhibited a generally increased secretion profile: nearly all cytokines 
analyzed in the array were considerably elevated in comparison to A549 secretion levels. The 
higher amount of microvessels in the A549.EpoB40 xenografts may thus result from the 
overall higher amount of pro-angiogenic factors secreted, inducing new blood vessel 
formation and protecting the existing tumor vasculature.  
 
We also analyzed the medulloblastoma cell line response to patupilone as compared to the 
microtubule destabilizing agent vincristine, part of the standard treatment regimen for 
medulloblastoma.  We observed equal inhibition of cell proliferation by both agents, however 
by a 10-fold lower dose of patupilone than vincristine. This finding is significant, as 
vincristine, used in a concomitant treatment schedule with IR, leads to severe side effects like 
neurocognitive sequelae.  At nanomolar concentrations, patupilone led to an accumulation of 
cells in the radiosensitive G2/M-phase of the cell cycle, and at sub-nanomolar concentrations, 
to minor changes in cell cycle distribution with some accumulation in a sub-G1 phase. The 
sub-G1 population represented cells undergoing apoptosis, as confirmed by caspase 3 
cleavage. Patupilone also induced autophagy in one of the three medulloblastoma cell lines. 
Regardless of the mode of induced cell death and genetic differences between cell lines, 
patupilone led to radiosensitization of all medulloblastoma cell lines studied. Most 
importantly, the combination of patupilone and IR resulted in strong supra-additive tumor 
growth delay with complete tumor remission in 3 out of 5 xenografts. The ability of 
patupilone to cross the blood brain barrier and to sensitize cancer cells to IR makes it a very 
promising compound in combined treatments with IR for CNS malignancies.  
 
In conclusion, the data provided in this work indicate that the combined treatment of 
patupilone and IR has a strong antitumoral effect on different tumor xenograft models. 
Patupilone exerts its effect through multiple complementary mechanisms: first, the 
accumulation of tumor cells in the radiosensitive G2/M phase of the cell cycle, and second, 
alteration of the HIF-1 protein level, with a resulting decrease of secreted VEGF and 
consequently more radiosensitive microvessels. Additionally, the overexpression of HIF-1 is 
often accompanied by a more aggressive phenotype. Especially for those cancers, the 
combination of patupilone with IR may emerge as a promising anti-cancer treatment strategy.  
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4.2. The importance of monitoring tumor hypoxia in anti-cancer treatment 
Hypoxia is one of the most undesired features of tumors for anti-cancer therapy, leading to an 
increase in aggressiveness and general treatment resistance. Hypoxia results from insufficient 
vascularization of the tumor, which can also reduce the potency of chemotherapeutics that 
have difficulty reaching all tumor cells. Furthermore, hypoxia leads to radioresistance due to 
decreased ROS-mediated damage in irradiated cells. In general, tumors with an oxygen 
pressure below 10 mmHg are considered hypoxic. It has been shown that a partial oxygen 
pressure below 2.5 mmHg, determined by the pO2 electrode, is prognostic for poor loco-
regional control after radiotherapy in head and neck cancer [14,15]. Tumor hypoxia below 5 
mmHg corresponds to a poor prognosis in both non-small cell lung carcinoma [16] and 
uterine cervix carcinoma [17]. These data indicate that even small differences in low oxygen 
tension are of clinical relevance. 
 
Within this work (Orlowski et al.), we established a non-invasive bioluminescence system to 
probe tumor hypoxia over a prolonged treatment and follow-up period in an in vivo tumor 
model. For this purpose, a vector construct in which a part of the ODD-domain of HIF-1 
was fused to the luciferase gene was designed. The vector construct is constitutively 
expressed due to a SV40 promoter 5’ of the luciferase gene. The ODD-luciferase protein is 
degraded under normoxia, which is initiated by the hydroxylation of proline564 within the 
ODD-domain by PHDs, leading to recognition by VHL followed by ubiquitination. 
Therefore, this construct depends on the proper functions of PHDs and VHL in transfected 
cells and has limited use in certain renal cell carcinoma cell lines in which VHL is mutated, as 
well as in tumors with altered PHD expression [18]. The advantage of this vector construct 
compared to other luciferase constructs reporting hypoxia in tumors is the stable activity of 
luciferase even under treatment conditions altering the protein level of the HIF-1 transcription 
factor. We therefore could accurately monitor the course of hypoxia under treatment with 
patupilone.  We further monitored the course of tumor hypoxia after treatment with the 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor PKI166 in A549 
xenografts expressing the ODD-luciferase construct. In these mice, treatment with PKI166 
decreased luciferase activity and therefore tumor hypoxia (data not shown), which is in line 
with results of Cerniglia and colleagues demonstrating decreased hypoxia after treatment with 
the EGFR inhibitor erlotinib [19]. 
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Luciferase measurements of two different xenograft models revealed a prolonged transient 
increase of luciferase activity after patupilone treatment. This increase occurred only in 
tumors that responded to patupilone with a delay in tumor growth. No substantial patupilone-
induced tumor growth delay was observed in three patupilone-treated xenografted mice, and 
luciferase activity likewise did not increase in these tumor xenografts. Nonetheless, as we are 
confident that the injection of the drug was performed correctly, we cannot explain the lack of 
tumor response in these mice. A possibility might be that patupilone did not reach the bulk of 
the tumor due to abnormalities in tumor vasculature in these mice or rapid absorption in other 
tissues. An acquired resistance of the tumor cells to patupilone without previous exposure to 
the drug is rather unlikely. Nevertheless, these data illustrate the correlation between the anti-
tumoral effect of patupilone and the increase in intratumoral hypoxia in response to 
patupilone treatment. The specific increase of tumor hypoxia after patupilone treatment as 
observed in our work is further supported by data of Ferretti and colleagues in which they 
demonstrated destruction of blood vessels and a decrease in tumor blood volume with 
patupilone treatment. As the destruction of blood vessels and decreased blood volume can be 
correlated with a decrease of interstitial fluid pressure, they suggest that the decrease in 
interstitial fluid pressure after patupilone treatment can be used as a surrogate biomarker for 
patupilone efficacy [3].  
 
Our data (Bley et al., 2009) revealed a decrease in microvessel density at day 4 after 
patupilone treatment, accompanied by an increase in pimonidazole positive areas. Another 
group demonstrated a reduction in blood volume at day 2 and a reduction in microvessel 
density at day 7 after patupilone treatment in a rat tumor model [3]. Both sets of data support 
the specific increase in tumor hypoxia after patupilone treatment as observed by our 
luciferase-based reporter gene approach (Orlowski et al.).  We analyzed microvessel density 
and pimonidazole staining in tumors expressing ODD-luciferase at day 10 after patupilone 
treatment. At this time point, luciferase activity was increased in all animals treated with 
patupilone compared to the control animals. Surprisingly, we could not detect any significant 
changes in microvessel density or pimonidazole staining in patupilone-treated versus control 
mice at this time point. One explanation might be that microvessel density 10 days after 
patupilone treatment already readjusted to control levels. Analyses of microvessel density and 
pimonidazole staining of the tumors at an earlier time point after treatment might reveal 
greater differences between patupilone-treated versus control tumors. Another possibility for 
the discrepancy between the luciferase and pimonidazole data could be that a tumor section, 
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as used for pimonidazole staining, cannot be used to quantify tumor hypoxia over a whole 
tumor as analyzed by bioimaging using luciferase. To test this possibility, we also analyzed 
luciferase activity in tumor sections derived from patupilone and control tumors at day 10 
after patupilone treatment. Consecutive frozen tumor sections were stained for pimonidazole 
and analyzed for luciferase activity using bioimaging. Some samples revealed areas of strong 
correlation between pimonidazole staining and luciferase signal, e.g. in tissue surrounding 
necrotic islets. However, we could also detect areas in which the two hypoxia analyses 
differed from each other. Therefore, we conclude that hypoxia determined by pimonidazole 
and ODD-luciferase activity measurements are not directly comparable.    
 
One reason for incompatible hypoxia measurements between the two methods could be a 
difference in sensitivity towards varying levels of hypoxia.  Indeed, we observed that 
pimonidazole staining allowed only the detection of differences in oxygen levels ranging from 
normoxia to 1% pO2, but not below. The ODD-luciferase reporter, in contrast, exhibited a 
much higher sensitivity for low oxygen tensions, as we could detect a 2.8-fold difference in 
luciferase signal between 1% and 0.2% pO2. The differences in sensitivity could explain the 
observed discrepancy between the pimonidazole staining and luciferase measurement data. 
Evans at al. demonstrated that binding intensity of the hypoxic marker EF5 correlated to 
different oxygen levels ranging from anoxia to 10% pO2 [20]. It would be of interest to 
determine whether EF5 staining and luciferase measurements correlate in their ability to 
detect hypoxia. A very reliable method to measure exact partial pressures within the tumor is 
the use of a pO2 electrode. However, applying this technique requires larger tumors than we 
used in our study, in order to obtain more than one data set of partial pressures within one 
tumor.  
 
Our luciferase measurements in the context of pimonidazole staining results suggest that the 
hypoxic fractions of the tumors have a pO2 less than 1%. However, only collective 
luminescence derived from the luciferase activity of the whole tumor can be determined with 
the IVIS apparatus, representing the mean tumor oxygenation status of the whole tumor. The 
highly sensitive camera within the IVIS apparatus detects emitted light from the surface of the 
tumor, generating a 2-dimensional picture of a 3-dimensional structure. The system does not, 
therefore, distinguish between areas within the tumors with high or low tumor hypoxia. 
Another disadvantage of the IVIS apparatus is the generation of low resolution images when 
light emitted from the luciferase-expressing tumor cells is low.  Cells expressing a higher 
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amount of luciferase would lead to a higher luciferase signal and therefore a slightly better 
resolution. However, scattered light emitted from the luciferase-expressing tumor cells would 
again decrease the resolution. Future in vivo bioimaging approaches with improved resolution 
are required to overcome these drawbacks. 
 
One key conclusion from our studies is that patupilone treatment does not affect sensitivity 
towards IR, despite increasing tumor hypoxia.  Several explanations could account for this 
result. First, tumors might contain only small areas with very high tumor hypoxia and 
consequently high overall luciferase activity, not reflective of the majority of the tumor. 
Wouters and Brown determined that tumor cells at intermediate hypoxia (0.5 – 20 mmHg) are 
the cells most susceptible to fractionated irradiation with doses of 2 Gy, and not hypoxic cells 
below 0.5 mmHg [21]. Therefore, small areas of highly hypoxic cells might not interfere with 
radiosensitivity in our tumor model. Hypoxic tumor cells below a partial pressure of 0.5 
mmHg, however, are highly important for tumor regrowth after treatment, or for radiation 
resistance at high dose irradiation. An experimental set-up analyzing long-term tumor control, 
or the influence of higher doses of irradiation, would be indicated if this scenario of small 
areas of highly hypoxic cells were indeed the case. A second explanation for the equal 
sensitivity towards IR of patupilone pre-teated and control mice is that a low, radiosensitizing 
level of patupilone is still present at the time point of irradiation and therefore counteracts the 
negative influence of hypoxia on sensitivity to IR.  
 
Hypoxia in tumors can also increase the aggressiveness of a tumor by promoting invasion and 
dissemination. Therefore, induction of hypoxia caused by patupilone treatment would be 
counterproductive as anti-cancer treatment.  Despite the poor premise, unpublished data from 
our group demonstrated that patupilone instead reduces invasiveness and migration in vitro. 
Matrix metalloproteinases (MMPs) are responsible for the degradation of extracellular matrix 
and therefore promote invasiveness and migration. Patupilone treatment led to a reduction in 
the secretion of these pro-invasive proteins. These data underline the very complex nature of 
this MSA in inhibiting tumor progression. 
In this work (Orlowski et al.), we demonstrated the feasibility of the developed in vivo 
bioluminescence system to successfully monitor tumor hypoxia over a whole treatment period 
in single animals. We demonstrated a transient increase in tumor hypoxia after treatment with 
patupilone, which seems to be a specific feature of the compound and could be used as a 
surrogate marker for treatment response. Patupilone-induced tumor hypoxia does not reduce 
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radiation sensitivity, which substantiates the feasibility of patupilone as part of both 
concomitant and neo-adjuvant treatments with IR. Nevertheless, concomitant treatment leads 
to a stronger tumor growth delay than the neo-adjuvant treatment schedule. Unpublished data 
from our group further demonstrated a patupilone-specific inhibition of the secretion of pro-
invasive proteins normally induced by hypoxia. Another very interesting feature of patupilone 
is that its activity remains unchanged regardless of the oxygenation level of the tumor. The 
developed in vivo bioluminescence system can be used to study additional treatment set-ups, 
e.g. anti-angiogenic agents like Avastin as part of a combined treatment modality with IR, to 
probe tumor hypoxia and treatment outcome. The disadvantage of the technique, however, is 
that it is only applicable in preclinical models.  
 
4.3. Translational importance  
This work describes a novel method to accurately report tumor oxygenation in vivo.  
Traditionally, non-invasive tumor hypoxia measurements are performed by using PET 
imaging with different hypoxia tracers. The most common tracer used in the clinics is F-
MISO. Different studies were performed to predict treatment response towards IR based on 
the hypoxic status of the tumor using F-MISO. Evidence demonstrates that hypoxia analysis 
during fractionated irradiation rather than before treatment correlates with treatment outcome 
[22,23]. However, measurements acquired by PET with the hypoxic tracer F-MISO did not 
correspond with measurements from the pO2 electrode, the gold standard, in a virtual voxel 
model. Tumors were in general more hypoxic based on the pO2 electrode measurements as 
compared to F-MISO PET [24]. Another hypoxic tracer, EF5, has been evaluated for its 
feasibility in the clinic and has demonstrated good pharmacological characteristics, 
biodistribution and safety profile [25]. Jenkins and colleagues compared binding of EF5 with 
hypoxia measurements using the pO2 electrode. In general, the amount of bound EF5 
correlated well with the level of tissue oxygen, even at very low oxygen levels down to 
anoxia.  There were still a few discrepancies, however, as the pO2 electrode overestimated 
hypoxia especially in necrotic tissues, whereas EF5 did not accumulate in these areas [26]. 
Evans and colleagues then applied EF5 binding to measure hypoxia in the clinical setting, first 
with the use of specific antibodies on tumor biopsies [27] and afterwards in a study with 18 
patients using PET scan [20]. In the PET scan study, higher EF5 binding correlated with high-
grade tumors, and patients with moderate to severe hypoxia were more likely to develop 
metastases.  
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While PET tracers have proven to be fairly accurate, non-invasive indicators of tumor 
hypoxia, our data obtained from luciferase measurements indicate that pimonidazole-related 
tracers might not allow detection of the exact hypoxic level of a tumor. This might explain the 
poor ability in some studies to predict treatment outcome based on the initial hypoxic level of 
the tumor measured by pimonidazole-related tracers. These studies also had difficulty 
predicting the outcome of individual patients depending on the hypoxic level of the tumors. 
Most of the studies used the mean hypoxic status of the tumors to predict general 
aggressiveness or treatment response. In another approach, Toustrup as well as Marotta and 
colleagues identified sets of genes that allow the identification of hypoxic tumors. The 
specific hypoxia gene expression classifier predicted responsiveness towards radiosensitizers 
when given to patients with hypoxic tumors. This very interesting technique is, however, also 
dependent on tumor biopsies and does not represent the tumor oxygenation level of the whole 
tumor [28,29]. Therefore, there is a strong need for a new non-invasive method of 
determining the tumor oxygenation level that can be applied uniformly in the clinics.  
 
Using our luciferase technique, we were able to probe longitudinal tumor oxygen levels 
throughout the course of treatment with IR or patupilone alone, or as part of a combined 
treatment modality.  While it is generally accepted that hypoxia impairs sensitivity to 
radiation, we showed that hypoxia induced by patupilone treatment did not appear to affect 
the response to IR.  Thus, combined treatment modalities of IR with compounds that could 
induce tumor hypoxia should not be prematurely rejected and should be evaluated.  
 
This work demonstrates that the combination of patupilone and IR is a very potent treatment 
modality in xenografts derived from different cancer cell lines. The concomitant treatment 
schedule with one dose of patupilone and 3 fractions of IR led in all cases to an at least 
additive tumor growth delay. The ability of patupilone to pass the blood brain barrier and to 
inhibit proliferation to the same extent as the microtubule-destabilizing agent vincristine, 
though at a 10 times lower dosage, makes it a very compelling compound for treatment of 
brain malignancies. The phase I study on patupilone with concurrent IR in central nervous 
system malignancies demonstrated promising results [10], however no phase II trial was 
initiated. Due to the fact that Novartis International AG is not continuing research on 
patupilone, other epothilones should be used for further studies of the promising combined 
treatment modality with IR.  
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Ixabepilone is a very promising epothilone B derivative already approved by the FDA for 
treatment of breast cancer. Ixabepilone is in various clinical trials in combination with other 
chemotherapeutics; however, no clinical or preclinical trials are being performed in 
combination with radiotherapy. Despite data from Kim and colleagues demonstrating a radio-
sensitizing effect of Ixabepilone on human NCI-H460 lung cancer cells in vitro and in vivo, 
no further research has been initiated in combination with IR [30]. Using the luciferase 
approach developed here, the combined treatment modality of Ixabepilone and IR could be 
analyzed in various experimental set-ups. In this way, treatment efficacy and tumor hypoxia 
could be monitored at the same time, and various scheduling possibilities could be analyzed. 
If preclinical data demonstrate promising results, clinical trials with already approved agents 
could be initiated more readily.  Based on the data presented in this work, further preclinical 
and clinical trials should be initiated analyzing the very potent combined treatment modality 
of microtubule stabilizing agents and ionizing radiation. 
 
 
5. Outlook 
 
Here we demonstrated that the concomitant combination of patupilone and IR leads to an at 
least additive tumor growth delay in different tumor xenografts. However, the tested treatment 
schedule consisted only of one single dose of patupilone followed by 3 low-dose fractions of 
IR. Since we demonstrated that the neo-adjuvant treatment did not improve nor impair 
radiation response, it would be of interest to analyze the effect of further treatment 
combinations on tumor growth. A combined treatment schedule of repetitive cycles of 
patupilone followed by IR over several weeks would allow us to analyze long-term local 
tumor control instead of tumor growth delay.  
 
Another promising strategy to analyze tumor growth delay could consist of a different 
compound in combination with patupilone, IR or both. Tumor cells that are resistant to 
treatment with one of the compounds like patupilone could still be sensitized for the 
consecutive treatment with IR. One radiosensitizing agent that acts on a completely different 
level than patupilone and can be used in such a combination is the mTOR inhibitor RAD001. 
An interesting approach would be to combine the three treatment modalities and analyze the 
tumor growth of A549-derived xenografts and patupilone-resistant A549.EpoB40 xenografts. 
In this manner, development of treatment resistance to one of the compounds could be 
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attenuated, and the dosage of the individual compounds could be reduced. To further 
investigate this question, tumor xenografts derived from a mixture of patupilone-sensitive and 
patupilone-resistant cells could be analyzed for the growth advantage of the single cell lines 
under the various treatments. The addition of RAD001 to these tumors should sensitize tumor 
cells derived from both cell lines towards IR.  Interestingly, a phase I clinical trial is currently 
analyzing the combined treatment modality of RAD001 and patupilone in a dose-escalation 
study on advanced cancer (clinicaltrials.gov). 
 
Having in hand a highly sensitive bioluminescence system to monitor tumor hypoxia in vivo, 
it would be of interest to analyze other combinations of treatment modalities for their effect 
on tumor hypoxia. The combination of anti-angiogenic agents like Avastin or DC101 with IR 
could be used to investigate the still-unanswered questions about tumor vasculature 
normalization after treatment with anti-angiogenic agents. Furthermore, optimal treatment 
scheduling for these combinations could be determined to help adapt already existing 
therapies. Most importantly, the use of the hypoxic tracer EF5 to replace the luciferase system 
for clinical use should be validated and analyzed in our in vivo model. If EF5-based hypoxia 
measurements correlate with luciferase measurements, the preclinical data obtained from 
scheduling experiments with the luciferase system could be validated and translated into 
clinical trials.  
 
In conclusion, this work illustrates the promise of combined MSA and IR treatments for 
cancer therapy and introduces a highly sensitive system for monitoring tumor hypoxia in vivo.  
It opens the door to countless future studies focusing on multi-compound treatment regimens 
for radiosensitization, as well as on optimal treatment scheduling, which can now be validated 
by measurements of tumor oxygenation throughout the treatment course using the novel 
bioimaging method. Together with a complementary non-invasive method for oxygen 
measurement feasible for clinical use, these results could ultimately be translated into clinical 
trials. 
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